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ABSTRACT
1- Repeated administration of ochratoxin A (OTA) caused renal 
morphological dose-related changes, that were associated with proximal 
tubular and glomerular damage the latter showing oedema and prominent 
PAS staining suggestive of glomerular basement membrane thickening. On the 
other hand, the combined administration of repeated doses of OTA and
aflatoxin (2.5 mg and 100 ug per kg, respectively), appeared to have a
synergistic effect, characterized by severe disruption of proximal tubules 
and general morphological derrangement of the glomerulus, involving 
intense and faint staining nuclei (suggestive of cell necrosis) and 
cytoplasmic vacuolation, which was not seen with either toxin alone. When 
clinical biochemical parameters were measured after repeated 
administration of a low dose of OTA, enzymuria, glucosuria, polyuria and
proteinuria were observed, with glucose and alkaline phosphatase as the
most sensitive parameters.
2- Metabolic studies performed in vitro showed that isolated pig and ' rat 
glomeruli incorporate different amino acids linearly for several hours at 
different rates and perform oxidative metabolism of glucose and fatty 
acids to CO 2  also linearly.
For pig glomeruli the order of amino acid incorporation was LEU »  PRO = 
HIS > LYS > GLY and for rat glomeruli it was TRP »  PHE > TYR = LEU > PRO 
> HIS. The same amino acids were incorporated in a similar way in rat 
tubules, but the incorporation rate is 10-fold lower.
When de novo synthesis of protein by pig glomeruli exposed to different 
chemicals was assessed, using proline (PRO) as the precursor, adriamycin
(ADR) and ethacrynic acid (ETA) inhibited protein synthesis more than 2- 
bromoethanamine (BEA) and streptomycin (STR), and much more than puromycin 
aminonucleoside (PAN).
3- When isolated rat glomeruli were exposed to low concentrations of OTA, 
there was a generalized inhibition on de novo synthesis of protein from 
the six amino acids tested and the aromatic amino acids (TRP, TYR and 
PHE) were more sensitive to OTA effect than PRO.
Low concentrations of OTA (10 - 100 uM) enhanced glomerular and tubular 
glucose metabolism to CO 2  and only high concentrations of the mycotoxin 
(1000 uM) caused significant inhibition of glomerular and proximal tubular 
linolenic acid metabolism.
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CHAPTER 1.
INTRODUCTION
Mycotoxins represent a very large number of chemicals that are 
ubiquitously distributed. They are secondary metabolites of toxigenic 
fungi that can be found on a variety of agricultural crops under field, 
harvest, as well as storage conditions. The accumulation of these toxic 
metabolites occurs under specific conditions of substrate, moisture and 
temperature. Insect and mechanical damage and improper drying and storage 
of grains are the main factors allowing fungal invasion with the 
subsequent mycotoxin production. Mycotoxins may also occur in finished 
foods and feeds since the ingredients destined for human or animal feeding 
may have been exposed at some point in time to mould contamination. In 
addition, more than one mycotoxin can occur simultaneously in foods and 
feedstuffs, since more than one species of moulds can grow on the same 
commodity, which may lead to the formation of more than one toxin 
(Lillehoj and Ciegler, 1975), and also some individual moulds may produce 
two or more different mycotoxins simultaneously. On the other hand, 
mixtures of various food or feed supplies can also be the source of more 
than one mycotoxin in the same commodity. Exposure to two or more 
mycotoxins introduces the possibility of interactions between these 
chemicals (Huff and Doerr, 1981).
The ingestion of mycotoxin contaminated feeds, has been responsible for 
acute and chronic diseases - called mycotoxicoses - in man and animals.
Some of the mycotoxins have been studied extensively. Because of the
1
diversity of chemical structures, the lesions produced by these compounds 
vary widely, but all of the major organs have been shown to be sensitive 
to the adverse effects caused by mycotoxins in experimental systems. 
These lesions are an accurate representation of what happens in animals 
and man with naturally occurring mycotoxicoses including those in which 
nephrotoxicity is an important problem.
While porcine and avian nephropathy are the most clearly identified renal 
lesions linked with a mycotoxin (most likely ochratoxin) aetiology, it is 
still not clear if Balkan endemic nephropathy (BEN) is caused by 
mycotoxins, although consensus currently suggests that ochratoxin A (OTA) 
is the most likely aetiological (or the most easily identifiable) factor. 
The nephrotoxicity of other mycotoxins in laboratory animals has been 
linked to other conditions of clinical significance. Indeed it has been 
suggested (Bach, P . personal communication) that mycotoxin exposure could 
be a key factor in the 50% of chronic renal failure and end stage renal 
disease that has no known aetiology. This is, however, speculation and may 
be untrue.
The problems associated with assessing the real role of mycotoxins in 
clinical nephropathies are extensive, and there needs to be a number of 
problems resolved before this question can be answered.
This thesis has aimed:
1- To identify the extent of glomerular involvement in the renal lesion 
caused by the acute administration of ochratoxin A in vivo and its 
interaction with aflatoxin B^ .
2- To identify metabolic changes taking place in the isolated glomeruli
2
exposed to ochratoxin A.
The experimental work is presented in two parts, the first one deals with 
the renal clinical biochemical and morphological effects produced by the 
administration of single and repetitive different doses of ochratoxin A 
alone or in combination with small doses of aflatoxin . In the second 
part, due to the findings of early glomerular changes after exposure of 
the animals to small repetitive doses of ochratoxin A, the studies were 
focused on the effect of this toxin in vitro. Glomeruli were isolated from 
rat kidneys by fractionated sieving and the effect of this mycotoxin was 
assessed on several metabolic pathways (i.e. De novo protein synthesis, 
and oxidative metabolism of glucose and fatty acids). For comparison 
proximal tubular fragments were also isolated and exposed to ochratoxin A.
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CHAPTER 2.
MYCOTOXINS IN HUMAN AND ANIMAL HEALTH. 
2.1 Mycotoxins in human and animal health.
2.1.1 Effects of Mycotoxins on Animal Health and Productivity
Mycotoxins can profoundly influence the health of most animal species. 
They can cause both acute and chronic primary diseases and in addition 
they can impair the animal's resistance and immunity to secondary 
diseases. In animal husbandry, the presence of those metabolites in 
feedstuffs has become a serious toxicological concern, since modern 
feeding practices in commercial organizations is aimed at a maximum growth 
or productivity, and therefore involve a high intake of concentrated 
feeds.
Administration of contaminated feeds to susceptible animals can cause 
substantial economic losses through increased mortality, slowed growth, 
and poor feed conversion reflected as lower productivity. In the field, 
outbreaks of mycotoxicosis are difficult to diagnose because of the 
complexity of the clinical syndrome, which can also resemble intoxication 
by other compounds. A causal relationship can only be demonstrated by the 
detection of the toxin in the feed, plasma or tissue, at concentrations 
sufficient to cause the toxic symptoms in the animal (Pier, et al 1975; 
1977; Nelson and Christensen, 1976).. Moreover, mild mycotoxin-induced 
disease syndromes can occur and can also be easily confused with diseases 
caused by pathogenic microorganisms, or by nutritional deficiencies and/or 
imbalances (Pier et al., 1980; Hamilton, 1977).
Individual mycotoxins can also affect more than one organ or metabolic 
system of an animal species, and different species may be affected in 
different ways (Table 2.1). On the other hand, mixtures of two or more 
mycotoxins can lead to a "multiple mycotoxicosis". These are much more 
complex and difficult to diagnose, since the symptom patterns of toxicity 
can differ from those that occur when only one of the mycotoxins is 
present, thus confusing the diagnosis.
2.1.2 Public health aspects of mycotoxins.
Some human diseases such as ergotism, alimentary toxic aleukia and acute 
cardiac beri beri, have been known for a long time, but it was some.time 
after they were described that they were attributed to fungal toxins. 
However, apart from these rarely occurring human mycotoxicoses, it is
difficult to determine the aetiology of most mycotoxicoses in man, because 
most of the information available on this matter has been derived from 
field or experimental animal studies and there is no direct evidence to 
show a causal relationship of fungal toxins in human disease. ' There is, 
however, some evidence such as epidemiological data and reports of
isolated incidences believed to relate human disease, to mycotoxins.
Some reports have associated aflatoxin with acute outbreaks of disease 
in humans (Yadgiri et al., 1970; Serck-Hanssen, 1970; Krishnamachari et 
al, 1975; Jukes, 1978) resembling the acute effects of the toxin in 
animals. Epidemiological studies in some areas of Africa and Asia support 
the positive association of aflatoxin ingestion and liver cancer in man 
(Shank, 1976). Aflatoxin cannot be excluded as a contributing factor to
some acute or chronic diseases in humans that have poorly defined
aetiologies, although other factors might also have been associated with
Table 2.1 Responses of different species to various amounts of selected mycotoxins.
(Pier et al., 1980)
Species Mycotoxin Quantity of toxin Effect
Cattle Aflatoxin 0.08 mg/kg a 
0.2 mg/kg (Bl)
0.7 ppm (Bl)b 
2 ppm
0.5 mg/cow/day 
14 to 46 ppb (B^) 
Approx. feed (B^) 
milk (M^) 
ratio - 200:1 
0.5 mg/kg
Reduced weight gain (calves)
Reduced weight gain coagulopathy _ 
(calves)
Reduced weight gain (steers)
Reduced milk production 
Detectable milk residue
Death (calf); icterus haemorrhage; 
hepatic necrosis; coagulopathy
Ochratoxin A 1.0 ppm
1.0 mg/kg
Death (steer)
Depression; reduced weight gain; 
nephritis enteritis
Swine Aflatoxin 
20 kg pig 
20 kg pig 
22 kg pig 
6.5 kg pig
0.26 ppm 
0.86 ppm 
2-4 ppm
0.62. mg/kg of body weight
Decreased growth rate 
Impaired immunogenesis 
Acute fatal toxicosis 
Single oral dose LD^g
Ochratoxin A 
20-90 kg pigs 
3 kg pig 
3 kg pig
0.2 ppm
2.0 ppm c
10.0 ppm c
Chronic nephropathy 
Nephrosis, slow growth 
Acute fatal enteritis
Poultry Aflatoxin 1-10 ppm
0.25 ppm 
0.6-1.0 ppm 
1.5-2.5 ppm
2-8 ppm
Acute death, hepatic necrosis and
haemorrhage
Impaired immunogenesis
Reduced resistance
Decreased gain
Decreased.egg production
Ochratoxin 4-16 ppm 
4 ppm • 
2-4 ppm 
2 ppm
Acute disease, diarrhoea, death 
Toxic nephropathy 
Reduced gain
Decreased egg production
* mg/kg- daily intake of toxin/kg of body weight. 
b Feed content expressed as ppm or ppb.
c Level estimated from mg/kg dose and National Research Council Feed Consumption Data.
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these conditions. For example, it has been also suggested that aflatoxin 
may play a role in the aetiology of the Reye's syndrome in children (Harwig 
et al., 1975). Therefore, there are still several aspects of the 
relationship between aflatoxin exposure and human disease that need to be 
clarified from more experimental and epidemiological data.
OTA has been found in foodstuffs of certain areas of the Balkans, and has 
been suggested to be involved in the potentially fatal disease known as 
Balkan Endemic Nephropathy (Krogh, 1979). The disease is characterized by 
renal disorders and occurs in certain very limited areas of Bulgaria, 
Romania and Yugoslavia. No direct proof of the -association between 
ochratoxin and the disease has been demonstrated so far in man (see 
below).
2.1.3 Natural occurrence of Ochratoxin A (OTA) and Aflatoxin (ATB^).
OTA can occur in a wide variety of feedstuffs. A natural occurrence of 
this toxin has been reported from Denmark, Sweden, Canada, USA and 
Yugoslavia (Table 2.2) and high concentrations have been found in sorghum, 
corn, wheat and barley, and have also been reported from green coffee 
beans, peanuts, and occassionally hay. Levels of approximately 27 ppm have 
been reported in Canadian wheat and Danish barley.
ATB^ has been found in a great diversity of agricultural products in 
several countries (Table 2.3). As it can be seen, high concentrations of 
aflatoxins have been detected in corn, peanuts, sorghum and wheat. In some 
cases these high levels have been associated with diseases and death in 
animals, and man. Several other commodities have been found contaminated 
with aflatoxins, such as oats, soybeans, cottonseed and their subproducts,
7
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kidney beans, cocoa, green coffe beans, cassava, etc.
.Simultaneous contamination of agricultural commodities with OTA and ATB^ 
have been reported to be of frequent occurrence in India (Giridhar and 
Krishnamurthy, 1977; Rao et al., 1979) and mixtures of these toxins have
been detected in Australian grains and animal feeds; in sorghum, the
level for OTA was 100 ug/kg and for ATB^ was 4.64 mg/kg; in animal feed, 
the concentration reported for OTA was 70 mg/kg, and ATB^ levels ranged 
between 0.51 and 2 mg/kg (Connole et al., 1981). In both cases the 
possibility of an interaction between both toxins was considered in
outbreaks of mycotoxicosis in pigs in the Queensland area (Ketterer et 
al., 1982). Both OTA and aflatoxin have also been reported as
simultaneous contaminants of feed ingredients and finished feed in the USA 
(Huff and Doerr, 1981).
Whereas mycotoxin levels have been studied extensively in Europe and USA, 
there are few reports from South America on the occurrence of mycotoxins 
in.foods and feedstuffs. In Brasil, peanuts is the most commonly surveyed 
agricultural commodity, and recent reports have indicated contamination 
with ATB^ ranging from 40 - 1040 ug/kg. In corn, the levels found ranged 
from 190 - 2000 ug/kg for the same toxin (Fonseca et al., 1982) . Acute
outbreaks of mycotoxicoses caused by other mycotoxins have been reported, 
but there are no data available on the levels found in animal feeds.
In Colombia, despite the fact that under storage conditions, many 
agricultural commodities are susceptible to fungi development, the 
published information on this matter is scarce, as well as that on levels 
of mycotoxins and natural occurrence. Some recent surveys of grains and 
stock feed, revealed that low to moderate levels either of ATB^ or OTA
- 10
have been detected, possibly associated with outbreaks of mycotoxicoses.
ATB^ has been reported in different products of human and animal 
consumption. In corn the levels of ATB^ ranged between 125 - 250 ug/kg
(ICA (1982) unpublished results), and in sorghum from different regions of 
the country, the levels of the toxin fluctuated between 33 - 27 6 ug/kg
(ICA (1983) unpublished results). In mixed poultry feed, the concentration 
of ATB1 was between 32 - 128 ug/kg (Pena et al., 1982). These values are 
much lower than those reported in most of the countries (Table 2.3), but 
this can be explained by the little information that is available on this 
topic.
OTA has been found in coffee beans as well as in some cereal grains and 
mixed feeds. Simultaneous occurrence of ATB^ and OTA in Colombian grains 
and animal feeds has been reported, but there is no published data on 
levels of contamination.
Although mycotoxins are mainly produced under natural conditions, in 
vegetable commodities, they can also be retained as residues in tissues 
and other products, from animals that have ingested contaminated food, 
and transferred to the human food chain in this way (Fig. 2.1).
2.2 Aflatoxin
2.2.1 Chemistry of ATB^
The term aflatoxin refers to the group of bisfuranocoumarin metabolites 
produced by strains of the Asoercrillus flavus and Aspergillus parasiticus 
(Schindler et al., 1967; Diener and Davies, 1966). The major members are 
designated B^, B2 , G^ and G 2  (Fig. 2.2).
11
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The aflatoxins are crystalline compounds that fluoresce strongly in 
UV-light: and B 2  produce a blue fluorescence (thus the designation "B")
whereas G1 and G2 produce a green (hence "G") fluorescence (Hartley 
et al., 1963) .
ATB^ is the most important of the group, due to the frequency and level of 
natural contamination as well as its toxic properties (Stoloff, 1976) .
2.2.2 Pharmacokinetics of ATB1 .
2.2.2.1 Distribution.
The fate of ATB^ was studied after a single ip dose of the
radiolabelled toxin given to rats (Wogan et al., 1967). At 30 min after
dosing, the kidneys contained approximately 5%, the liver 17% and the
eviscerated carcass 27% of the recovered radioactivity. At 2 hr
radioactivity in the kidneys and liver decreased rapidly so the kidneys
and liver contained less than 1% and 10% respectively. The animals
14retained about 20% of the C activity, 24 hr after administration. The 
liver had the highest concentration, which was equal to the content of the 
remainder of the carcass (5 - 8% of the recovered radioactivity). Plasma 
was not examined for ATB^ content.
When pigs were fed rations containing aflatoxins at levels of 300 - 500
ug/kg for 4 months (Krogh et al., 1973), the highest concentrations of the 
toxin were also found in liver, with residual levels also detected in 
kidneys, muscle and adipose tissue. In poultry, following 8 weeks of 
ingestion of rations contaminated with 15 mg/kg of ATB^ (Mintzlaff et a l ., 
1974), the liver contained the greatest amount of the toxin, and there 
were also residues in muscle tissue.
14
In humans, under suspected natural exposure to ATB^, the toxin has been 
detected in several tissues, including serum (Siraj et al., 1981; Wray and
Hayes, 1980; Tsuboi et al., 1984) and liver (Siraj et al., 1981; Phillips
et al., 1976) .
ATB^ binding to albumin in rats, is the principal interaction with plasma 
protein in vitro (K = 30 mM and in vivo (Dirr and Schabort, 1986; Wild 
et al., 1986; Sabbioni et al., 1986; Dirr et al., 1987; Nassar, et al.,
1982). The mycotoxin binds strongly with either bovine or human serum
albumin in vitro (Bassir and Bababunmi, 1973). This will increase the 
half life of the toxin and the complex aflatoxin-albumin may act as a 
continuous endogenous source of the toxin to the liver.
2.2.2.2 Metabolism
In relation to ATB^ metabolism it is believed to be transformed in the 
liver into three hydroxylated metabolites (aflatoxicol, aflatoxin and
aflatoxin P^) that apparently may be conjugated with glucuronic acid and 
rapidly eliminated from the body via urine. Fig 2.3 shows the different 
pathways for the metabolism of ATB^ in liver.
2.2.2.2.1 Metabolic Activation
Two routes for the metabolic activation of ATB^.have been proposed. The 
first involves the metabolic conversion of ATB^ to its hemiacetal ATB 2 a, 
which is bound strongly to protein and has been detected in livers of 
animal species with susceptibility to acute aflatoxin poisoning 
(Patterson, 1971), and liver tumour induction (Hsieh et al., 1977) . The 
second route, which is probably the more important form of metabolic 
activation is the formation of the 2,3-oxide. Although there is only 
indirect evidence for this, it has been shown that when ATB^ is incubated
15
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in vitro with liver microsomes and RNA or DNA, or after in vivo ip 
injection of the toxin, a nucleic acid adduct was formed, which after mild 
acid hydrolysis, yielded the 2,3-dihydrodiol (Swenson et al., 1974; 1977). 
It is now generally accepted that the epoxide of ATB^ (which is mutagenic) 
is also the proximal carcinogen. Conjugation with glutathione might 
provide a route for detoxification of the epoxide (Raj et al., 1975).
After a single ip dose of radiolabelled ATB^ to rats, at least 80% of the 
dose was excreted within 24 hr of administration, and not less than 65% 
of the initial dose was excreted in fasces. The remaining amount was 
excreted in the urine (Wogan et al., 1967; Bassir and Osiyemi, 1967; 
Wogan, 1969). Aflatoxin is excreted conjugated or unchanged via the urine, 
faeces or milk. Elimination of ATB^ in the milk of dairy cows is mainly 
through the excretion of the metabolite ATM^ in a ratio 1/300 of the 
concentration of the toxin in the dairy ration (Rodricks and Stoloff, 
1977). ATM^ is almost as acutely toxic as ATB^. ATH^ has also been found 
in urine of cows, sheep and rats, after experimental administration of 
ATB^ (Ueno and Ueno, 1978).
2.2.3 Biochemical effects of ATB^
2.2.3.1 Mitochondrial effects
Studies on the effects of aflatoxins in isolated rat liver mitochondria 
showed that the compounds inhibited respiration, uncoupled phosphorylation 
and affected ATPase (Doherty and Campbell, 1973; Pai et al., 1975). 
Succinate dehydrogenase, which is associated with the inner membrane of 
the mitochondria, was inhibited in both liver and kidney of rats after ip 
administration of the toxin (Bai et al., 1977). In mice, however an 
elevation of this enzyme activity has been reported (Shankaran et al., 
1970). This species-difference is reflected by the relative resistance of
17
mice to the hepatotoxic effects of aflatoxins. Other enzymes such as 
isocitrate dehydrogenase and malate dehydrogenase were not affected in rat 
liver up to 48 hr after injection of ATB^, but decreased 3 to 5 days after 
administration (Clifford and Rees, 1967). In chick liver, these enzymes 
as well as succinate dehydrogenase were inhibited 24 hr after a single 
dose of the mycotoxin (Raj et al., 1974). Bai et al., (1977) observed no 
inhibition of isocitrate and malate dehydrogenase in rat liver, 48 hr 
after a single ip dose of ATB^, but these enzymes were remarkably 
inhibited in kidney. Succinate dehydrogenase was inhibited in both liver 
and kidney. The mitochondrial effects of ATB^ on kidney may be related to 
the nephrotoxic effects of the toxin and also with the synergism that has 
been found between ATB^ and other toxins (eg. OTA).
2 .2 .3 .2 • Protein and RNA synthesis
Aflatoxins were observed to be in vitro inhibitors of amino acid 
incorporation in liver slice preparations (Clifford and Rees, 1967), and 
in tissue culture (McIntosh et al., 1976). Several studies have aimed at 
pin-pointing the exact mechanism of inhibition of protein synthesis and 
have concluded that the inhibition is early and due to the alteration of 
RNA synthesis (Moule, 1974). Nuclear RNA synthesis appeared to be a 
primary target for aflatoxin action. This biochemical process was the 
most affected by the toxin and it was amongst the more sensitive (Wogan, 
1969) . !
2.2.3.3 Carbohydrate metabolism
In chicks, ATB^ reduced hepatic glycogen, by inhibiting glycogen 
synthetase and glucose-6-phosphatase activities (Feuer et al., 1965; 
Shankaran et al., 1970). The reduction in the activities of the enzymes
18
may be attributed either to direct inhibition of the enzymes, or to
reduction in the enzyme levels. Some dehydrogenases of the pentose shunt 
pathway showed increased activity (Shankaran et al., 1970), suggesting a 
stimulatory effect of ATB^ on this metabolic route.
2.2.4 Nephrotoxicity of ATB^
Although the focus of most studies on ATB^ has been the liver, there are 
few reports describing toxic effects in the kidney, such as non-specific
renal changes in ducklings given large doses (Asplin and Carnaghan, 1961).
In monkeys that were fed daily with 1 mg of ATB^ for 4 weeks
(Madhavan et al., 1965), the kidneys were grossly enlarged and yellow and
histological sections showed marked accumulation of fat in the tubular
epithelial cells which were swollen and vacuolated, along with exudates in 
Bowman's spaces. Other changes included fatty liver and biliary fibrosis.
Acute aflatoxin poisoning in guinea pigs, after daily administration of 
500 and 250 ug of the toxin per animal for 7 days, showed renal changes 
mainly in the proximal tubules, which were necrotic and often displaced 
into Bowman's spaces. There was also eosinophilic cytoplasmic degeneration 
and nuclear pyknosis in the epithelium of some proximal tubules. The 
necrotic changes were accompanied by separation of the epithelial segments 
from the basement-membrane and protrusion of the separated mass into 
tubular lumen (Madhavan and Rao, 1967). When rats and monkeys were given 
500 ug of aflatoxin/animal daily for 3 weeks, the kidneys showed tubular 
necrosis and epithelial reflux, with accumulation of granular material in 
Bowman's space (Madhavan et al., 1965). As the tubular epithelial reflux 
was found in the presence of severe liver damage, ‘ it was difficult to 
decide whether the renal lesions were directly due to the aflatoxin or 
indirectly to the liver damage.
Alterations in kidney function can be induced in rats after administration 
of a single low dose of ATB^, not capable of producing gross liver or 
kidney changes (Grosman et al., 1983, 1984). In vivo studies demonstrated 
that the toxin decreased glomerular filtration rate, tubular reabsorption 
of glucose, and tubular transport of p-aminohippurate. There was also 
increased urinary excretion of sodium and potassium and urinary 
gamma-glutamyl transferase content. Furthermore, renal cortex slices from 
the same rats had a diminished capacity to accumulate p-aminohippuric acid 
and showed alterations in water and electrolyte content.
Ketterer et al., (1982) described field cases of aflatoxicosis in pigs 
involving liver damage and acute renal tubular changes with abnormaly 
eosinophilic tubular epithelial cells and luminal dilatation with 
proteinaceous material. The cortex showed mild multifocal interstitial 
nephritis with infiltration of reticuloendothelial cells, plasma cells and 
fibroblasts. Diffuse interstitial infiltration was also seen in the 
medulla.
2.3 Ochratoxin A (OTA).
2.3.1 Chemistry of OTA
The ochratoxins constitute a group of related isocoumarin derivatives 
(Fig. 2.4), produced by several species of Aspergillus and Penicillium 
(Van der Merwe et al., 1965) . The name ochratoxin was derived
from A. ochraceous, and the first compound discoverd was OTA. Only this 
product and its dechloro-analogue, OTB have been found as natural 
contaminants in food, feed and their processed products. The remaining 
ochratoxins, including 4-0H-0TA, the methyl and ethyl esters, and the 
isocoumarin part of OTB (OT-Beta) , have only been isolated from fungal
20
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cultures under experimental conditions.
OTA is a colourless, crystalline compound, intensely fluorescent in 
UV-light, emitting green and blue fluorescence in acid and alkaline 
solutions respectively. The toxin is slightly soluble in water, soluble in 
diluted aqueous bicarbonate and polar organic solvents.
2.3.2 Pharmacokinetics of Ochratoxin A 
2.3 .2.1 Absorption
After oral administration to rats OTA (10 mg/kg) is absorbed by .the 
stomach (Galtier, 1974b; Lillehoj et al., 1979), and distributed 
particularly to the liver, the kidneys and muscle. Although this is a high 
dose that may cause injury to the tissue, the site of absorption was 
confirmed by another study using lower concentrations of the toxin (288.8 
ug/kg), similar to those encountered in naturally contaminated feed (Kane 
et al., 1986a).
In a study on intestinal absorption, the jejunum was regarded as a site of 
maximal absorption of OTA from the intestinal tract (Kumagai and Aibara, 
1982) after injection of low doses of the toxin (1.4 mg/kg) which did not 
induce observable macroscopic damage to the alimentary tract. No 
comparison was made with higher doses of OTA in this study to see if the 
toxic effects on the gastrointestinal tract changed its absorption.
2.3.2 .2 Distribution
After a single iv dose of OTA (2.5 mg/kg), the toxin is distributed into 
two compartments; a central compartment that includes the plasma and 
well perfused tissues, and a peripheral compartment (Galtier et al.,
22
1979). The two compartments differ in their relative accessibility to OTA 
and in the ease with which the toxin can leave them. After 1 hour, 
approximately 44% of the injected radioactivity was in the ' plasma, 
decreasing to 24% by 6 hr, and to about 9% by 48 hr. One hour after the
injection, the liver contained 6% of the injected dose, followed by
testes (5.7%), small intestine (4.3%), small intestine contents (4.2%), 
fat (1.8%), and kidneys (1.2%). However, at this time-point, muscle 
contained the largest percentage of radioactivity (li.6%), and only 
decreased to 8.4% at 48 hr after the injection. OTA exhibited a. long 
biological half-life which was around 55 hr for either oral or iv
administration; a finding strongly suggestive of tissue accumulation.
14 . .When C-OTA (highly labelled m  its phenylalanine (PHE) moiety) was
given to rats in a single ip dose of 1 mg of the toxin per animal (Chang
and Chu, 1976), the levels of the.toxin in serum, liver and kidney, 30
mins after the injection accounted for 90, 4.5 and 4.4% respectively of
the dose. These decreased gradually to 56, 1.7 and 1.2% respectively, at
24 hours. No other tissues were examined for the presence of OTA. The
serum half-life of the toxin was 12-18 hr which is considerably shorter
than that reported by Galtier et al., (1979) for the same species when
14 . .C-OTA (uniformly labelled) was administered orally or iv. This
discrepancy could be due to the different routes of administration,
and/or characteristics of the radio labels used.
The distribution of radioactivity in rat tissues after oral administration 
of labelled OTA as studied by Lillehoj et al., . (1979), showed
preferential association with stomach tissue early after dosing, where a 
significant fraction remains 24 hr after the treatment. . With the 
exception of stomach, kidney exhibited a higher count than other tissues 
during the first 3-12 hr after treatment, but this decreased during the
subsequent 12 hr. Other organs such as liver and intestine exhibited
the greatest counts 18 hr after toxin exposure. Plasma was not examined 
for radioactivity.
The pharmacokinetic profile of OTA shows big differences among various 
animal species. When Galtier et al., (1981) administered the toxin 
orally, peak plasma concentrations were observed after 10, 1 and 0.33 hr 
in pig, rabbit and chicken respectively; and the fractions of the
administered dose that were absorbed were 66, 56 and 40% respectively. The 
biological half-life of OTA was about 90 hr for the pig, 8 hr for the
rabbit and 4 hr for the chicken. These results and the lower elimination 
rate constant obtained in the pig, provide evidence that OTA accumulates 
in the tissues of this animal, as had been previously demonstrated in the 
rat (Galtier et al., 1979). Large apparent volumes of distribution were 
found for the rabbit and chicken in contrast to the pig, which implied a 
wider tissue distribution and this, rather than accumulation, may account 
for problems of residues in these two species.
The observed species differences may be related to differences in the 
physiological processes that determine the disposition of the toxin in the 
animal, such as binding to serum albumin, digestive flow rate and
biotransformation rates of the mycotoxin in the digestive tract. OTA has
been found to interact with porcine serum albumin with higher affinity 
constants (7.1 x 104M-1) than with chicken (5.07 x 10^m ” )^ or rat (4.01 
10^M )^ serum albumins (Galtier, 1979).
OTA.has been reported to bind strongly to bovine serum albumin in vitro, 
with affinity constants of 3.17 x 10^M  ^ (Chu, 1971) and of 7.67 x 10^M ^
24
(Uchiyarria et al., 1985)-. Both observations showed that two molecules of 
the toxin were bound to one molecule of bovine serum albumin (BSA) at a 
common binding site, indicating that such binding may play an important
role as a.large mobile depot of the OTA.
The possibility of interaction of other ochratoxins with BSA has also been
examined (Chu, 1974). OTB and OTC resembled OTA in their mode of
interaction with bovine serum albumin, but in the case of OT-alpha and 0T-
beta only one molecule of either ochratoxin was bound to one molecule of
BSA. The affinity of OTA for serum albumin is, however, not so high when
compared to the binding of the toxin to other plasma constituents. Recent
in vitro studies showed a specific and high affinity binding of OTA- with
a protein of molecular weight of 29,000 found in human and porcine sera
10 -1(Stojkovic et al., 1984). The association constants were 2.3 x 10 M 
10 -1and 0.59 x 10 M respectively. Such low molecular weight protein bound 
with OTA can easily pass through normal glomerular membrane, before being 
taken up by proximal tubular brush border and broken down to amino acids 
and polypeptides, with the subsequent release of OTA. All thus filtered 
bound mycotoxin could accumulate in the kidney through this mechanism, and 
this selective delivery may explain the nephrotoxic effect in ■ mammals. 
The same cannot happen with OTA bound to albumin, because it is not 
filtered unless there is a breakdown of the glomerular permselectivity. 
This specific low molecular weight, high-affinity ochratoxin A binding 
plasma macromolecule has not yet been identified. While binding of OTA 
to serum albumin has. also been reported in vivo (Galtier, 1974a; Chang 
and Chu, 1977), there is no such data on the in vivo binding of the 
toxin to other plasma constituents.
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2.3.2.3 Metabolism of OTA
Four metabolites of OTA are known so far (Fig 2.5). However no active 
forms of this toxin have so far been identified. OTA has been reported to 
be hydrolysed by proteolytic enzymes such as carboxypeptidase A and alpha- 
chymotrypsin, in vitro, with the formation of OT-alpha plus the amino acid 
PHE (Pitout, 1968). In vitro formation of OT-alpha by liver, small 
intestine and large intestine homogenates has also been reported by Doster 
and Sinnhuber (1972). This metabolite has also been found in vivo 
(Galtier et al., 1979). OT-alpha is much less toxic than the parent toxin 
in all acute in vivo and in vitro test systems assessed (Chu et al., 
1972) .
OTA is metabolized by rat liver microsomal fractions into more polar 
metabolites. Stormer and Pedersen (1980) identified a major metabolite 
(90% of the total product) as 4-OH-OTA. This metabolite has also been 
identified as a major urinary excretion product of OTA in rats.
4-OH-OTA has been shown to be non-toxic when single ip doses of 40 mg/kg 
were given to rats (Hutchinson and Steyn, 1971). Recently, human and pig 
liver microsomal fractions were shown to catalyze the formation of the 
isomers (4R)- and (4S)- OH-OTA (Stormer et al., 1981). The rates of
formation for the two metabolites varied from species to species. In 
humans and rats the major metabolite was the (R) isomer; whereas in pigs 
it was the (S) isomer.
Studies on the metabolism of OTA by primary cultures of rat hepatocytes at 
37° showed the formation of the (4R) and (4S) hydroxylated metabolites 
(Hansen et al., 1982). The major product was the (4R) isomer, and 4.4% 
of the substrate added was converted to this metabolite. A longer
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incubation time was needed for the detection of small amounts of (4S)-0H- 
OTA. A new metabolite, identified as 10-OH-OTA, has been reported to be
produced by rabbit liver microsomes in addition to the (4R) and (4S)
isomers (Stormer et al., 1983).
In comparing two rat strains phenotyped as extensive (Lewis) and slow
metabolizers of debrisoquine, it was observed that the former strain also 
extensively metabolized OTA to its 4-OH metabolite, both in vivo and in 
vitro (Hietanen et al., 1986). It was not suggested whether the 
hydroxylation took place in the cis or trans position.
The formation of all hydroxylated metabolites in the different species, is 
inhibited by the addition of carbon monoxide and metyrapone to the 
incubation system and is stimulated in vivo when animals are pretreated 
with phenobarbital, suggesting .that cytochrome P-450 catalyzes the 
reactions. This has been confirmed in a study where the metabolic 
transformation of OTA in the reconstituted cytochrome P-450 of the rat 
liver was investigated (Ueno, 1985) . Cytochrome P-450 Ila fractionated 
from PCB-microsomes plays a major role in the formation 4 (R)-4-OH-OTA 
whereas the formation of 4 (S)-4-OH-OTA was the highest with P-450 I-C.
As in the rat hepatic microsomal system, 4 (R)-4-OH-OTA was the major 
metabolite in the reconsitituted cytochrome P-450 system.
2.3.2.4 Excretion of OTA.
. . 14OTA is . excreted via faeces and urine. When C-labelled OTA was
administered in a single ip dose (lOmg/kg) to rats (Chang and Chu, 1977), 
the toxin was excreted primarily as the parent compound in the urine, as 
50% of the total radioactivity, during the first 24 hr. In the same period 
the excretion of OTA in the faeces was only 13%, and small proportions of
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OT-alpha, the hydrolysed product of the mycotoxin, were found in urine and 
faeces. These findings are in agreement with previous studies (Purchase 
and Nel, 1967; Nel and Purchase, 1968; Van Walbeek et al., 1971), in which 
OTA and also small amounts of OT-alpha were reported to be excreted in the 
urine and faeces of rats that had been given the toxin.
After single oral or iv doses (2.5 mg/kg) of 14C-labelled OTA given to
rats, the radioactivity excreted via faeces (56%) was greater than via
urine (32%) for up to ten days after the treatment (Galtier et al., 1979). 
The parent compound and OT-alpha were recovered in the faeces and urine, as 
the two main excretion products. Although 5 more metabolites were found in 
urine, they remained unidentified.
In another study, when OTA was administered to rats either ip or per os 
(6.6 mg/kg), the excretion of the toxin was mainly via urine (Storen et 
al, 1982), with OT-alpha as the main excretion product (26%), followed by 
OTA (6%). Small amounts of other metabolites were also found in urine, but 
not identified. Only traces of OTA and OT-alpha were found in faeces.
Few excretion studies have been'performed in other species. OTA, OT-alpha 
and OT-beta were found in the urine and faeces of pregnant pigs (Shreeve et 
al., 1976; Patterson et al., 1976), that were given a mixture of OTA and 
OTB. In cows fed on OTA, OT-alpha was the main excretion product in the
urine (Still, 1973). In another study in which high doses of OTA were
administered to cows (Ribelin et al., 1978), the toxin was found in milk 
and urine, in spite of previous reports on the capability of ruminal flora 
to hydrolyze OTA .into its non-toxic metabolite, OT-alpha, preventing the 
absorption of the toxin (Hult et al., 1976; Galtier and Alvinerie, 1976) .
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There is recent evidence to show that OTA undergoes enterohepatic
circulation in the rat as well as in the mouse. Fuchs et al., (1988)
.observed that OTA was rapidly excreted into the bile, in the conjugated
form, with the highest concentrations measured during the first 6 hr after
oral dosing. When the bile from OTA treated animals was administered to
untreated rats, either into the stomach or the duodenum, the toxin was
found in plasma, suggesting the existence of enterohepatic circulation for
OTA in rats. OTA measurements in plasma were performed 24 hr after the
administration of the toxin in bile, and no other time points were
assessed, nor were the levels in other tissues or fluids measured. There
was therefore no confirmation by other means. Roth and coworkers (1988)
3observed that after 1 m injection of H-OTA to mice, the mycotoxin was 
rapidly absorbed and distributed in the organs, and found in serum, bile, 
intestinal contents and urine 30 min after administration. When measured 
at other time points, a cyclic pattern was shown, that corresponded to the 
absorption from the intestine to serum and re-excretion through bile into 
the intestine. OT-alpha plus PHE were the metabolites found in intestinal 
content. In bile OTA was found mainly in conjugated form, although the 
hydroxylated metabolites and a small proportion of free OTA were also 
detected. When cholestyramine, an inhibitor of the enterohepatic
circulation was given prior to OTA, the elimination pattern of the toxin 
was completely changed, with smaller amounts of OTA being found in bile, 
indicating that the compound prevented OTA reabsorption from the intestine 
and confirming the enterohepatic circulation of OTA. Although PHE seemed 
to facilitate the absorption of OTA when both compounds were given 
simultaneously by gavage, the enterohepatic cycle of OTA appeared to be 
suppressed (Roth et al., 1988) . This could possibly have happened through 
competition between the two compounds for the metabolism of OTA by the
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intestinal microflora and by a competition for the . intestinal
reabsorption.
The urinary excretion of OTA has recently been shown to increase in mouse
. . . 3after simultaneous administration of H-OTA and PHE (Roth et al., 1988). 
The toxin was eliminated mainly as OT-alpha and PHE, and in the OTA and 
PHE treated animals, 40H-0TA was also found.
2.3.3 Biochemical effects of OTA
2 .3 .3 .1 Mitochondrial effects.
OTA inhibited respiration to 55% of the control at the concentration of
— 6 —42.1 x 10 M and completely blocked the respiration at 4.2 x 10 M. As the
presence of 2,4-dinitrophenol overcame the effect of the toxin, it was
concluded that OTA inhibited ADP-stimulated respiration by blocking some 
point in the mitochondrial respiratory chain beyond the action site of 
2,4-dinitrophenol (Moore and Truelove, 1970). Furthermore it has been 
demonstrated that OTA not only inhibits succinate-supported respiration, 
but also acts as a competitive inhibitor of mitochondrial transport 
carrier proteins such as ADP and Pi exchange proteins (Meisner and Chan, 
1974). However the exact site and action of the toxin in mitochondrial
respiration was not found.
More recently, it was found that when OTA was added to isolated liver 
mitochondria respiration was decreased as the concentration of the toxin 
increased (Wei et al., 1985). Mitochondrial respiration was gradually
uncoupled by the toxin when its concentration was raised above
-6 -41.2 x 10 M, and became fully uncoupled at 6.2 x 10 M. Oxidative
phosphorylation was not damaged until the toxin concentration was higher
-5 -4than 9.3 x 10 M and at concentrations above 1.0 x 10 M OTA inhibited
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the succinate dehydrogenase/ succinate-cytochrome C reductase, and 
succinate oxidase activites of the respiratory chain. The activities of
the latter two enzymes were decreased by 50% in the presence of
— 4 - 48.0 x 10 M and 6.2 x 10 M OTA, respectively. However, activities of
either cytochrome oxidase or NADH dehydrogenase in the mitochondrial 
respiratory chain were not inhibited by the mycotoxin. OTA exerts its 
effect on mitochondrial respiration and oxidative phosphorylation through 
alteration of the mitochondrial membrane and inhibition of the 
succinate-supported electron transfer activities of the respiratory chain. 
Inhibition of mitochondrial respiration and oxidative phosphorylation will 
diminish the supply of ATP, which is essential for the active transfer of 
molecules by the proximal tubular cells, thus causing impairment to the 
tubular reabsorptive functions.
2.3.3.2 Protein synthesis
3 . -5OTA inhibited protein synthesis from H-leucme by 60% when 9 x 10 M of
the toxin were incubated with cultured hepatoma cells (Creppy et al.,
1979a). There was also a delayed inhibition of RNA synthesis, which began
2.5 hr after treatment, and was probably a consequence of the effect on
protein synthesis. There was no inhibition of DNA synthesis up to 5 hr.
OTA induced inhibition of protein synthesis can be completely prevented if
PHE is present simultaneously in the cell culture medium at a
-5concentration of 5 x 10 M (Creppy et al., 1979a). The reversal of 
inhibition could be interpreted as an impairment of entry of OTA into the 
cells by a competition with PHE for some cell receptors.
MDCK cells were much more sensitive to OTA effects (Creppy et al., 198 6). 
Protein synthesis was inhibited by 94% and 50% when the cells were
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incubated with 2.5 and 1.5 x 10 ^ M of OTA respectively for 24 hr. Similar 
effects were obtained with the same concentrations of the toxin on RNA and 
DNA synthesis, suggesting that MDCK cells are very sensitive to the 
mycotoxin. With simultaneous addition of PHE and 2.5 x lO-'* M OTA, the 
inhibition of protein synthesis dropped from 94% only to 40%.
The metabolite (4R)-OH-OTA, which has been shown to be non-toxic in vivo 
(Hutchinson and Steyn, 1971), inhibited protein synthesis in hepatoma cell 
cultures within a few hours (Creppy et al., 1983). As this effect was also 
prevented by PHE and the metabolite OT-alpha had no effect i-t was 
suggested that the PHE moiety plays an important role in the toxicity of 
OTA.
The effects of OTA on protein synthesis have not been assessed in renal in 
vitro systems other than MDCK cells, such as isolated nephron segments, 
other cell lines, or isolated glomeruli or proximal tubular fragments.
3 3 .In vivo, renal protein synthesis from H-PHE or H-leucme (LEU) is
reduced by 30 - 40% in rats given 2 mg of OTA/kg/day, orally for two days
(Meisner and Meisner, 1981), and a single ip dose of 1 mg/kg OTA caused a
68% inhibition of protein synthesis in mice kidney, 5 hr after
administration of the toxin (Creppy et al., 1984). No other species have
been assessed for the in vivo effect of OTA on protein synthesis in
kidney.
OTA may act as an analogue of PHE with regard to aminoacylation of tRNA in 
bacteria and eucaryotes (Konrad and Roschenthaler, 1977; Nishino et al., 
1979; Creppy et al., 1979b), a reaction that is catalysed by PHE-tRNA 
synthetase (PheRS) and is essential for all living organisms. OTA
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competitively inhibited the formation of PHE-tRNA. The effect of OTA and 
its 4R epimer was tested in vitro on the catalytic action of PheRS
(Creppy et al., 1983), and both compounds inhibited the reaction by about
70%. This would suggest that the toxicity may be related to the inhibitory
effect on PheRS, perhaps due to the binding of OTA to the PHE sites of the 
enzyme.
2.3.3.3 Carbohydrate metabolism
The effect of OTA on carbohydrate metabolism in the liver has been
investigated in rats by. Suzuki et al., (1975a). The toxin caused 
depletion of hepatic glycogen, reduced activity of glycogen synthetase and 
increased serum glucose levels. By contrast, phosphorylase activity was 
increased. These effects were in part attributed to the inhibition of the 
active transport of glucose into liver tissue. In contrast to the OTA 
effect on carbohydrate metabolism in rats, Huff et al., (1979) found.that 
in chickens, liver glycogen levels were increased, implying inhibition of 
glycogenolysis. It was suggested that in this species OTA primarily 
affects cAMP-dependent protein kinase which .initiates the enzymatic 
cascade leading to glycogenolysis.
Regarding the kidney, which is considered the target toxicity organ, 
gluconeogenesis was inhibited in rats fed 2 mg/kg/day OTA for two days 
(Meisner and Selanik, 1979). Renal gluconeogenesis from pyruvate was 
decreased by 26%, and phosphoenol pyruvate carboxykinase (PEPCK) activity 
was lowered by about 55%. Hepatic PEPCK was unchanged or slightly 
increased; and hexokinase activity remained unaffected in both organs. The 
decrease in renal gluconeogenesis was therefore probably due to inhibition 
of PEPCK, which was decreased to a greater extent than gluconeogenesis.
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Furthermore, renal cytosplic PEPCK activity was inhibited by OTA in a dose
dependent pattern when the toxin was fed to rats (Meisner and Meisner,
1981). The enzyme's activity was inhibited 50% by a total OTA dose of 0.3 
0.5 mg, and renal gluconeogenic capacity was reduced only after PEPCK
activity had been inhibited by 50%. Hepatic PEPCK was unaffected. Other 
proximal , tubular enzymes such as gamma-glutamyl transpeptidase, pyruvate 
carboxylase and Na, K-ATPase were also not affected. Renal PEPCK was also 
inhibited in swine fed OTA for one to four weeks (Meisner and Krogh,
1982) .
Removal of the PHE group from the toxin, prevented the in vivo inhibition 
of PEPCK activity (Meisner and Meisner, 1981), suggesting that the- PHE 
residue of OTA may play a role in the enzyme inhibition.
Apart of the gluconeogenic pathway, there is no published data on the
study of other routes of carbohydrate metabolism in the kidney, with
relation to OTA toxicity, either in vivo or in vitro.
2.3.3.4 Effect of OTA on mRNA.
To find out whether the reduction of renal PEPCK activity was associated 
with a reduction in the level of mRNA coding for this enzyme Meisner et 
al., (1983) measured the effect of OTA on the level of translatable mRNA 
for PEPCK in kidneys of rats fed the toxin for 2 days. It was found that 
OTA greatly reduced the concentration of the mRNA coding for PEPCK in 
kidney, while the rate of transcription of PEPCK-RNA was not affected. The 
role played by these biochemical events in the pathology of OTA lesion is 
still unknown. The effect of OTA on mRNA pool size is a distinguishing 
feature of the biochemical action of the nephrotoxin. The reduction has 
been attributed to a rapid turnover on mRNAs (Meisner et al., 1983) .
A recent study in isolated kidney mRNA from rats fed OTA for 2 - 5 days,
identified several mRNAs whose concentration were changed within 2 days 
by the toxin (Meisner and Polsinelli, 1986). The transcription rate of 
each mRNA, was measured m  nuclei. The incorporation of P-UMP into PEPCK 
mRNA and the synthesis of other RNAs were not affected, suggesting that 
the toxin must therefore affect the concentration of certain mRNAs by a 
post-transcriptional mechanism, which has not been defined yet.
2.3.4 Nephrotoxic effects of OTA.
The major effect of OTA in animals is damage to the kidneys, both in field 
intoxications and in experimentally dosed animals. OTA is a major 
determinant of porcine nephropathy, a disease occurring endemically in 
several countries.
2.3.4.1 Porcine nephropathy.
This peculiar renal disorder of spontaneous occurrence in swine, and 
initially designated as "mold nephrosis", has been known in Denmark for 
many years and more recently in Sweden, and other European countries 
(Elling and Moller, 1973; Rutqvist et al, 1978; Sandor et al, 1982). The 
disease is now associated with the ingestion of feed contaminated with 
OTA. The histopathological changes which have been described include 
tubular degeneration and atrophy, accompanied by interstitial fibrosis. 
The changes in renal function are characterized by impairment of proximal 
tubular function (Elling and Moller, 1973).
Several workers have tried to reproduce the disease symptoms in 
experimental animals. Pigs exposed to A. ochraceus cultures or pure OTA
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in the range 0.2 to 2.0 mg/kg, developed renal damage within one to three
week's (Szczech, et al., 1973a). However, changes in other organs like
gastrointestinal tract, liver and lymphoid tissues and progressive
leukocytosis were also found, which may well be attributed to the high
levels of OTA used, amounts which are unlikely to be encountered in 
naturally contaminated feed. Alterations in renal function resulted in 
polydipsia, polyuria, low -urinary specific gravity, proteinuria, 
glucosuria, increased blood urea, and increased urinary excretion of 
lactate dehydrogenase, isocitrate dehydrogenase and glutamic oxaloacetic 
transaminase. Structurally necrosis of renal tubular epithelium was most 
frequent in the convoluted tubules and there were many dilated tubules.
Pigs fed naturally contaminated rations containing 0.2 - 4 ppm of OTA, or 
the pure toxin over four months, developed nephropathy identical to that 
in the spontaneously occurring cases, without changes in other organs or 
tissues different to the kidneys (Krogh et al., 1974; 1976). The toxin
doses corresponded to those naturally occurring in animal feed. The 
changes in renal function was characterized by impairment of proximal 
tubular function, indicated by decrease in transport capacity for p-amino 
hippuric acid, reduction in the ability to concentrate urine and by 
increased urinary excretion of glucose, leucine amino peptidase and 
proteins. Structurally there was degeneration of proximal tubules, 
interstitial formation of connective tissue, and at later stages 
development of atrophied and sclerotic glomerular tufts. Long-term 
administration of the toxin induced progressive nephropathy in pigs, 
without reaching a state of terminal renal failure (Krogh et al ., 1979),
with functional and morphologic, changes similar to those found in the 
previous studies with naturally contaminated feed given to pigs for three
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months (Krogh et al., 1974), and to those in spontaneously occurring
mycotoxic porcine nephropathy (Elling and Moller, 1973).
The examination of early structural changes in OTA-induced nephropathy 
after short-term exposure, identified a process of condensation of 
cellular material with disappearance of membranes and continuous 
desquamation in the lower part of the proximal convoluted tubules (Elling 
et al., 1985) . This process appeared to be linked to enhanced levels of 
peroxisomal beta-oxidation in the soluble kidney fractions.
2 . 3.4 .2 Avian nephropathy
Toxicity of OTA in poultry has also been observed. Spontaneous avian 
nephropathy associated with the ingestion of feed contaminated with OTA, 
has been reported in Denmark (Elling et al., X975), with frequencies 
similar-to those observed for porcine nephropathy in the same counties and 
during identical time periods. Structurally the lesions are characterized 
by degeneration of the tubular epithelium in the form of dilated tubules, 
"ballooning" and desquamation of epithelial cells. Giant nuclei are 
frequently seen in epithelial cells. These changes are accompanied by 
formation of interstitial fibrous tissue.
Avian nephropathy similar to spontaneously occurring cases was observed in 
chickens and hens following exposure to 0.3 and 1 ppm OTA feed during one 
year (Krogh et al., 1976). The histopathological changes were similar to 
those in the spontaneously occurring cases. The changes in renal function 
were characterized by impairment of glomerular and tubular function, as 
indicated by decreases in inulin clearance, maximum tubular secretion rate 
of p-amino hippuric acid and urine concentrating ability. The same 
alterations in renal function have been observed in hens fed OTA at levels
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of 0.3 - 1 ppm OTA for 4 9 weeks (Svendsen and Skadhauge 1976)
Sublethal concentrations of OTA ( 2 - 4  ppm) fed to young broiler chicks 
(Dwivedi and Burns, 1984) , mainly affected the proximal convoluted tubules 
of the kidney, causing severe distension, enlargement and hypertrophy, 
together with thickening of the glomerular basement membrane. There were 
changes in liver as well, such as vacuolation and glycogen accumulation in 
the hepatocytes. The toxin also caused regression of, and a drastic 
reduction in, the lymphoid cell population in the immunological organs. 
Nephrotoxicity, accompanied by hepatotoxic effects in OTA-fed chicks, have 
also been documented in other studies (Peckham et al., 1971.
Other effects of OTA in poultry have been described. The toxin causes 
impaired blood coagulation (Doerr et al., 1974), anaemia (Huff et al., 
1979), bone abnormalities (Huff et al 1980) and type X glycogen storage 
disease (Warren and Hamilton 1980).
OTA has also been shown to produce nephropathy in controlled laboratory 
studies in rats and acute doses have shown that the female is more 
sensitive. Fatal doses of OTA, led to severe necroses of the renal 
tubules, in particular the proximal tubules (Purchase and Theron 1968) . 
Necrosis of periportal cells in the liver was also seen. However, another 
study using sublethal doses of OTA, did not elicit any evidence of renal 
damage (Kanisawa et al., 1977), instead the administration of small 
repetitive doses were able to induce recognizable changes without killing 
the animal consisting of massive acidophilic degeneration with necrosis 
and. desquamation of the epithelium in the proximal tubules. Lymphatic 
tissues were also sensitive to the toxin, and hepatic changes were
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injected ip produced death, but this was not preceded by any alterations 
in renal function (Berndt and Hayes, 1979) . On the other hand, daily 
administration of OTA to rats in doses of 0.75 and 2 mg/kg for five days 
caused functional renal changes characterized by a significant depression 
of urine osmolality and increased excretion of protein and glucose. The 
requirement for repeated doses of OTA to produce an alteration of renal 
function, suggested the necessity for accumulation of the toxin before any 
overt nephrotoxic effect was noted.
Following a single oral dose of OTA (15 mg/kg) urinary enzyme activities 
were measured (Obara et al., 1984). Urinary excretion of alanine 
aminopeptidase and leucine aminopeptidase was significantly increased by 
OTA . When nephron segments were isolated, both enzymes were localized in 
the proximal tubule, showing much higher activity in the straight portion 
than in the convoluted one. Enzyme release from this part in the presence 
of OTA revealed a dose-dependent relationship and was inhibited by 
probenecid, and it was suggested that OTA might enter the proximal tubule 
cell through the basolateral membrane and release enzymes such as alanine 
aminopeptidase and leucine aminopeptidase located in the luminal brush 
border membrane.
Biochemical changes in urine and tissues from rats treated with 5 
consecutive daily doses of OTA (10 mg/kg) were studied (Ngaha, 1985) and 
found to consist of elevation of urine volume, urinary proteins, and 
enzymuria. Excretion of muramidase, was significantly raised 24 hr after 
the first dose, but increases in alkaline phosphatase, acid phosphatase, 
and glutamate dehydrogenase levels occurred very much later during the 
course of treatment with OTA. Kidney alkaline phosphatase and acid 
phosphatase, lactic dehydrogenase and glutamate dehydrogenase were reduced
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seven days after the beginning of the treatment.
In a subchronic study, the activities of 5 enzymes in urine and renal 
tubules were measured, following oral administration of small doses of OTA 
to rats (145 ug/kg per day for 8 - 1 2  weeks (Kane et al., 1986b). Urinary 
activity of gamma-glutamyl transpeptidase, alkaline phosphatase and 
leucine amino peptidase were increased after one week of the treatment, 
and N-acetyl-beta-D-glucosaminidase and lactic dehyrogenase activities 
remained normal. All the enzymes showed their maximun increase in the 
fourth week, followed by a decrease in week 5 - 7 ,  increasing again in the 
8th week and suggesting a cycle of degeneration and regeneration of the 
cells. However, histological studies were not performed to support this 
assumption. In tubules the activity of all the enzymes decreased, but N- 
acetyl-beta-D-glucosaminidase exhibited less decrease than other enzymes, 
suggesting that the effect of low doses of OTA is essentially directed 
towards the brush, border membrane and is slight on the lysosomal membrane. 
The study also showed that 20 ppm of phenylalanine partially prevented the 
nephrotoxic effects of OTA under subchronic conditions (Kane et al, 
198 6b).
In a subacute study in which rats were fed dietary levels of OTA (0.2 - 5 
mg/kg) for three months (Munro et al., 1974), renal damage, including 
desquamation of cells in the proximal tubules and thickening of the 
basement membrane was observed at all dose levels. Administration of high 
levels of ochratoxin A (5 mg/kg/day) to rats for three days, demonstrated 
an acute toxic effect on renal function in rats consisting of decrease of 
both inulin and p-aminohippuric acid clearance (Suzuki et al., 1975b). On 
histological examination, thickening of the basement membrane was observed 
and attributed to be the cause of the tubular malfunction.
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More recently the effects of low levels of OTA were investigated in 
partially nephrectomized rats (Stein et al., 1984). The changes in renal 
function were characterized by decreased urine osmolality and inulin, 
creatinine and p-aminohippurate clearances. The histopathological 
findings showed considerable renal tubular necrosis and subcellular 
damage. Although similar changes were observed in OTA-treated control 
animals, partially nephrectomized rats were more susceptible, not only 
with regard to renal function, but also in exhibiting enhanced 
morphological end points.
In spite of the fact that some studies have demonstrated that probenecid 
has a protective effect against nephrotoxicity of some compounds normally 
cleared by renal secretion (Tune, 1975; Berndt and Hayes 1982), such an 
effect against OTA-induced nephrotoxicity was not observed when probenecid 
was administered to rats before or simultaneously with the mycotoxin 
(Stein et al., 1985). On the contrary, the animals exhibited signs of 
increased nephrotoxicity which included significant decreases in urine 
osmolality, Na+ and K+ concentrations, body weight and increased OTA 
concentrations in the kidneys. However, histopathological data to support 
these findings were not reported.
The clinical and clinicopathologic features of experimental ochratoxicosis 
in dogs have been studied. The animals were exposed for one to three weeks 
to A. ochraceous cultures or crystalline OTA in the range to 0.2 to 3 
mg/kg (Szczech et al., 1973 b,c.). Changes in renal fuction were described 
as characterized by polydipsia, polyuria, low urinary specific gravity, 
glucosuria, proteinuria, and increased urinary excretion of the following
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enzymes: lactic dehydrogenase, isocitrate dehydrogenase, leucine
aminopeptidase, glutamic-piruvic transaminase, glutamic-oxaloacetic 
transaminase. Renal structural changes consisted of necrosis and 
desquamation of epithelial cells mainly but not exclusively . in proximal 
convoluted tubules. Additional findings were colitis, necrosis of lymphoid 
tissues and hepatic alterations. Ultrastructural changes were described 
primarily in the epithelial cells of renal proximal tubules (Szczech et 
al., 1974) .
2.3.5 Effect of combined OTA and ATB^ administration.
The effect of simultaneous administration of OTA and . ATB^ has been 
reported. In a chronic study in rats fed the toxins simultaneously, the 
collecting tubules showed degenerative changes in epithelial cells and 
some of these cells were anaplastic with hyperchromatic nuclei, after 4 
months of treatment (Rati et al., 1981). These changes were not observed 
in animals fed either OTA or ATB^, alone, suggesting that the combined 
action of the toxins might be synergistic.
In a study with chickens fed both OTA and ATB^ simultaneously for three 
weeks, the interaction between the mycotoxins was manifested by 
nephropathy as the primary effect (Huff and Doerr 1980). No 
histopathological assessment supported this interaction.
2.4 OTA and Balkan Endemic Nephropathy (BEN).
Balkan Endemic Nephropathy is a chronic disease affecting the human 
population in localised areas of Yugoslavia, Bulgaria and Rumania. 
Although the condition has been recognized since the 1950s, the astiology 
of the disease is still unknown.
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The clinical picture is of a slowly progressive renal degeneration, 
including proteinuria and uraemia, leading to end stage renal disease. The 
pathology of BEN (Fig. 2.6) shows shrunken kidneys with atrophied tubules 
interstitial nephritis and marked glomerular basement membrane thickening 
and hyalinization (Hall and Dammin, 1978). BEN is also associated with a 
high frequency of carcinoma of the renal pelvis, ureter and urinary 
bladder (Ceovic et al., 197 6; Chernozemsky et al., 1977; Nicolov et al., 
1978).
Various factors such as' bacterial infection, heavy metal toxicity, 
immunologic and genetic factors have been implicated in the aetiology of 
BEN, but as yet there is no conclusive evidence to definitively identify 
the causative agent(s). The hypothesis that mycotoxins may be involved in 
this disease, has emerged as the most probable (WHO, 1979; Krogh, 1972), 
in view of the higher frequency of OTA contamination that has been 
encountered in foods of endemic compared to disease-free areas (Krogh et 
al., 1977, Pavlovic et al., 1979) and of the higher levels of OTA bound to 
plasma proteins, that has been detected in inhabitants of endemics areas 
of Yugoslavia and Bulgaria than in control groups within or outside the 
endemic area (Hult, et al., 1982). Evidence for the involvement of OTA in 
BEN, is also based on the fact that the mycotoxin is a major disease 
determinant of porcine nephropathy (Krogh, 1978; 1979), in which the
pathological and functional features resemble those of the human disease 
(Table 2.4) . However the final determination as to whether OTA has a
causal role in BEN, awaits further evidence.
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Fig. 2.6
Pas stained section of BEN tissue showing sclerosis and thickening of Bowman’s 
capsule membrane (arrow) and the glomerular tuft together with fibrosis and tubular 
atrophy (xl72).
Table 2.4 Endemic (Balkan) nephropathy and ochratoxin A-induced 
porcine nephropathy (Krogh, 1977) .
Common features
Renal function
Impairment of proximal tubular function 
(decreased 
Subsequent impairment of glomerular 
function (decreased CIn)
Renal structure
Atrophy of tubules 
Hyalinization of glomeruli 
Interstitial fibrosis
Epidemiology
Endemic ocurrence 
Sex-specific distribution
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CHAPTER 3
THE GLOMERULUS AS A SITE OF TARGET TOXICITY 
3.1. Introduction
In spite of its small mass in relation to the body weight, the kidney 
receives approximately 25% of the resting cardiac output. Therefore, any 
drug or chemical capable of being excreted by the kidney, will be 
delivered to the organ in significant amounts from the systemic 
circulation, and will undergo concentration and dilution in different 
parts of the nephron.
The functional unit of the kidney is the nephron (Fig 3.1), which consists 
of the renal corpuscle (glomerulus), the proximal tubule, the thin limbs, 
the distal tubule and the connecting segment. The location of the renal 
corpuscles within the cortex, is the determining factor for three major 
types of nephrons: superficial, midcortical and juxtamedullary. There are
clear differences in the size of glomeruli and rates of filtration; 
juxtamedullary nephrons having a greater filtration rate (Ulfendahl et al, 
1981) .
The focus of most toxicological studies has been the proximal tubule, 
because of the large number of chemicals that damage this region, while 
the glomerulus has not generally been considered as an area affected by 
many toxic chemicals. Therefore there are, so far few studies on the 
effect on glomerular metabolism of compounds known to cause injury to the 
glomerulus. There are also several compounds known to cause renal injury,
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Fig* 3*1 Short looped
nephron on the left side, long looped nephron on the right 
side, /.renal corpuscle; 2,proximal convoluted tubule; 
3,proximal straight tubule; 4,distal descending thin limb 
of the loop of Henle; 5,ascending thin limb; d.thick as­
cending limb; 7,macula densa; S.distal convoluted tubule; 
9.connecting tubule (9*,arcade formed by connecting tu­
bule); 10,cortical collecting duct; //.outer medullary col­
lecting duct; /2,inner medullary collecting duct; /J.papil- 
lary collecting duct. Arrows indicate joining of other 
nephrons. Zonal division of the kidney: C.cortex; OM, 
outer medulla with outer stripe fOS/and inner stripe (IS):
IM ,inner medulla (From Bachmann et al, 1986)
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whose effects have mainly been related to tubular lesions. Among these 
chemicals there are some mycotoxins such as ochratoxin A, which have been
related to animal and human nephropathies, where there appear to be
glomerular involvement. In the case of BEN, although morphological
glomerular changes are present, these, and the clinical signs of the
disease appear so late that it has not been possible to have an accurate 
picture of the early degenerative events that lead to this condition. 
Therefore, it is necessary to determine the metabolic role played by 
glomeruli on the functional and morphological lesion caused by compounds 
such as ochratoxin A and by possibly several other chemicals (in which 
glomerular involvement may have been overlooked), and this has been • the 
aim of this study.
3.2. Glomerular Metabolism
The glomerulus (Fig 3.2) is the structural unit of the nephron whose 
function has been considered to be the passive filtration of molecules up 
to a certain size from the plasma into the tubules. However, its 
maintenance, regulation, and reaction to disease, suggests a more complex 
function, which involves the coordinated interaction among the different
cell types that constitute it (Table 3.1).
The normal function of the glomeruli requires the constant integration of 
many complex biochemical processes. Toxic insult to one or more of these
processes could alter or interrupt this integration and lead to a change
in renal function and eventually to irreversible morphological changes.
3.2.1. Methodological approaches
Current knowledge on glomerular biochemistry and metabolism (Table 3.2)
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Fig. 3.2 The glomerulus, a The major components o f a 
renal corpuscle are demonstrated. P.parietal epithelium; 
A/.podocyte o f the visceral epithelium; E,capillary endo­
thelial cell; M.mesangial cells; US.urinary space; ^ . a f ­
ferent arteriole; Tf.efferent arteriole. Next to the glomer­
ular arterioles the juxta-glomerular apparatus is seen with 
extraglomerular mesangial cells and the macula densa 
(MD). TEM, bar = 10 urn. bCross section o f a glomerular
capillary. An endothelial cell (E) is seen in contact with the 
mesangial cell (M). The basement membrane is indicat­
ed by the arrow; Pd, processes o f podocytes. TEM , 
bar= 1 um. cThe filtration barrier. The fenestration o f the 
endothelium (E) is open (arrows). The basement mem­
brane (BM)is three layered; the filtration slits between the 
podocyte foot processes (Pd) are bridged by slit dia­
phragms. TEM, bar =  0.5 pm
(From Bachmann et al, 1986)
TABLE 3.1. Summary of the Functions of the constituents of the 
filtration barrier
FILTRATION OTHER
Endothelium: 'Valve' which controls
access of filtrate to 
the GBM
SYNTHESIS OF GBM
Basement
Membrane
Epithelium:
Main filter 
(size and charge)
a
Monitors filtrate and 
recovers lost protein 
(by endocytocis)
Regulates hydraulic flux 
by providing "porous support" 
for GBM
SYNTHESIS OF GBM
Mesangium: Phagocytosis of filtration
residues (particles, immune 
complexes, etc.)
REMOVAL OF GBM 
CONTRACTION
From Farquhar (1978)
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TABLE 3.2. Summary of the Biochemical Characteristics of Glomeruli
1. Energy producing metabolism.
Glycolysis 
Gluconeogenesis.
Pentose phosphate shunt 
Lipid oxidation.
2. Metabolism of structural compounds.
Proteosynthesis 
Synthesis of nucleic acids.
Synthesis of membrane components.
a
Metabolism of extracellular glomerular matrix (GBM and MM).
3. Metabolism of regulatory substances.
Synthesis of chemical mediators:
Prostaglandins.
Renin
Synthesis and catabolism of histamine.
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has been obtained mainly from studies using isolated glomeruli.
Different procedures have been used to isolate glomeruli for metabolic or 
biochemical studies. Microdissection of fresh or frozen tissue (Imbert et 
al, 1974; Burch et al, 1980) gives a preparation of the highest purity, 
but the total amount of tissue obtained is so little that the method 
cannot be used routinely.
Larger-scale isolation of glomeruli has been performed by mechanical 
mincing and/or enzymatic digestion of the cortex, followed by sequential 
sieving and centrifugation (Misra, 1972), by perfusing the kidney with 
particulate iron oxide, followed by the harvesting of glomeruli with a 
magnet (Meezan, et al 1973), and by other modifications of these basic
methods (Dousa, 1981) . Highly purified preparations of intact glomeruli,
most of them without Bowman's capsule, can be obtained by these methods 
with relative faility and no need of sophisticated or expensive
apparatus. Although minor structural damage is caused to the glomeruli 
(Noorgard,1976), the preparations are generally well preserved and 
maintain many of their metabolic functions for several hours, and are 
therefore isuitable for specific biochemical studies.
In addition, studies on isolated glomeruli offer several advantages over 
both the intact animal and other in vitro techniques such as perfusion, 
slices and isolated cells. Contrary to in vivo studies, considerable 
information can be obtained with the use of small numbers of animals and 
several different parameters can be assessed from the same tissue,
allowing comparison of data, while minimizing tissue variability. Isolated 
glomeruli allow the study of glomerular characteristics, or functions as 
well as metabolic properties, in a defined environment and independent of
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haemodynamic changes or other extraglomerular factors. This permits the 
distinction of direct and indirect effects and the assessment of precise 
dose-effect and time-course relationships for a given chemical.
Studies with isolated glomeruli however, have some limitations, some of 
which are inherent to most in vitro systems, such as the short viability 
which restricts the study of morphological and biochemical effects to the
investigation of acute responses following a toxic insult. In addition,
due to the cellular heterogeneity it is not possible to correlate the 
observations to specific cell types. In the in vitro situation, the
chemical is not presented to the glomeruli as part of the blood supply.
There is no previous metabolism, no plasma binding, and no pharmacokinetic 
distribution of the compound. Therefore, the interpretation and 
extrapolation of data from observations performed on isolated glomeruli 
may present some difficulties and care must be taken in interpreting the 
results and in deciding what is or is not an artifact, as the conclusions 
have to be compatible with what occurs in vivo. Although histochemical 
studies of kidney' tissue have also given useful information about the 
biochemistry of glomeruli (Burch et al, 1980; Dousa et al, 1977; Nevins 
and Michael, 1981) by providing precise information on the localization of 
specific biochemical characteristics, the major limitation of the method 
is that it can not be used to study dynamic metabolic processes.
Other studies on glomerular metabolism, have employed freshly isolated 
cells (Camazine et al, 1976), and different glomerular cell types in 
culture. Although the culture of glomerular cells has been limited by 
problems common to all tissue culture (dedifferentiation, loss of 
polarity, etc), and the origin and preserved differentiation of each cell
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type are controversial (Foidart et al, 1981), this could be another 
useful approach to gaining knowledge on the glomerular cell metabolism. 
This topic has been reviewed elsewhere (Foidart et al, 1981; Kreisberg 
and Karnovsky, 1983; Striker and Striker, 1985).
3.2.2. Intermediary Metabolism in Glomeruli
3.2.2.1. Enercrv-producinq metabolism
Studies on isolated glomeruli have shown that this part of the nephron has 
a high energy turnover. Oxygen consumption and production of CO2  from 
different radiolabeled substrates have been the parameters measured to 
determine the rates of energy (ATP)-producing glomerular metabolism 
(Gregoire et al, 197 6). The ATP content of glomeruli in situ is similar 
to (or only slightly lower than) that in the proximal tubular and 
medullary tubular segments i.e. 8 mmol/kg for glomeruli vs. 10 mmol/kg dry 
weight for proximal tubular segments (Burch et al, 1980), indicating a 
high metabolic activity.
A variety of intermediary substrates are known to be utilized by isolated 
glomeruli. For example, oxidation of carbohydrates, and fatty acids has 
been demonstrated in preparations of isolated glomeruli (Fong and 
Drummond, 1969; Brendel and Meezan, 1973), and the presence of 
tricarboxylic acid cycle activity was observed by Nowinski and Pigon 
(1967) . However, in comparison with renal tubules, lower activities of 
some key tricarboxylic acid cycle enzymes, such as isocitrate and 
succinate dehydrogenase, are present in glomeruli (Schmidt and Guder, 
1976), as it is the activity of glomerular glucose-6-phosphate 
dehydrogenase a key enzyme of the hexose monophosphate shunt.
Other in vitro studies have suggested that respiration of glomeruli is
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also lower than in cortical tubules (Gregoire, 1975; Gregoire et al, 
1976). However, the respiration rates measured in isolated glomeruli 
(Brendel and Meezan, 1973) and cortical slices (Cohen and Barac-Nieto, 
1973) showed similar values, suggesting a high metabolic rate for 
glomeruli. Isolated rat glomeruli are also capable of gluconeogenesis at a 
rate comparable to that observed in tubules (Brendel and Meezan, 1973).. 
Thus, there is evidence to suggest that glomeruli have a quite high 
metabolic rate, and it is believed that the energy released is utilized to 
build the specific cellular and extracellular structures required to 
accomplish their specialized functions.
3.2.2.2 Metabolism of structural components of glomerular cells 
Isolated glomeruli are capable of incorporating aminoacids and glucosamine 
into macromolecules (Walker and Hulter, 1969; Brendel and Meezan, 1973), 
indicating that glycoproteins and glycosaminoglycans (GAG) are synthesised
(Kornfeld and Ginsburg, 1966). Isolated glomeruli have been reported to
3 . . 3incorporate H-cytidine (Walker and Hulter, 1969) and H-uridine (Brendel
and Meezan, 1973) into RNA. This indicates that major biosynthetic 
pathways that are common to all tissues, involving protein, nucleic acids, 
and membrane components in general, are present in glomeruli.
The main function of the glomerulus as a refined and highly specialized 
ultrafilter relies on the metabolism of its complex extracellular matrix, 
which needs to be continually synthesized and maintained by the glomerular 
cells (Venkatachalam and Rennke, 1980). It appears that the metabolic 
processes involving synthesis and catabolism of glomerular basement 
membrane are unique to the glomeruli, or much more prominent here as 
compared with other parts of the nephron.
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The biosynthesis of extracellular matrix is a very intricate process, 
since it involves the formation of complex macromolecular compounds such 
as collagen, glycoproteins and GAG (Kefalides et al, 1979; Lindahl and 
Hook,1978; Spiro, 1969).
Biosynthesis of components of the glomerular matrix has been studied in 
vivo and in vitro in isolated glomeruli (Brown et al, 1981), isolated GBM 
and tissue-cultured glomerular cells (Foidart et al, 1980a,b; Oberley 
et al., 1979). Several approaches have been used, like incorporation of 
radiolabelled precursors such as aminoacids, monosaccharides and sulphate, 
and the determination of post-transcriptional side-chain modifications 
such as the hydroxylation of proline and hydroxylysine, sulphatation of 
GAG and glycosylation of collagen. Labelled proline and lysine are 
incorporated in isolated glomeruli, and carbohydrate-rich proteins, 
containing OH-lysine and OH-proline, are synthesized, indicating the 
formation of collagen-like protein (Grant et al, 1975).
In vitro and in vivo studies on the biosynthesis of components of 
glomerular matrix indicate that non-collagenous glomerular proteins are 
rather quickly synthetized and incorporated, whereas collagenous 
components are deposited at a slower rate (Hjelle et al, 1979). The 
turnover of GBM collagen takes about 100 days which is slower than the 
turnover of non-collagen glomerular proteins which takes only 9 days 
(Price and Spiro, 1977).
In relation to the catabolism of GBM components, a role of the hydrolytic 
actions of lysosomal enzymes in the metabolism of glomerular extracellular 
matrix has been suggested (Davies et al, 1980a,b; Davies and Bonney, 1980;
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Dousa et al, 1980; Matsuo and Yamada, 1980; Velosa et al, 1980; 1981).
There is evidence that both epithelial and endothelial cells are involved 
in the synthesis of GBM components and that mesangial cells are active in 
removal and catabolism of extracellular matrix (Michael et al, 1980; 
Nayyar et al, 1980) as well as in its biosynthesis (Foidart et al, 1980b).
3.2.2.2.1 Composition of GBM
Collagens type IV and V have been localized to the mesangial matrix region 
of the glomerulus as well as to the peripheral capillary wall (Courtoy et 
al, 1980a; Scheinman, 1980; Houser et al., 1982). Type IV collagen is 
largely concentrated in the lamina densa of the GBM - Fig. 3.3A - (Roll et 
al, 1980). The collagenous component of the GBM is secreted in the form 
of procollagen and is deposited in the extracellular matrix without any 
further reduction in molecular size (Kefalides, 1978).
The procollagen molecule is composed of a collagen tripple-helix having 
non-helical, largely non-collagenous extensions at the carboxyl and amino 
termini (Fig. 3.4). The procollagen molecules are thought to interact with 
one or more glycoproteins, non-collagenous in nature. The relative 
proportion of procollagen in GBM is approximately 25% (Kefalides, 1981). 
The procollagen and non-collagen glycoproteins interact via hydrogen bonds 
and disulphide cross-linkages. The amino acids composition of the intact 
GBM (Table 3.3) shows a high content of the aminoacids proline and 3- and 
4-hydroxyproline, of the non-polar amino acid glycine and the basic 
aminoacid hydroxylysine; resulting in high ratios of 3-hydroxyproline to 
total hydroxyproline, and hydroxylysine to lysine (Kefalides et al, 1979; 
Spiro, 1969 and 1973). The monosaccharides constitute approximately 10%
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TABLE 3.3.
Amino acid and carbohydrate components of glomerular basement membranes3 .
Component Human GBMb Rat GBMC
Hydroxylysine 24.5 36.7
Lysine 26.0 19.9
Histidine 18.7 14.5
Arginine 48.3 42.7
3-Hydroxyproline 7.0 4.4
4-Hydroxyproline 66.0 91.7
Aspartic acid 65.0 60.2
Threonine 40.0 32.7
Serine 60.0 51.3
Glutamic acid 103.0 82.0
Proline 62.0 72.0
Glycine 227.0 240.3 .
Alanine 58.0 55.9
Half-cystine 2^.0 13.2
Valine 36.0 37.7
Methionine 7.0 14.1
Isoleucine 28.0 27.3
Leucine 66.0 57.8
Tyrosine 14.5 15.2
. Phenylalanine 28.0 27.8
Glucose 2.5 2.41
Galactose 2.6 2.15
Mannose 1.7 0.81
Fucose 0.7 0.20
Glucosamine 1.7
Galactosamine 0.3
Sialic acid 1.5
N-Acetylneuraminic acid 1.00
N-Acetylgalactosamine 1.08
N-Acetylglucosamine 0.23
Amino acids expressed as residues per 1000 residues; carbohydrates 
expressed as grams of sugar per 100 gm. 
bKefalides (1971) 
cKoide et al (1981)
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of GBM material, and is composed largely of galactose and glucose and 
amino sugars and other monosaccharides such as glucosamine, galactosamine, 
mannose, fucose and sialic acid, are present in significant amounts 
(Kefalides et al, 1979; Spiro, 1973; Wargo et al, 1982). The 
oligosaccharide units are linked to asparagine.
The non-collagenous components of the GBM include the sulphated 
glycosaminoglycans (GAG), fibronectin, laminin and entactin. The major 
sulphated GAG synthesized by cultured human and rat glomerular epithelial 
cells is heparan sulphate (Striker et al, 1980; Foidart et al, 1980b). 
This component of GBM contributes significantly to the total anionic 
charges of the GBM and of the entire glomerular capillary wall (Kanwar and 
Farquhar, 1979). The main localization includes lamina rarae and MM 
(Fig.3.3B). Heparan sulphate appears to be linked to the collagen backbone 
of the GBM by disulfide bonds (Parthasarathy and Spiro, 1981). It has a 
high content of uronic acids (glucuronic and iduronic), N-linked sulphur, 
xylose and serine. It has been suggested that the polysaccharide chains 
are attached to the polypeptide via xylose-serine covalent links 
(Kefalides, 1981).
The non-collagen glycoproteins are believed to play a vital role in the 
adhesion of the glomerular components. Fibronectin is known to be involved 
in cell-to-cell and cell-to-substrate attachment (Yamada and Olden, 1978) 
and it is located mainly in the mesangial matrix, at the interface between 
mesangial and endothelial cells, and to a lesser extent in the lamina rarae 
of the GBM - Fig. 3.3C- (Courtoy et al, 1980a,b; Houser et al, 1982; 
Oberley et al, 1979). Two subunits constitute the molecule of fibronectin 
which are connected by a disulfide bridge. Asparagine acid residues 
connect fibronectin oligosaccharide components to polypeptides (Yamada and
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Olden, 1978), there are also sialic acids in the terminal positions of the 
oligosaccharides. The amino acid composition of fibronectin is shown in 
Table 3.4. Residues of aromatic amino acids such as TRP and TYR appear to 
play an important role in the secondary and tertiary structure of 
fibronectin. The intactness of these residues seems t^o be necessary for 
cell spreading, cytoagglutinating process, and therefore for adhesive 
activity (Yamada and Olden, 1978; Yamada, 1983).
Cultured glomerular epithelial and mesangial cells from humans and rats 
have been shown to be capable of producing fibronectin (Fish et al, 1975; 
Scheinman and Fish, 1978; Oberley et al, 1979; Foidart et al, 1980b). 
Cellular . fibronectin is synthesized in the rough endoplamic reticulum 
(Yamada et al, 1980; Hedman, 1980) as a monomer with high mannose 
oligosaccharides, and rapidly becomes a disulfide-linked dimer, and after 
some molecular rearrangements, is secreted via the Golgi apparatus ’(Olden 
and Yamada 1977; Choi and Hynes, 1979; Olden et al, 1980; Uchida et al, 
i980) . Fibronectin undergoes protein turnover on the cell surface (Olden 
and Yamada, 1977). It has been suggested that fibronectin levels on the 
cell surface can be modulated by a variety of events such as altered 
growth conditions, transformation, hormonal stimulation, and embryonic 
differentiation (Yamada, 1983). This regulation may occur through altered 
synthesis, turnover or binding to the cell surface, but the mechanisms of 
these effects remain to be determined. These studies have been conducted 
on different cells other than glomerular ones, therefore it is necessary 
to perform studies on the role of fibronectin in glomeruli and the effect 
of chemical toxicity on this part of the nephron.
Laminin is a sialoglycoprotein similar to fibronectin, but it differs in
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TABLE 3.4
Amino Acid and Carbohydrate Compositions of Fibronectin
Amino acid
Bovine' 
(g of amino
a Human*3 
acid/100 g of protein)
Aspartic acid 9.1 9.3
Threonine 9.8 9.7
Serine 8.0 6.8
Glutamic acid 11.4 11.6
Proline 7.9 7.6
Glycine 9.1 8.0
Alanine 4.6 4.3
Cystine 2.0 2.6
Valine 7.6 8.1
Methionine 1.0 1.1
Isoleucine 4.3 4.4
Leucine 5.6 5.7
Tyrosine 4.0 4.5
Phenylalanine 2.2 2.7
Lysine 3.9 3.6
Histidine 1.8 2.1
Arginine 5.2 5.2
Tryptophan 1.8 2.8
Carbohydrate
Hexose (%) 1.8 1.8
Hexosamine (%) 2.2 2.1
Sialic acid (%) 1.1 1.2
Total (%) 5.1 5.1
aFrom Iwanaga et al.(1978). 
^From Mosesson et al. (1975) .
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its amino acid composition and immunologic reactivity (Timpl et al, 1979). 
This protein is involved primarily in attachment of epithelial cells onto 
collagenous substrates, such as collagen type IV (Courtoy et al, 1982) . 
Laminin has been localized to the lamina rarae of the peripheral capillary 
wall in the rat and human glomerulus - Fig. 3.3C - (Courtoy et al, 1980a; 
Scheinman et al, 1980; Madri et al, 1980).
Entactin, a sulphated glycoprotein, has been localized to the lamina rarae 
of the rat GBM as well as the mesangium and may also be involved in cell 
adhesion (Bender et al, 1981; Carlin et al., 1981). Table 3.5 shows the 
amino acid composition of entactin.
3.2.3. Glomeruli as site of synthesis of prostaglandins
Another unique property of glomeruli is their ability to synthesize 
chemical mediators, such as prostaglandins which are related to glomerular 
functions and which are also believed to contribute to the major 
pathophysiological events leading to glomerular changes.
The prostaglandin-forming enzyme cyclooxygenase has been localized in the 
mesangial cells by immunofluorescence (Smith and Bell, 1978), its specific 
activity (per mg protein) is 10 - 40 times higher in glomeruli than in 
cortical tubules (Hassid et al, 1979), and it is also higher than in the 
renal medullary region suggesting an important role in glomerular 
physiology.
Subsequently, isolated rat glomeruli have been shown to convert 
arachidonic acid to prostaglandins and thromboxanes which accumulate in 
the incubation medium, (Folkert and Schlondorf, 1979; Hassid et al, 1979) .
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Prostacyclins and thromboxanes have also been detected. The glomeruli 
seem to be the major site of prostaglandin production in the cortex.
Glomerular prostaglandin synthesis may be modulated by kinins such as 
angiotensin II (Schlondorff et al, 1980) which has functional consequences 
on glomeruli, since prostaglandins can reduce the angiotensin II-induced 
reduction of glomerular surface area thus modulating contractile 
properties of the mesangium and therefore influencing GFR. Glomerular 
prostaglandin synthesis also increased by reactive oxygen species (Baud et 
al, 1981).
The role of prostaglandins in glomerular physiology appears to be related 
to the secretion of renin, and to the vasoreactivity of the glomerular 
capillaries and their permeability to water.
3.3 Metabolic changes in glomeruli induced by toxic injury
Glomerular metabolism may be changed by toxic insult or disease. Damage to 
glomeruli after toxic injury has been mainly assessed by morphological 
changes, and there is still a lack of knowledge on the early biochemical 
alterations which lead to the loss of t h e ■ structural and functional 
properties of the filtration barrier.
Among the compounds that are recognized to cause injury to the glomeruli, 
puromycin aminonucleoside (PAN) has been the most extensively studied. In 
glomeruli isolated from rats with PAN-induced nephrotic syndrome, the 
oxidative metabolism of glucose and alanine was markedly decreased (Kaplan 
et al, 1974) ; while other substrates such as acetate and citric acid were 
unaffected. Histochemical studies on several enzymes showed increased 
activities of glucose-6-phosphate, lactate and malic dehydrogenase (Dubach
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and Recant, 1960; Kissane and Hoff, 1962).
When incorporation of radiolabeled proline into glomerular protein was 
measured (Blau and Michael, 1971), increased incorporation was observed in 
glomeruli from PAN-treated rats, which was converted to hydroxyproline. 
Kefalides and Forsell-Knott (1970) reported that the GBM of PAN nephrotic 
rats contained lower amounts of hydroxylyisine and hydroxyproline and 
higher amounts of lysine and proline than in the controls, suggesting that 
the compound could interfere with the hydroxylation of both amino acids by 
inhibiting the proline and lysine hydroxylase enzymes. However this has 
not been confirmed in other studies.
Although depletion of the sialoglycoprotein coat on the surface of 
glomerular epithelial cells of PAN-treated rats with consequent loss of 
the negative charges on the surface of glomerular epithelial cells, and 
decreased content of sialic acid in GBM has been observed in histochemical 
studies (Michael et al, 1970), there was an increase in the rate of
sialic acid catabolism, with secondary enhanced synthesis and increased
3 . . .incorporation of H-glucosamine into glycoproteins of the glomeruli (Blau
and Michael, 1972). Repair of the anionic coat may account for this 
effect. By constrast no changes on sialic acid content were found by 
another group (Kefalides and Forsell-Knott, 1970). Methodological 
differences may have been responsible for the conflicting findings.
There was a decrease in GBM heparan sulphate content as shown by 
immunohistochemistry, after PAN treatment (Caulfield and Farquhar, 1978 
Mynderse et al, 1983). However when the synthesis of GAG was assessed on 
isolated nephrotic glomeruli of PAN treated rats, it did not appear to be
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a net change in the heparan content of the GBM, but increased synthesis
of new, lower molecular weight heparan-sulphate proteoglycans was observed
(Klein et al, 1984). This is in agreement with published observations on
perfused kidneys of PAN treated rats (Lelongt et al, 1987), which describe
a generalized increase in the synthesis of heparan sulphate-proteoglycan,
35as shown by the increase incorporation of S-sulphate. However, no 
significant changes in the macromolecula.r composition of heparan sulphate- 
proteoglycan were detected. The differences in the techniques applied may 
account for the different species of the GBM component synthesised.
Regarding the catabolism of GBM components and the role played by the 
lysosomal enzymes, it is important to mention that in PAN nephrotic rat 
kidneys the number and sizes of lysosomes were found to be increased in 
glomerular epithelial and mesangial cells (Cauldfield et al, 1976; Grond 
and Elema, 1981). This suggests that the changes in the amount of acidic 
glycoproteins and acidic GAG of the glomerular matrix in aminonucieoside 
nephrosis could be due to an accelerated breakdown by lysosomal enzymes, 
or an accumulation blocking the turnover of other material.
Studies on glomerular epithelial cells in culture exposed to PAN, showed 
immediate and marked depression in the utilization of precursors of 
protein, sugar, and sialoprotein synthesis (Fishman and Karnovsky, 1985). 
Incorporation of these precursors returned to control levels after a brief 
or continuous exposure to PAN, suggesting that metabolic pathways other 
than those involved in the uptake of glycoprotein precursors must be 
injured in PAN exposure.
Oxidative metabolism of glucose and palmitic acid was studied in isolated 
glomeruli from rats pretreated with nephrotoxic serum (Fong and Drummond,
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1969). There was marked increase in the oxidation rates of the two 
compounds. Although enzymatic activity was not measured, there exists the 
possibility of increased enzymatic activity in the tricarboxylic acid 
cycle (Dubach and Recant, 1960) that may account for this effect. It has 
also been reported that in nephrotic serum nephritis, both the turnover 
of glomerular sialic acid and hydroxyproline and the uptake of N-acetyl 
glucosamine were increased (Chow and Drummond, 1969).
The effects of adriamycin on glomeruli, have been studied mainly from the
ultrastructural point of view, where thickening of basement membrane,
fusion and detachment of foot processes and focal dilation of cisternae of
the rough endoplasmic reticulum (Bertani et al, 1982). There are few
studies concerning the effect of this compound in glomerular metabolism.
3 . . .Incorporation of H-proline into isolated rat glomeruli exposed to a 
concentration of 32 uM adriamycin was decreased by 70%; of the total amino 
acid incorporated into glomeruli, 55% was shown to be incorporated into 
GBM. The incorporation of radioactive lysine and histidine were not 
affected by the same concentration of the drug (Ahmed et al, 1987) . This 
suggests that proline incorporation into glomerular and GBM protein is 
sensitive to adriamycin and may be a selective index of glomerular 
toxicity.
Isolated glomeruli of nephrotic rats that had been administered 
adriamycin, showed abnormal arachidonic acid metabolism which led to a 
significant increase in thromboxane generation (Remuzzi et al, 1985). This 
may be in connection with alterations of GBM permeability to proteins.
Further metabolic studies in glomeruli affected by adriamycin toxicity,
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are necessary to fully elucidate the mechanism of toxicity of the compound 
on this part of the nephron.
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CHAPTER 4
MATERIALS AMD METHODS
4.1. Materials and Instrumentation.
4.1.1. Chemicals
All chemicals used were analytical reagent grades or of the highest purity 
that is commercially available unless otherwise specified. They are listed 
according to the suppliers. Water for analysis was glass distilled.
Adriamycin was a gift from Carlo Erba (St Albans, Hertfordshire).
Gamma-glutamyl-p-nitroanilide, glycylglycine, naphtylethylene-diamine 
dihydrochloride, p-nitroanilide 1-alanine-p-nitro aniline, ochratoxin A, 
aflatoxin HEPES, Earles salts, Tris, BSA, . L-tryptophan, L-
phenylalanine, L-tyrosine, L-leucine, L-histidine, glucose, collagenase, 
puromycin aminonucleoside, streptomycin, folic acid and ethacrynic acid, 
were purchased from the Sigma London Chemical Co Ltd (Poole, Dorset).
9
2-methoxy-4 (2 -nitrovinyl)-phenol (MNP); and MNP-2-acetamindo-2-deoxy- 
beta-D-glucopyranoside were obtained from Dr R Price, University of 
London, London, UK.
Alkaline phosphatase OPT KIT, Glucose Rapide Test and Protein Kit, were 
supplied by Roche (Welwyn Garden, Hertfordshire).
3 3 . i 3 . 3 . 3  . 3H-glycine, H-histidme, H-leucme, H-lysme, H-phenylalanme, H-
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proline, ^H-tryptophan, ^H-tyrosine, /^C-glucose, 14C-linolenic acid, ^ C -
. 14 , 14 . 14 ,
oleic acid, C-steanc acid, C-palmitic acid and C-mevalonic acid, 
were purchased from Amersham . International P.lc (Aylesbury, 
Buckinghamshire).
2-bromoethanamine, methanol, dimethyl sulphoxide, DPX and fibrowax were 
obtained from British Drug House Ltd (Poole, Dorset).
Haematoxylin and eosin were supplied by Gurr/British Drug House.
OptiSafe scintillant liquid was purchased from LKB.
All the photographic material was supplied by Eastman Kodak Co. 
(Rochester, USA).
4.1.2. Instrumentation
Lambda Spectrophotometer (Perkin Elmer Corp, Norwalk, USA).
Cobas Bio Centrifugal autoanalyser (Roche Diagnostica, Roche Products Ltd, 
Welwyn Garden, Hertfordshire).
Histokinette Automatic Tissue Processor (British American Optical Co Ltd, 
Slough, Berkshire).
Rotary microtome (American Optical, P.A., U.S.A.).
1219 Rack beta scintillation counter (LKB, Wallak, Finland).
Leitz Dialux 400 microscope (E. Leitz Instruments Ltd, Luton, UK).
TJ-6 Centrifuge (Beckman Instruments, Paloalto, Cal., USA).
Phase Contrast light microscopy (Nikon Instruments UK Ltd, Telford, 
Shropshire).
Leitz Dialux 20 microscope (E. Leitz Instruments Ltd, Luton, UK) with 
attached Nikon UFX-II Photographic Camera (Nikon Instruments UK Ltd, 
Telford, Shropshire).
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Stainless steel sieves (Endecotts, London).
Plastic scintillation vials, Plastic cuvettes, Pyrex conical flasks, G/FA 
glass-fibre discs (Whatman) and rubber Suba-Seal stoppers, were supplied 
by FSA Laboratory Supplies, Loughborough, Leics.
Plastic centre wells (Burkard, Scientific (Sales) Ltd, Uxbridge, Middx). 
Paraffin wax embedding oven (R.A. Lamb, London).
4.1.3. Animals
Male Wistar rats, University of Surrey strain (Guildford, Surrey). ' Large 
White pig kidneys (Steve Chitty and Sons Ltd, Dorking, Surrey).
4.2. METHODS
4.2.1. In vivo experiments
4.2.1.1. Animals
Wistar rats, with an initial weight of approximately 200 g, were -housed 
in plastic cages (North Kent Plastic Cages Ltd, GSI), with free access to 
food (Laboratory Animal Diet No. 1 pellets. Labsure Laboratory Animal 
Diets Poole, Dorset) and tap water. The animals were kept in a controlled 
environment, of 22°C temperature and 40-50% humidity, and a cycle of 12:12 
hours light:dark starting at 0700 hr GMT. For collection of urine for the 
single dose regime, the animals were kept in plastic metabolic cages 
(Techniplast. Code 1700872 Forth-Tech Services, Dalkeith) designed for 
separate collection of urine and faeces, and fed Lab Diet 2 Powdered Diet 
(Spratts, Barking). For the repeated doses regime, the animals were kept 
in metallic metabolic cages under 18-hr food restriction, and had access 
to food for 6-hr periods (1200-1800 hr daily). Tap water was supplied ad 
libitum.
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4.2 .1.2. Urinalysis
Urine samples were refrigerated for the entire period of collection, after 
which they were centrifuged at 3000 r.p.m. for 15 min, to separate debris 
and particulate matter. The supernatant of the urine was diluted as 
appropriate for each enzyme determination, and GGT, ALP and NAG activity 
were measured the same day of collection. Samples for protein and glucose 
were frozen at -20°C and analysed within one. week of collection.
4.2.1.2.1. Gamma-Glutamyl Transpeptidase (GGT)
The assay is based on the transfer of the glutamyl group from 1-glutamyl- 
p-nitroanilide to glycylglycine catalyzed by GGT as follows (Naftaline et 
al, 1969):
L-glutamyl-p-nitroanilide + glycylglycine. GGT ----> p-nitroaniline +
glutamyl glycylglycine.
The para-nitro aniline liberated is then diazotized:
p-Nitro aniline + NaN02 ----- > acid diazo compound.
Diazo compound + N-(1-naphtyl)-ethylene diamine — — > pink azo-dye.
The absorbance of- the pink azo-dye is measured at 540 nm, and is 
proportional to GGT activity.
Reagents
0.1 M Tris-HCl buffer, pH 9.0
Substrate solution: 4.6 mM L-gamma-glutamyl-p-nitroanilide.
0.1 M glycylglycine in 0.1 M Tris-HCl buffer, pH 9.0 
0.1 % Sodium nitrate.
1 % Ammonium sulphamate.
2 mM Naphthylethylenediamine dihydrochloride.
0.1 M p-Nitroanilide.
1.7 N Acetic acid.
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Method
Urine was assayed for GGT by adding 20 ul of the sample to 0.5 ml of a 
solution containing L-glutamyl-p-nitroanilide and glycylglycine and the 
mixture incubated at 37°C for 20 min. The reaction was stopped by adding 
.2 ml of acetic acid solution.
In time sequence, the following reagents were added: 1 ml of sodium
nitrite and after 3 min, 1 ml of ammonium sulphamate solution and after 3 
min 1.0 ml of naphthylethylene diamine solution. A blank for the reagents 
was also carried out. The absorbance of the azo-dye was measured at 540 
nm and the enzyme activity was determined from a calibration curve, 
prepared using the diazo-compound. Results were expressed as Units/24 hr 
or Units/18 hr urinary volume.
4.2.1.2.2. N-Acetyl B-D Glucosaminidase (NAG)
The assay is based on the release of 2- methoxy-4(2'-nitrovinyl)-phenol 
(MNP) from the substrate MNP-2-acetamido-2-deoxy-beta-D-glucopyranoside 
(MNP-GLcNAc) catalyzed by N-acetyl-beta-D-glucosaminidase as follows (Yuen 
et al, 1982) :
NAG
MNP-GLcNAc----- > MNP
The absorbance of the product is measured at 505 nm.
Reagents
1.5 mM MNP-GLcNAc.
0.15 M Citrate-phosphate buffer pH 4.5.
0.5 M Carbonate-bicarbonate buffer pH 10.0 
1 mM MNP.
A 0.1 ml aliquot of urine is added to 0.5 ml of incubation buffer (0.15M 
citrate-phosphate buffer) pH 4.5 and 1 ml of 1.5mM MNP-GLcNAc. The mixture
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is then incubated for 30-45 min at 37°C.
The reaction is stopped by addition of 0.5 ml sodium carbonate-bicarbonate 
buffer, pH 10.0. The absorbance of the solution is read at 505 nm, and 
the enzyme activity is calculated from a calibration curve, prepared using 
MNP. The activity was expressed as nmol/ml/18 hr or 24 hr.
4.2.1.2.3. Alkaline Phosphatase (ALP)
Alkaline phosphatases catalyze the hydrolysis of p-nitrophenyl-phosphate 
to p-nitrophenol and phosphoric acid. The p-nitrophenol produced is 
proportional to the phosphate activity and is measured in alkaline media 
at 405 nm.
Reagents
1 M Diethanolamine buffer pH 9.8.
0.5 mM Magnesium chloride.
10 mM p-nitrophenyl phosphate.
The assay was performed kinetically on a Cobas Bio Centrifugal 
autoanalyser using alkaline phosphatase OPT KIT (Roche). The activity was 
expressed as nmol/ml/18 hr or 24 hr.
4.2.1.2.4. Alanine aminopeptidase (AAP)
AAP activity was assayed kinetically (Mondorf et al, 1978) . The enzyme 
catalyzes the hydrolysis of L-alanine-p-nitro aniline to p-nitroanilide 
and L-alanine. The p-nitroanilide produced is proportional to the 
peptidase activity and is measured at 405 nm.
Reagents
-2L-alanine p-nitroanilide (1.66 x 10 M ) .
0.1 M Phosphate buffer pH 7.6.
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A volume of 0.2 ml of urine was pipetted into plastic cuvettes, using 0.1 
ml of substrate in 0.4 ml phosphate buffer and the absorbance was recorded 
against a water reference after 0 and 5 min. The enzymatic activity is 
expressed as nmol/ml/18 hr or 24 hr.
4.2.1.2.5. Glucose
Urinary glucose was measured enzymatically by the hexokinase (HK) method 
in which glucose is converted to glucose-6-phosphate (G6P) by the enzyme 
and then to the gluconate by G6P-DH in the presence of NAD:
HK
D-glucose + ATP ------- > G6P + ADP
G6P-DH
G-6-P + NAD -------- > D-gluconate-6-P + NADH+ + H+
The increase in the NADH+ concentration is directly proportional to the 
glucose concentration and is measured at 340 nm.
Reagents
50 umol ATP.
50 umol NAD+ .
7 U HK.
8 U G6P-DH.
0.25 M Tri-ethanolamine pH 7.5.
The assay was performed on a Cobas autoanalyzer using Glucose Rapide Test 
(Roche). The concentration was expressed as mmol/18 h urinary volume.
4.2.1.2.6. Total protein
Protein was measured by the biuret method (Kingsley, 1939) in which a 
coloured complex is produced, in alkaline solution with copper salts 
(biuret reaction). The colour intensity is proportional to the protein 
concentration and is measured at 546 nm.
Reagents
76
Biuret reagent.
20 mM Potassium-sodium tartrate.
12 mM Cupric sulphate.
10 mM Potassium iodide.
0.2 M NaOH.
The reaction was performed in a Cobas autoanalyser using a protein kit 
(Roche). The results are expressed as mg of protein /18 hr urine volume.
4.2.1.3. Dosing regime of mycotoxins
Single and repetitive doses of ochratoxin A (OTA) and aflatoxin B1 (ATB^) 
and a combination of both mycotoxins were given i.p. to different groups 
of rats as shown in Tables 4.1 and 4.2. Those receiving single doses were 
killed and tissue used for histopathology at 24, 48, 72 and 96hr. From
the 96 hr group one 24-hr control urine sample was collected before the 
injection of the mycotoxins and daily 24-hr urine samples were collected. 
Urinary volume was measured and the activities of GGT, NAG and ALP and AAP 
were assayed.
The groups receiving repetitive doses were given three daily doses of 
either toxin or a combination and killed 24hr after the last dose for 
histopathological examination.
A two week experiment was performed with rats receiving 2.5 mg OTA/kg, 
after which the animals were killed. One 18-hr control urine sample was 
collected before the first injection of OTA subsequent to which 2 daily 
injections were made. Daily 18-hr urine collections were made on each of 
the days of injection, and on each sample, volume, protein and glucose 
were measured and also NAG, GGT, AAP and ALP activities, were measured.
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TABLE 4.1
SINGLE DOSE REGIME OF OTA AND ATBX ALONE OR 
IN COMBINATION
COMPOUND DOSE OF 
COMPOUND
VEHICLE
(ml)
NO. OF ANIMALS PER 
GROUP/TIME POINT
SINGLE MYCOTOXIN ADMINISTRATION
OTA* 1 0.1 3
5 0.5 5
ATB1** 100 0.2 3
COMBINED ADMINISTRATION
OTA* 1 0.1 3
ATB1** 100 0.2
OTA* 5 0.5 5
ATB1** 100 0.2
* mg/kg 
** ug/kg
Vehicle for OTA : 0.1 M NaHCOg
Vehicle for ATB^ : DMSO
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TABLE 4.2
REPETITIVE DOSE REGIME OF OTA AND ATB^ 
ALONE OR IN COMBINATION
COMPOUND DOSE
TREATMENT
VEHICLE
(ml)
NO. OF ANIMALS PER 
GROUP/TIME POINT
OTA*, (alone) 7.5 1.50 3
5.0 0.5 6
2.5 0.25 3a, 5b
0.5 0.05 3
ATB^** (alone) 100 0.20 3
COMBINED ADMINISTRATION
r r
OTA* 5 0.50 3
ATBX** 100 0.20
OTA* 2.5 0.25 5
ATB1** 100 0.20
OTA* 0.5 0.05 3
ATBX** 100 0.20
a for histopathy
k for urinalysis and further pathology
* mg/kg
** ug/kg
Vehicle for OTA : 0.1 M NaHCOg 
Vehicle for ATB^ : DMSO
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A control group for each treatment was set up in which equal volume of the 
respective vehicle was injected.
4.2 .1.4. Autopsy
The rat and all its tissue were allocated accession numbers. Rats were 
sacrificed under ether anaesthesia and the abdominal cavity was opened. 
Abnormal macroscopic findings such as abdominal fluid, enlarged organs, 
etc. were noted. The kidneys were removed and weighed. Samples of liver 
were also taken.
4.2.1.5. Histopathological Assessment
4.2.1.5.1. Fixation of tissues
Pieces of tissue taken immediately after the death of the animal were 
fixed in 10 % neutral buffered formalin (NBF) , pH 7.4,. The container was 
gently shaken to avoid adherence of the tissue to the bottom. The tissue 
was left for at least one week in the fixative before being embedded in 
wax (Lillie and Fulmer, 1976).
4.2.1.5.2. Preparation of paraffin-wax embedded sections (Culling, 1974).
Reagents
Methanol.
Paraffin-wax (Fibrowax).
Toluene.
Method
Fixed tissue was trimmed to pieces of approximately 5 mm thick, placed in 
a plastic processing container and covered with a metal lid. The 
containers were placed in a tissue basket which was then fitted to the 
Histokinette Automatic Tissue Processor. The process of dehydration,
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clearing and impregnation with wax were carried out as follows:
Dehydration:
70 % (v/v) Ethanol/water 1 hr
85 % (v/v) Ethanol/water 1 hr
95 % (v/v) Ethanol/water 1 hr
Absolute ethanol I, II and III 1 hr each
Clearing
Toluene I and II 1 hr
Impreanat ion
Paraffin Fibrowax at 58°C 1 hr each.
After this process the tissue containers were transferred to an embedding
pair of electrically heated forceps and placed into a metal mould 
containing a small amount of soft wax. The tissue was orientated so that 
the surface to be cut rested on this layer of wax facing the base of the 
mould. The mould was then filled with molten wax covered with a plastic 
guard. After framing, the wax blocks were removed from the moulds. 
Excess wax was cut off the blocks and the block mounted into a Rotatory 
Microtome. The block was trimmed until the tissue was exposed and 7 urn 
thick sections were cut.
The sections were floated on distilled water (50°C) to flatten them and 
then mounted onto single frosted edge slides The animal's accession number 
was clearly printed in the frosted edge of the slide. The slides were 
placed in a rack and dried in an oven at 50°C for 2-3 hr.
4.2.1.5.3. Dewaxing and Rehydration
The process is schematically described as follows:
oven containing paraffin Fibrowax at 58°C and the tissue removed using a
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Xylene I and II, to remove wax 2 min each.
Absolute methanol (Rehydratation process) 1 min.
80 % (v/v) Methanol/water 1 min.
60 %. (v/v) Methanol/water 1 min.
Tap water (rinse) 1 min.
4.2.1.5.4. Haematoxylin and eosin staining (Culling, 1974).
Reagents
Harris haematoxylin.
Acid alcohol. 1 % HC1 in 70 % methanol.
Scott's tap water. 0.2 % potassium bicarbonate,
2 % (w/v) Magnesium sulphate in tap water.
1 % (w/v) Eosin in distilled water.
D . P . X .
Slides were examined using a Leitz Dialux 400 microscope at X60, X100 and
X250 magnification.
Method
The section was dewaxed and hydrated (4.2.1.5.3) and stained as follows:
Erlich's acid haematoxylin 15 minutes
Tap water (washing) 5 minutes
Differentiation in acid alcohol 5-10 seconds
Immersion in Scott's tap water 1-2 minutes
At this step the sections were examined to ensure proper 
differentiation of nuclei.
Counter staining with 1 % (w/v) aqueous eosin 2 minutes
Tap water (rinse) 30 seconds
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85 % Methanol/water (dehydration) 30 seconds
Absolute methanol I and II 30 seconds each
Xylene I and II 30 seconds each
The sections were mounted in D.P.X. by placing a drop on a clean 
coverslip, taking the slide directly from the xylene, inverting it over 
the coverslip and pressing it gently, so that the D.P.X. spread under the
coverslip and air bubbles were removed.
4.2.1.5.5. Sections stained with periodic acid-Schiff (PAS) staining
(Culling, 1974).
Reagents.
1 % Periodic acid.
Schiff reagent for the detection of aldehydes.
Mayer's haemalum.
Xylene.
D.P.X.
Method
Two sections of the same block were passed through the dewaxing process 
and brought into water (4.2.1.5.3). One slide of each tissue was labelled 
as "control".
The slides were exposed to periodic acid for 5 min, washed gently in tap 
water and rinsed twice with distilled water after which they were 
transferred to Schiff reagent for 15 min, at the end of this period, the 
slides were washed again with distilled water and dehydrated in absolute 
ethanol for 1 min, cleared with xylene and mounted in D.P.X.
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4.2.2. In vitro studies
A schematic representation of the procedures used for the in vitro studies 
is shown in Fig. 4.1.
4.2.2.1. Isolation of glomeruli and proximal tubular fragments from rat 
kidney.
Groups of ten 150g male University of Surrey Wistar rats were killed by 
cervical dislocation. The kidneys were disected free, decapsulated,' and 
the papillary tissue removed. The freshly chopped cortical tissue was 
forced through a 250 urn stainless steel sieve to be disrupted, tubules 
were harvested on the 150 um sieve and glomeruli were collected on the 75 
urn sieve, and suspended in Tyrodes phosphate buffered salt solution 
supplemented with glucose or Earles-HEPES buffer, pH 7.4. The glomerular 
and tubular fractions were then washed and centrifuged at 300 rpm for 3 
min, and the pellet resuspended in 25 ml buffer.
4.2.2.2. Isolation of glomeruli from pig kidney
Pig kidneys collected from freshly slaughtered female Large White pigs, 
aged 1 6 - 2 4  weeks, were cleaned, decapsulated, the cortex sliced and 
chopped very finely, and then incubated with calcium-free Krebs-Henseleit 
or Earles-HEPES buffer and in the presence of EDTA, for 15 min. 
Subsequently, the tissue was rinsed with buffer plus calcium and incubated 
with collagenase in buffer plus calcium for another 15 min. Following 
this, the tissue was forced through a 250 um stainless steel sieve and
then the glomeruli collected on a 90 um sieve, and suspended in buffer.
The glomerular fragments were then washed and centrifuged for 3 times and 
resuspended in 50 ml of buffer.
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Fig. 4.1. Schematic representation of the procedures used in the in vitro studies.
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4.2.2.3. De novo synthesis of protein
4.2.2.3.1. Incorporation of proline
3 . . .The time course of H-prolme uptake and incorporation was followed by
incubating 0.5 ml aliquots of the suspension of glomeruli at 37°C in 0.5ml 
of incubation buffer, containing 2.5 uCi of the labelled amino acid, for 
0-4 hr.
The effect of nephrotoxins on isolated rat or pig glomeruli and rat 
proximal tubular fragments (where applicable) was studied through the 
incorporation of radiolabelled proline, for 4 hr. Equal aliquots of 
glomerular suspension were incubated in the presence of several different
i '
3concentrations of the nephrotoxins and H-proline. As far as possible all 
compounds to be tested were dissolved in the corresponding incubation 
buffer. The chemicals tested (Table 4.3) were the following: adriamycin
(ADR), puromycin aminonucleoside (PAN), streptomycin (STR), ochratoxin A 
(OTA), folic acid (FA), 2-bromoethanamine (BEA) and ethacrynic acid (ETA).
After incubation, the reaction was stopped with 3 ml of ice-cold 6% (w/v) 
trichloroacetic acid (TCA), containing 1 mM "cold” (non-radioactive) 
proline. The samples were centrifuged at 3000 rpm for 5 min and the 
supernatant removed. The precipitates were washed twice in cold 6% (w/v) 
TCA by centrifugation and aspiration of the supernatant to remove 
radioactivity. Washed samples were filtered onto glass-fibre discs 
(Whatmans) in a 25mm filter holder (stainless steel) and dried with 
absolute alcohol and residual TCA was removed with diethyl ether. The 
filter discs were transferred to plastic scintillation vials and the 
precipitate dissolved in 0.2 ml of 0.5M NaOH, after which 4 ml of 
scintillant OptiSafe were added and samples counted on a Rack Beta 
spectral scintillation counter.
TABLE 4.3
CHEMICALS USED TO STUDY IN VITRO TARGET TOXICITY
Compound Range of concentrations
Assay
Protein OXM*
ADR3 7.8 - 10000 uM + +
STR3 0.25 - 2 mM + +
PAN3 0.25 5 mM + +
BEA3 1.0 10 mM + +
ETA3 0.1 0.5 mM + +
FA3 1.0 - 10 mM . + -
OTA3 1.6 3.2 mM
r  r
+ -
OTAb 10.0 - 1000 uM + +
3 pig glomeruli
rat glomeruli and tubular fragments 
* Oxidative metabolism
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4.2.2.3.2. Incorporation of other amino acids
3The time course of other H-labelled a m m o  acids incorporation, (Table 
4.4) was performed in the same way as for proline (see section 4.2.2.3.1) .
4.2.2.4. Oxidative Metabolism
14 . . 14The time-course of CO2  production from different C-labelled substrates
(Table 4.4) was followed by incubating 0.5 ml aliquots of the pig or rat
glomerular suspension, or rat proximal tubular fragments containing 0.1 ml
of the labelled substrate, in a closed reaction system for 0 - 4  hr, at
37°C in a shaking water bath, in 0.5 ml of Earle's-HEPES buffer, pH 7.4.
14The reaction and collection of CO2  took place m  a 10 ml conical flask 
with elongated neck (20 mm) tightly closed with a rubber Suba-Seal stopper 
to which a plastic center well had been attached (Fig. 4.1), so that the 
released CC>2 could be trapped into a filter paper strip embeded with 0.5 
ml of 1M NaOH resting inside the well.
The effect of several toxins in the oxidative metabolism by pig glomeruli
14and rat proximal tubular fragments was studied by determining CO 2  
release, at several different drug concentrations, for 4 hr. Equal 
aliquots of glomerular suspension were incubated in the presence of the 
nephrotoxins and either labelled glucose (2 uCi) or fatty acids (50 nCi), 
as shown in Table 4.4.
After the incubation the reaction was stopped with 0.5 ml of 0.2M HC1
— 14which acidified the buffer releasing any HCOg as free CO2  which was 
subsequently trapped as NaCO^ by NaOH.
The flasks were then allowed to stand for 15 min at room temperature, 
following which the filter.paper strips were transferred to a plastic
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TABLE 4.4
RADIOLABELS USED TO STUDY IN VITRO GLOMERULAR AND 
PROXIMAL TUBULAR METABOLISM
Synthesis of Protein Oxidative Metabolism
Amino acids3 Glucose*3'd'e
Prolined,e Fatty acidsc
Histidined'e 01eicd
Leucined Linolenicd'e
r • d Lysine Palmitic^
Glycined
, f
Stearic
Phenylalaninee Mevalonate
Tryptophane
Tyrosinee
a specific activity 2.5 uCi/ml 
specific activity 2 uCi/ml 
c specific activity 50 nCi/ml 
d pig glomeruli
e rat glomeruli and proximal tubules 
^ rat proximal tubules
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scintillation vial, the wells were washed twice with 0.5 ml of distilled 
water, to remove any residual radioactivity. Four ml of the scintillant 
were added and the radioactivity counted.
4.2.2.5. Determination of protein
Aliquots of the glomerular or tubular preparation (0.5 ml) were dissolved 
in 0.5M NaOH overnight, for protein analysis by the Coomassie blue dye- 
binding method (Read and Northcote, 1981), in which to 0.2 ml of the 
homogeneous sample were added 3.75 ml of the Coomassie blue reagent, the 
mixture allowed to stand for 10 min and the absorbance recorded at 595 nm.
The protein concentration was determined from a calibration curve prepared 
with different concentrations of BSA.
4.2.2.6. Assessment of Purity
4.2.2.6.1. The purity of the preparation is assayed by phase contrast 
light microscopy (using xlO or x20 lens), where a slide prepared using 50 
ul of glomerular suspension is examined in a number of fields. The purity 
is presented as a percentage of tubular contamination. Fig. 4.2 shows the 
aspect of the glomerular preparation as seen under the microscope.
4.2.2.6.2. Glomerular viability
Two combined fluorescence probes (Rotman and Papermaster, 1966; Edidin 
1970) were used to assess cell viability: fluorescein diacetate (FDA) and 
ethidium bromide (EB). FDA is a nonpolar compound that enters the cell 
membrane readily, where non-specific esterases convert it to fluorescein, 
which is retained by intact cells, giving a green/yellow fluorescence. In 
contrast EB which is a negatively charged molecule penetrates intact cells 
slowly, but rapidly enters damaged cells where it forms a bright red
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fluorescent complex with nucleic material. A 25 ul of the glomerular 
suspension was incubated with 25 ul of a solution containing FDA dissolved 
in acetone (5 ug/ml) and EB dissolved in phosphate buffered isotonic 
saline (200 ug/ml), for 3 min. The preparation was then examined by 
fluorescent microscopy (590 nm). Viable cells presented a bright green 
fluorescent cytoplasm. In contrast non-viable cells showed a weekly green 
cytoplasm and a bright red fluorescent nucleous.
4.2.3 Statistical analysis
Results were analysed by t-test. Results are expressed as mean + SD. 
Tables of results and statistics are located in Appendices 1 and 2.
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Fig. 4.2 Glomerular preparation as seen under the phase contrast light microscope.
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CHAPTER 5
IN VIVO STUDIES: OCHRATOXIN A AND AFLATOXIN B1 NEPHROTOXICITY
5.1. Urinalysis
5.1.1. Single dose regime
-Urinary enzyme excretion was determined over four consecutive 24-hr 
periods, after a single injection of OTA alone, ATB^ alone or the combined 
administration of both toxins. Histological findings of the kidneys, 
removed and fixed 96 hr after the injection are described in section 5.2.
5.1.1.1. OTA alone
When OTA was administered in a single ip dose of 1 mg/kg urinary ALP
activity decreased on day 1 and 2, but was increased on day 3. On day 4
there was a statistically significant increase (P < 0.05), up to 272% of 
the control (Table 5.1.1, Appendix 1; Fig. 5.1.1A and B) . Urinary AAP 
activity was decreased on day 1 and 2, the latter being significantly
different from the control (P < 0.05, Table 5.1.2, Appendix 1; Fig. 5.1.2A
and B) and was elevated on day 4 (to 143% of the control), although it was 
not statistically significant. There were no significant variations on 
the GGT and NAG urinary activity, as compared to the control (Tables 5.1.3 
and 5.1.4, Appendix 1; Figs. 5.1.3A and B, and 5.1.4A and B) throughout 
this experiment. Urinary volume was higher for the control than for the 
treated group, (Table 5.1.5, Appendix 1/ Figs. 5.1.5A and B) however there 
were not significant differences.
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Fig. 5.1.1A
Mean level of alkaline phosphatase in 24-h urine before (day 0) and after a single ip dose 
of ochratoxin A (1 mg/kg), in comparison to a group injected with the vehicle only 
(control). The height of each bar is the mean value for n=3. Significant increase (P < • 
0.05) was seen on day 4 (*).
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Urinary alkaline phosphatase excretion calculated as a percentage o f the control group.
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Fig. 5 .U A
Mean level o f alanine aminopeptidase in 24-h urine before (day 0) and after a single ip 
dose of ochratoxin A (1 mg/kg), in comparison to a group injected with the vehicle only 
(control). The height of each bar is the mean value for n=3. Significant decrease (P < 
0.05) was seen on day 3 (*).
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Fig. 5.1.2B
Urinary alanine aminopeptidase excretion calculated as a percentage o f the control group.
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Mean level of gamma-glutamyl transpeptidase in 24-h urine before (day 0) and after a 
single ip dose of ochratoxin A (1 mg/icg), in comparison to a group injected with the 
vehicle only (control). The height of each bar is the mean value for n=3.
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Fig. 5.1 JB
Urinaiy gamma-glutamyl transpeptidase excretion calculated as a percentage o f the control
group.
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Mean level of N-acetyl-beta-glucosaminidase in 24-h urine before (day 0) and after a 
single ip dose of ochratoxin A (1 mg/kg), in comparison to a group injected with the 
vehicle only (control). The height of each bar is the mean value for n=3.
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Urinary N-acetyl-beta-glucosaminidase excretion calculated as a percentage o f the control
group. *
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Mean volume in 24-hr urine before (Day 0) and after a single ip dose of ochratoxin A (1 
mg/kg), in comparison to a group injected with the vehicle only (control). The height o f 
each bar is the mean value for n=3.
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Fig. 5.1.5B
Urinary volume calculated as a percentage o f the control group.
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When the concentration of OTA was increased to 5 mg/kg ALP activity 
increased on day 2, showing significant differences from the control on 
day 3 and 4 (Table 5.1.6, Appendix 1; Figs. 5.1.6A and B). AAP activity 
first increased on day 2 and was significantly different (P < 0.05) from 
the control on days 3 and 4 (Table 5.1.7, Appendix 1; Figs. 5.1.7A), up to 
209 and 196% (Fig. 5.1.7B). NAG activity was significantly higher than the 
control up to 184% (P< 0.05) on day 4 (Tables 5.1.8, Appendix 1; Figs. 
5.1.8A and B). Urinary GGT activity did not show significant variations 
compared to the control (Table 5.1.9, Appendix 1; Figs. 5.1.9A and B) at 
any time point in this experiment. Urinary volume rose significantly (P< 
0,05) compared to the control on day 3 (Table 5.1.10, Appendix 1; Figs. 
5.1.10A and B).
Discussion. These data show that single low doses of OTA caused changes in 
the urinary excretion of several enzymes. At the lowest concentration of 
OTA tested, ALP showed a decrease on day 1 and 2 of the treatment, but 
increased on day 3 and 4, and with 5 mg/kg of the toxin, the enzyme 
activity was also increased on day 3 and 4. Both doses of the mycotoxin 
caused a rise in ALP activity, however this was not dose-related, since 
the increase on day 3 is similar for both concentrations, and on day 4 the 
lowest concentration caused the highest increase in the enzyme activity.
AAP showed an initial decrease and further slight elevation, at the low 
concentration of OTA, and when the concentration was increased, it showed 
a considerable increase towards day 3 and 4, suggesting a dose-response 
effect. Although GGT changes were not statistically significant at the low 
concentration of OTA, this enzyme followed a similar trend to ALP, with an 
initial decrease, and further elevation, and also a similar pattern to 
that of ALP is followed by GGT at the high concentration of the compound.
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Fig. 5.1.6A
Mean level of alkaline phosphatase in 24-h urine before (day 0) and after a single ip dose 
o f ochratoxin A (5 mg/kg), in comparison to a group injected with the vehicle only 
(control). The height for each bar is the mean value for n=4 in the control group and n=5 
for the treated group.
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Fig. 5.1.6B
Urinary alkaline phosphatase excredon calculated as a percentage of the control group.
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Fig. 5.1.7A
Mean level of alanine aminopeptidase in 24-h urine before (day 0) and after a single ip 
dose of ochratoxin A (5 mg/kg), in comparison to a group injected with the vehicle only 
(control). The height o f each bar is the mean value for n=4 in the control group and n=5 
in the treated group. Significant increases(P < 0.05) were seen on days 3 and 4 (*).
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Fig. 5.1.7B
Urinary alanine aminopeptidase excretion calculated as a percentage o f the control group.
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Fig. 5.1.8A
Mean level of N-acetyl-beta-glucosaminidase in 24-h urine before (day 0) and after a 
single ip dose o f ochratoxin A (5 mg/kg), in comparison to a group injected with the 
vehicle only (control). The height o f each bar is the mean value for n=4 in the control 
group and n=5 in the treated group. Signficant increase (P < 0.05) was seen on day 4 (*).
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Fig. 5.1.8B
Urinary N-acetyl-beta-glucosaminidase excretion calculated as a percentage o f the control
group.
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Fig. 5.1.9 A
Mean level of gamma-glutamyl transpeptidase in 24-h urine before (day 0) and after a 
single ip dose of ochratoxin A (5 mg/kg), in comparison to a group injected with the 
vehicle only (control). The height of each bar is the mean value for n=4 in the control 
group and n=5 for the treated group.
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Fig. 5.1.9B
Urinary gamma-glutamyl transpeptidase excretion calculated as a percentage o f the control
group.
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Mean volume m 24-hr urine before (Day 0) and after a single ip dose of ochratoxin A (5 
mg/kg), in comparison to a group injected with the vehicle only (control). The height o f 
each bar is the mean value for n=4 in the control group and n=5 in the treated group 
Significant increase (P < 0.05) was seen on day 3 (*).
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Fig. 5.1.10B
Urinary volume calculated as a percentage o f the control group.
104
643075
NAG excretion did not show any statistically significant changes relative 
to the control at the lowest concentration of OTA, but it decreased on day 
1 and rose slightly over the control values, on days 3 and 4. When the 
concentration of the mycotoxin was 5 mg/kg, the enzyme activity was 
elevated on day 3 and 4, suggesting a dose-response effect.
The decreased activity of some enzymes, below the control values, is 
difficult to explain. A rise would be normally expected as a consequence 
of the tubular injury, with the subsequent enzymatic leaking, loss of the 
brush border and/or the exfoliation of renal tubular cells. One possible 
explanation for the lower enzymatic activity of the treated group may be 
either the presence of inhibitors in the urine samples, or the high
variability seen between animals in both control and treatment group. All 
of these were on day 1 or 2, therefore may also represent renal functional 
changes involving decrease in the normal enzyme turnover.
5.1.1.2. ATB1 alone
When a small dose of ATB^ (100 ug/kg) was administered ip to the rats, AAP 
activity remained constant from days 1 - 3  and showed a significantly 
different decrease (P < 0.05) (Table 5.1.11, Appendix 1; Fig. 5.1.11A) to 
78% of the control, on day 4 (Fig. 5.1.11B). Urinary GGT activity 
increased on day 2, and started to decrease on day 3, to show a 
significant decrease (P < 0.05) to 67% of the control on day 4 (Table
5.1.12, Appendix 1; Fig. 5.1.12A and B). NAG activity was significantly 
lower (P < 0.05) than the control on day 1 (Table 5.1.13, Appendix 1; Fig.
5.1.13A), to 85%. On day 2 there was a significant increase (P < 0.01) to
182% of the control (Fig. 5.1.13B). ALP activity did not show significant 
variations in relation to the control throughout the experiment (Table 
5.1.14, Appendix 1; Fig. 5.1.14A and B). There were no singificant
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Fig. 5.1.11A
Mean level of alanine aminopeptidase in 24-h urine before (day 0) and after a single ip 
dose of aflatoxin B, (100 ug/kg), in comparison to a group injected with the vehicle only 
(control). The height o f each bar is the mean value for n=3. Significant decrease (P < 
0.05) was seen on day 4 (*).
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Fig. 5.1.11B
Urinary alanine aminopeptidase excretion calculated as a percentage o f the control group.
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Fig. 5.1.12A
Mean level of gamma-glutamyl transpeptidase in 24-h urine before (day 0) and after a 
single ip dose of aflatoxin B, (100 ug/kg), in comparison to a group injected with the 
vehicle only (control). The height of each bar is the mean value for n=3. Significant 
decrease (P <0.05) was seen on day 4 (*).
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Fig. 5.1.12B
Urinary gamma-glutamyl transpeptidase excretion calculated as a percentage o f the control
group. ■
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Fig. 5.1.13A
Mean level of N-acetyl-beta-glucosaminidase in 24-h urine before (day 0) and after a 
single ip dose of aflatoxin B, (100 ug/kg), in comparison to a group injected with the 
vehicle only (control). The height of each bar is the mean value for n=3. Significant 
decrease (P < 0.05) was seen on day 1(*) and increase (P < 0.01) on day 2(**).
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Fig. 5.1.13B
Urinary N-acetyl-beta-glucosaminidase excretion calculated as a percentage o f the control
group.
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Fig. 5.1.14A
Mean level o f alkaline phosphatase in 24-h urine before (day 0) and after a single ip dose 
of aflatoxin B j (100 ug/kg), in comparison to a group injected with the vehicle only 
(control). The height of each bar is the mean value for n=3.
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Fig. 5.1.14B
Urinary alkaline phosphatase excretion calculated as a percentage of the control group.
109
differences in urinary volume between the control and treated groups
(Table 5.1.15, Appendix 1; Figs. 5.1.15A and B).
Discussion. These results showed that single low doses of ATB^ caused 
some changes on the excretion of urinary enzymes such as ALP, AAP, GGT and 
NAG. ALP activity was below the control values on days 1 and 2, but none 
of the differences were statistically significant. AAP excretion was lower 
for the treated group on most of the days; on day 4 the decrease was
statistically different from the control. GGT was increased maximally on
day 2, and started to decrease on day 3, at which it was still
significantly different from control. NAG values were significantly lower 
than the controls on day 1, and significantly higher on day 2, after which 
the activities remained within the control range.
There have been no published studies on the effect of single small doses 
of ATB^ on urinary enzymes such as ALP, AAP and NAG; there is one report 
in which administration of a single dose of 100 ug ATB^/kg is reported to 
have caused a significant increase in urinary GGT within 6 to .7 hr after 
injection (Grosman et al, 1983), after which the enzymic activity 
diminished, but remained higher than the control. The results in these 
studies are not consistent with that report, but several factors may
account for this difference. These include the different, timed period for 
the collection of urine samples, and also the wide variations between
animals, and other factors such as purity of the sample and type of diet.
5.1.1'.3. Combined administration of OTA and ATB^
When OTA and ATB^, were administered ip simultaneously (1 mg and 100 
ug/kg, respectively), urinary ALP activity increased on day 2 and 3 (Table 
5.1.16, Appendix 1; Fig. 5.1.16A), rose significantly (P < 0.05) to 208%
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Fig. 5 .i.l5 A
Mean volume in 24-hr urine before (Day 0) and after a single ip dose of aflatoxin B j (100 
ug/kg), in comparison to a group injected with the vehicle only (control). The height of 
each bar is the mean value for n=3.
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Fig. 5.1.15B
Urinary volume calculated as a percentage of the control group.
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Fig. 5.1.16A
Mean level o f alkaline phosphatase in 24-h urine before (day 0) and after combined 
administration of ochratoxin A and aflatoxin B j (1 mg and 100 ug/kg respectively), in 
comparison to a group injected with the vehicle only (control). The height of each bar is 
the mean value for n=3. Significant increase (P < 0.05) was seen on day 3 (*).
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Fig. 5.1.16B
Urinary alkaline phosphatase excretion calculated as a percentage of the control group.
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of the control (Fig. 5.1.16B). The enzyme activity continued to increase
on day 4, but was not statistically significant due to the high variance.
GGT activity decreased up to day 3 and then increased significantly (P < 
0.05) from the control, on day 3 (Table 5.1.17, Appendix 1; Fig. 5.1.17A) 
by 33% (Fig. 5.1.17B). NAG activity, showed a significant elevation (P < 
0.05) on day 1 (Table 5.1.18, Appendix 1; Fig. 5.1.18A) up to 161% of the
control (Fig. 5.1.18B) and also on day 3, to 149% of the control. The
enzyme activity was also increased on day. 4, but not significantly.
Although AAP activity of the experimental group was higher than the
control on day 3, this was not statistically significant (Table 5-. 1.19, 
Appendix 1; Fig. 5.1.19A and B). Urinary volume rose significantly (P< 
0.05) compared to the control on day 3 (Table 5.1.20, Appendix 1; Figs. 
5.1.20A and B).
When OTA was increased to 5 mg/kg and administered simultaneously with 100 
ug/kg of ATB^, ALP activity was significantly decreased on day 1 (P <
0.01), to 71% of the control (Table 5.1.21, Appendix 1; Fig 5.1.21A and
B) , and increased on day 2, reaching a peak of 217% of the control on day 
3 that was significant (P < 0.05) after which the enzyme activity 
decreased. GGT activity in the experimental group was lower than the 
controls throughout the experiment (Table 5.1.22, Appendix 1; Fig. 
5.1.22A), having presented a significant decrease (P < 0.05) to 63% of the 
control, on day 1 (Fig. 5.1.22B). AAP activity remained lower for the 
treatment group than for the control on days 1 and 2, but there were no 
significant differences (Table 5.1.23, Appendix 1; Fig. 5.1.23A and B) . 
NAG activity was lower for the treatment group on day 1 and after that the 
activity values remained very close to the controls (Table 5.1.24, Fig. 
5.1.24A and B). There were no statistically significant differences. 
Urinary volume (Figs. 5.1.25A and B remained lower for the treated group
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Fig. 5.1.17A
Mean level of gamma-glutamyl transpeptidase in 24-h urine before (day 0) and after 
combined administration of ochratoxin A and aflatoxin B j (1 mg and 100 ug/lcg 
respectively), in comparison to a group injected with the vehicle only (control). The 
height of each bar is the mean value for n=3. Significant increase (P < 0.05) was seen on 
day 3 (*).
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Fig. 5.1.17B
Urinary gamma-glutamyl transpeptidase excretion calculated as a percentage of the control
group.
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Fig. 5.1.18A
Mean level of N-acetyl-beta-glucosaminidase in 24-h urine before (day 0) and after 
combined administration of ochratoxin A and aflatoxin B j (1 mg and 100 ug/kg 
respectively), in comparison to a group injected with the vehicle only (control). The 
height of each bar is the mean value for n=3. Significant increases (P < 0.05) were seen 
on days 1 and 3 (*).
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Fig. 5.1.18B
Urinary N-acetyl-beta-glucosaminidase excretion calculated as a percentage of the control
group.
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Mean level of alanine aminopeptidase in 24-h urine before (day 0) and after combined 
administration of ochratoxin A and aflatoxin B j (1 mg and 100 ug/kg respectively), in 
comparison to a group injected with the vehicle only (control). 1116 height o f each bar is 
the mean value for n=3.
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Fig. 5.1.19B
Urinary alainine aminopeptidase excretion calculated as a percentage o f the control group.
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Mean volume in 24-hr urine before (Day 0) and after a single ip dose o f ochratoxin A and 
aflatoxin B j (1 mg and 100 ug/kg respectively), in comparison to a group injected with the 
vehicle only (control). The height of each bar is the mean value for n=3. Significant 
increase (P < 0.05) was seen on day 3 (*).
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Fig. 5.1.20B
Urinary volume calculated as a percentage of the control group.
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Mean level of alkaline phosphatase in 24-h urine before (day 0) and after combined 
administration of ochratoxin A and aflatoxin B j (5 mg and 100 ug/kg respectively), in 
comparison to a group injected with the vehicle only (control). The height of each bar is 
the mean value for n=4 in the control group and n=5 for treated group. Significant 
decrease (P < 0.01) was seen on day 1 (**) and increase (P < 0.05) on day 3 (*).
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Fig. 5.1.21B
Urinary alkaline phosphatase excretion calculated as a percentage o f the control group.
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Control
Treatment
Mean level of gamma-glutamyl transpeptidase in 24-h urine before (day 0) and after 
combined administration of ochratoxin A and aflatoxin B j (5 mg and 100 ug/kg 
respectively), in comparison to a group injected with the vehicle only (control). The 
height of each bar is the mean value for n=4 in the control group and n=5 for the treated 
group. Significant decrease (P < 0.05) was seen on day 1 (*).
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Fig. 5.1.22B
Urinary gamma-glutamyl transpepddase excretion calculated as a percentage o f the control
group.
119
URINARY AAP ACTIVITY
5000 -i
4 0 0 0 -
£  3 0 0 0 -
1000-
0 1 2 3 4
8 CONTROL
TREATMENT
DAYS OF TREATMENT
Fig. 5.1.23A
Mean level o f alanine amino peptidase in 24-h urine before (day 0) and after combined 
administration of ochratoxin A and aflatoxin B j (5 mg and 100 ug/kg respectively), in 
comparison to a group injected with the vehicle only (control). TTie height o f each bar is 
the mean value for n=4 in the control group and n=5 for the treated group.
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Fig.5.U 3B
Urinary alanine amino peptidase excretion calculated as a percentage o f the control group.
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Fig. 5.1.24A
Mean level of N-acetyl-beta-glucosaminidase in 24-h urine before (day 0) and after 
combined administration of ochratoxin A and aflatoxin B j (5 mg and 100 ug/kg 
respectively), in comparison to a group injected with the vehicle only (control). The 
height o f each bar is the mean value for n=4 in the control group and n=5 for the treated 
group.
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Fig. 5.1.24B
Urinary N-acetyl-beta-glucosaminidase excretion calculated as a percentage of the control
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Mean volume in 24-hr urine before (Day 0) and after a single ip dose of (ochratoxin A and 
aflatoxin B t (5 mg and 100 ug/kg respectively), in comparison to a group injected with the 
vehicle only (control). The height of each bar is the mean value for n=4 in the control 
group and n=5 in the treated group.
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Fig. 5.1.25B
Urinary volume calculated as a percentage o f the control group. 
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throughout the experiment, however there were no significant differences 
with the control group.
Discussion. These data show some changes on the excretion of the urinary 
enzymes tested. Among the enzymes tested, ALP seemed to be the most 
sensitive urinary enzyme marker, the activity of which started to increase 
from day 2 and and remained higher than the control group throughout the 
experiment.
The pattern of interaction for ALP, AAP, GGT and NAG is different and not 
consistent with the one seen when either ATB^ or OTA were administered
alone. Thus it can be concluded that there is an interactive effect caused
by the simultaneous administration of the two mycotoxins. This cannot be 
classified as either additive or synergistic on the basis of excretion of 
those urinary enzyme markers tested after the combined administration of 1 
mg OTA/kg and 100 ug ATB^/kg to the rats.
The data on the effect of the combined administration of 5 mg OTA/kg and 
100 ug ATB^ show that ALP excretion was again the highest of the enzymes 
assessed. AAP and GGT activities showed lower values than the control at 
most time points tested, and ALP and NAG also decreased on day 1. ALP 
pattern of interaction was consistent with the one seen with the 5 mg 
OTA/kg alone, where the activity started to rise on day 2, reached a peak 
on day 3, which was higher in the combined administration and although
started to decrease, remained high on day 4. However, once again it can
not be said that a synergistic or additive effect took place, only that 
there was an interaction. The ALP pattern of interaction following both 
mycotoxins was different from the ATB^ and OTA treatment. AAP, GGT and 
NAG pattern of interaction were also different from those obtained after
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administration of either 5 mg OTA/mg or ATB^ alone.
In general, it is difficult to draw final conclusions from the single 
doses studies. There were some difficulties, under the experimental 
conditions of this study, such as recovering the entire 24-hr urine 
sample, and avoiding contamination with faeces or food; although the 
metabolic cages were designed for separate collection of faeces and urine, 
sometimes some urine went into the faeces collection flask or some faeces 
went to contaminate urine. In addition, there were considerable animal- 
to-animal variations in the levels of' enzyme excretion, and urinary volume 
in both control and treated group, the day-to-day values for the control 
groups showed also considerable variations. The urinary enzyme levels 
were adjusted to the urinary volume in 24-hr specimens, to have the total 
enzymatic activity per 24 hr; however the problem of wide variations in 
this parameter still persisted.
Therefore it can be concluded that for the study of the effect of low 
single ip doses of OTA and ATB^ alone or after simultaneous 
administration, on renal function, the study of enzymes such as ALP, AAP, 
GGT and NAG, over 24-hr period is not a suitable sensitive test, and does 
not give a dose related response. It is possible that the measurement of 
urinary enzymes under the same regime give better results if performed at 
earlier time points than those performed in the present study. Other 
parameters of renal function should be assessed in parallel to help define 
the nature of the interaction between the two mycotoxins.
In order to decrease one factor that contributed to the variability of 
data that may be introduced by the contamination of urine samples with 
food, it was decided to collect 18-hr urine along with food restriction
, 1 2 4
for the same period of time. This was applied to the repetitive dose 
study detailed below.
5 . 1 . 2  R e p e t i t iv e  doses o f  OTA.
Urinary enzyme xcretion and other parameters of renal function where 
determined, over daily 18 hr periods following ip administration of 2.5 mg 
OTA/kg/day, on 3 consecutive days. From a dose-response histopathological 
assessment of a range of concentrations, this was the dose regime that 
showed the minimal morphological changes, and under which nephrotoxicity 
was exacerbated by the simultaneous administration of ATB^. Histological 
findings on kidneys removed 24 hr after the last dose, and two weeks after 
the first dose, is described in section 5.2.
5 . 1 . 2 . 1  Enzym uria
ALP activity started to increase on day 3, and showed the highest
elevations on day 6 and 7 (1616 and 1752% of the control), which due to 
the high variance, were not statistically significant (Table 5.1.26,
Appendix 1; Fig. 5.1.26A). The activity elevated to 337% on day 8, and was 
highly significantly different (P < 0.01) from the controls (Fig.
5.1.26B). GGT activity started to increase from day 2 onwards, showing a 
significantly elevated difference (P < 0.05) on days 4 and 5 (Table 
5.1.27, Appendix 1; Fig. 5.1.27A) to 184 and 196% of the control group, 
respectively (Fig. 5.1.27B). The enzyme activity remained elevated until 
day 8 and then started to decrease, although not significantly until day
11. From day 12 until the end of the experiment, the enzyme activity
values remained very close to those in the controls. AAP activity started 
to rise from day 2 onwards, and showed a significant increase (P < 0.05)
on days 4, 5, 6 and 8 (Table 5.1.28, Appendix 1; Fig. 5.1.28A),
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Fig. 5.1.26 A
Mean level o f alkaline phosphatase in 18-hr urine before (day 0) during (arrows) and after 
3 consecutive daily ip doses of ochratoxin A (2.5 mg/kg), in comparison to a group 
injected with the vehicle only (control). The height o f each bar is the mean value for 
n=5. Significant increase (P <0.01) was seen on day 8 (**).
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Fig. 5.U6B
Urinary alkaline phosphatase excretion calculated as a percentage of the control group.
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Fig. 5.1.27A
Mean level o f gamma-glutamyl transpeptidase in 18-hr urine before (day 0) during (arrows) 
and after 3 consecutive daily ip doses of ochratoxin A (2.5 mg/kg), in comparison to a 
group injected with the vehicle only (control). The height o f each bar is the mean value 
for n=5. Significant increases (P < 0.05) were seen on days 4 and 5 (*).
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Fig. 5.1.27B
Urinary gamma-glutamyl transpeptidase excretion calculated as a percentage o f the control
group.
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Fig. 5.1.28 A
Mean level o f alanine aminopeptidase in 18-hr urine before (day 0) during (arrows) and 
after 3 consecutive daily ip doses of ochratoxin A (2.5 mg/kg), in comparison to a group 
injected with the vehicle only (control). The height o f each bar is the mean value for 
n=5. Significant increase (P < 0.05) were seen on days 4,5 ,6  and 8 (*).
URINARY AAP ACTIVITY
500 t
400 4
200 4
100 4
^
P . f t P i P  I p  I p i P  I P  I p i p  I p  I P  I p  I p  I p , I p
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
DAYS OF TREATMENT
Fig. 5.1.28B
Urinary alanine aminopeptidase excretion calculated as a percentage o f the control group.
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corresponding to 432, 400, 201 and 243% respectively of the control group
(Fig. 5.1.28B). With the exception of days 10 and 11, the enzymatic 
activity remained elevated through the rest of the experiment. The 
assessment of NAG activity was not possible, due to technical difficulties 
of unknown origin, where the blanks had higher values than the actual 
urine samples.
Discussion. These data show that all 3 enzymes assessed, increased 
considerable from the control value, during the course of the experiment. 
Although AAP and GGT activities started to increase earlier than ALP, this 
enzyme maximum value was 15 fold the control, reached on day 5, in 
contrast to AAP and GGT maximum increases (4- and 2-fold respectively), on 
days 4 and 5. Therefore, ALP seemed to be the most sensitive enzyme in
terms of amount released, (as was the case for single dose studies) and
AAP showed its maximum release at an earlier time than the two other 
enzymes. This means that low repetitive doses of OTA (2.5 mg/kg) caused
major elevations of urinary enzymes such as ALP, AAP and GGT, which may be
reflecting early and minimal injury to the proximal tubule.
Although there are no reports in the literature, on the effect of small 
repetitive doses of OTA, such.as those used in this experiment, on 
urinary enzymes, these findings are consistent with reports on elevation 
of these parameters, after administration of five consecutive daily sc 
doses of 10 mg/kg (Ngaha, 1985), in which ALP became elevated and remained 
so throughout the experiment. In spite of the length of the treatment and 
large doses of the toxin used by Ngaha (1985) the maximun increase of the 
enzyme activity was much lower than that in this study (6-fold vs. 15- 
fold) . ALP and GGT activity has also been reported to increase after 
subchronic oral administration of small doses of OTA to rats (Kane et al,
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1986a). It is difficult to establish comparison between different 
treatments, unless it is done on very general bases, since there is 
evidence to show that the pattern of urinary excretion is not only 
dependent on the type of toxin, but also on the manner in which it is 
administered (Cottrell et al, 197 6). Also probably the sex and strain of 
test animals, other dietary factors and technical considerations such as 
food and faecal contamination may be source of differences between 
treatments.
Amongst the enzymes tested in this study, ALP appeared to be the most 
sensitive indicator of proximal tubular injury caused by small repeated 
doses of OTA, although GGT and AAP showed a lower effect, they also 
reflected proximal tubular injury.
The measurement of urinary enzyme activity appeared to be a sensitive 
means of monitoring nephrotoxicity caused by small repetitive doses of 
OTA, but the considerable variability seen restricts it usefulness to 
massive effects. The variance of the enzymatic urinary data did seem to 
have improved under the 18-hr food restricted urine collection. This 
probably helped avoid factors that increased variability such as those 
introduced by the contamination of the samples with food. However, the 
problem of the wide variations remained, not only for enzyme activity, but 
for the other parameters measured (see below). Lower values for the 
treated group, than for controls were also seen for ALP and GGT activities 
towards the end of the experiment. The specific enzymatic activity was 
adjusted for variation in urine flow, but this parameter was also very 
variable, it is possible that this can be the real cause for lower enzyme 
activities found in the treated groups. When adjustment for other factors
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was done (ie. creatinine), there was no improvement in the variability
(data not shown).
5.1.2.2. Other urinary parameters.
a. Glucose. After presenting values similar to the control group,
urinary glucose in the treated group, increased on day 5, which became 
significantly different (P < 0.05) on day 6 when it reached a peak and 
also on day 7 (Table 5.1.29, Appendix 1; Fig. 5.1.29A), accounting
for 8789 and 5932% of the control (Fig. 5.1.29B). On day 10, urinary
glucose decreased significantly (P < 0.01) to 61% of the control, and on 
days 11, 12, and 13 the values remained very close to those for the
controls to get a further highly significant (P < 0.01) decrease on day 14
to 40% of the controls value.
Discussion. These data show that the excretion of glucose was strongly 
affected, having started to rise on day 5, reaching a maximum value on day 
6, which was 90-fold the control values. This means that the administered 
dose of OTA, was able to impair considerably the mechanism of reabsorption 
of the proximal tubule. This is in agreement with previous reports by 
Krogh et al (1976) and Berndt and Hayes (1979), who found increased
glucose excretion in pigs and rats treated with OTA.
b. Urinary protein. This parameter was elevated from day 1 through to
day 7, showing significant differences from the controls (P < 0.05) on 
days 2 and 4 (Table 5.1.30, Appendix 1; Fig. 5.1.30A) up to 200 and 537% 
(Fig. 5.1.30B). From day 8 onwards, the urinary protein was decreased, but
not significantly, until the end of the experiment.
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Fig. 5.1.29A
Mean level o f glucose in 18-hr urine before (day 0) during (arrows) and after 3 
consecutive daily ip doses of ochratoxin A (2.5 mg/kg), in comparison to a group injected' 
with the vehicle only (control). The height of each bar is the mean value for n=5. 
Significant increases (P <0.05) were seen on days 6 and 7 (*) and significant decreases (P 
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Fig. 5.1.29B
Urinary glucose excretion calculated as a percentage o f the control group.
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Discussion. These data show that excretion of protein was increased with 
the administration of OTA. It started to increase on day 2 and reached a 
maximum value on day 8 which was 7-fold the control value.
According to several studies, an increase of the total urinary protein
excretion is a sensitive indicator of renal damage induced by some toxic
agents (Balazs et al, 1963, Nomiyama et al, 1973; Sharrat and Frazer, 
1963), however, this parameter on its own fails to provide information 
concerning the site and nature of the lesion.
The findings on proteinuria means either that protein macromolecules have 
been allowed to cross the glomerular barrier and therefore appeared 
excreted in urine, which would suggest glomerular involvement or that 
small molecules of protein were not reabsorbed by the tubules, therefore 
appearing excreted in urine, indicating tubular damage. Both renal
changes may also have occurred simultaneously. In addition, enzymuria can 
also contribute to the increase in total urinary protein.
Fractionation of urinary protein on the basis of molecular size would
allow us to determine the origin of proteinuria (Balant and Fabre, 1979). 
Proteinuria of glomerular origin differs from tubular proteinuria by a 
larger albumin to low molecular weight protein ratio in the urine.
These findings are in agreement with the proteinuria reported previously 
in rats and pigs (Berndt and Hayes, 1979; Szczech et al., 1973a). Krogh, 
et al. (1974) found increased amounts of albumin in the urine of pigs fed 
OTA for three months, which suggests glomerular involvement. 
Histopathological studies performed on different species treated with OTA 
have shown glomerular changes (Albassam et al, 1987; Dwivedi and Burns,
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1984; Krogh et al, 1974; 1976) and these have become a focus of several
major studies in this project detailed below (Section 5.2 and Chapter 6).
c. Urinary volume. This parameter started to increase from day 1 and 
remained higher for the treated group than for the control throughout the 
experiment. On days 5 - 8 the elevated levels were significantly
different (P < 0.05) from the control'values up to 216, 222, 273 and 276%
(Table 5.1.31, Appendix 1; Fig. 5.1.31A and B).
Discussion. These data show that reabsorption of water is decreased by 
OTA, causing an increase in the urinary volume, which started after the 
first dose of the toxin, reaching a peak value of 3 fold the control, on 
day 8. This also indicates impairment of the reabsorptive properties of 
the proximal tubules, caused by administration of OTA. This is in
agreement with findings by Berndt and Hayes, 1979, who reported a slight 
increase in the urinary volume, and consistent with the finding of 
polyuria by the chronic and acute administration of OTA to pigs (Krogh et 
al, 1974; Szczech et al, 1973a), but not with Suzuki et al. (1975b) who
found decreased urine volume in rats treated with 3 daily doses of 5 mg
OTA/kg. Increased urine volume may have a number of causes ranging from 
RPN to acute tubular necrosis and are therefore this parameter is of
little direct mechanistic value.
Although in these experiments the histopathological changes were minimal 
at the two time points measured, renal function was considerably 
disrupted, following the administration of three consecutive daily doses 
of 2.5 mg OTA/kg. The most sensitive parameters were glucose and ALP 
excretion.
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Mean volume in 18-hr urine before (day 0) during (arrows) and after 3 consecutive daily ip 
doses of ochratoxin A (2.5 mg/kg), in comparison to a group injected with the vehicle only 
(control). The height o f each bar is the mean value for n=5. Significant increases (P < 
0.05) were seen on days 5 to 8 (*).
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5.2. Histopathological assessment
5.2.1 Single doses of OTA alone or in combination with ATB^
There were no detectable changes on the kidneys assessed 
histopathologically by H&E and PAS staining at the end of all experiments 
in which single doses of OTA and ATB^ either alone or in combination were 
administered to the rats.
The fact that single doses of the different concentrations of OTA tested 
(1 . and 5 mg/kg), did not produce histological changes, is in agreement 
with reports that low, single, nonlethal doses of the toxin do not cause
morphological changes (Berndt and Hayes, 1979), and that only single
lethal doses caused mild proximal tubular alterations (Kanisawa et al, 
1977) or severe tubular necrosis (Purchase and Theron, 1968). With regard 
to ATB^, which did not cause renal histological alterations, at the 
concentration tested, this is also in agreement with reports where only
large doses of the toxin caused non-specific renal changes in ducklings 
(Asplin and Carnagham, 1961), and only repeated or chronic administration
of ATB^ was able to induce renal morphological changes. Combined doses of 
OTA and ATB^ did not produce microscopic renal changes, suggesting also 
the necessity for accumulation of the toxins. . However another factor may 
have contributed to the lack of sensitivity of the histopathological
assessment, in which the tissues were embedded in wax with subsequent H&E 
and PAS staining only. It is possible that the use of semithin resin 
embedded sections, and other more sensitive techniques, such as enzyme and 
immunohistochemistry will allow the detection of renal changes caused by 
low single doses of the mycotoxins assessed.
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5.2.2 Repeated doses of OTA.
Figs. 5.2.1A, 5.2.IB and 5.2.1C show outer and deeper cortex and medulla
respectively, from control rat kidneys.
The kidneys of animals dosed with 7.5 mg/kg for 3 days, showed 
microscopic changes such as patchy tubular damage (Fig. 5.2.2A), 
consisting of disruption of the proximal tubular brush border, shrunken 
nuclei, large vacuoles and cytoplasmic extrusion. Consequently there was a 
large amount of cellular debris within the proximal tubular lumen. There 
was dilatation of the loops of Henle and distal tubules with PAS positive 
staining casts in the lumen. There was proliferation of the interstitial 
cells in the corticomedullary junction. In the superficial cortex,
glomeruli looked abnormal, with no Bowman's space and very wide
interstitial spaces; partial glomerular sclerosis and thickening of 
basement membrane were also observed (Fig. 5.2.2B).
The kidneys of animals administered 5 mg OTA/kg for. two days and 
sacrificed 24 hr after the last dose, showed patchy proximal tubular
disruption of brush border, vacuolation of cytoplasm (Fig 5.2.3),
occasional extruded nuclei in lumen, and an occasional mitotic figure
present.
The kidneys of animals dosed with 5 mg OTA/kg for 3 days showed patchy 
proximal tubular damage in the superficial cortex, consisting of 
cytoplasmic vacuolation, blebbing and extrusion with detachment of cells 
into the lumen. There was also interstitial cell proliferation around
distal tubules and collecting ducts (Fig. 5.2.4). There were very large,
and rounded nuclei in dilated distal tubules. There were some basophilic 
areas around the distal tubules. The glomeruli showed prominent nuclei.
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Fig. 5.2.1A
Section of control rat kidney outer cortex showing typical appearance of proximal 
tubules (PT), glomerulus (G) and distal tubules (DT). H&E (xl72).
Fig. 5.2.1B
Section of control rat kidney deeper cortex showing proximal tubules, S3 segment with 
distinct brush borders (BB) and vascular bundle (VB). H&E (xl72).
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Fig. 5.2.1C
Section o f control rat kidney showing typical appearance o f medulla. H & E  (x l72).
Fig. 5.2.2A *
OTA 7.5 mg/kg for 3 days. Section showing proximal tubular necrosis (arrow head), pycnotic 
nuclei present (arrow). H&E (xl72).
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Fig. 5.2.2B
OTA 7.5 mg/kg for 3 days PAS staining casts in dilated distal tubules (arrow), 
glomerular sclerosis and thickening of basement membrane (arrow head). x!07.
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Fig. 5.2.3
OTA 5mg/kg for 2 days. Section showing proximal tubular disruption of brush borders 
and cytoplasm. PAS (x!72).
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The kidneys of animals dosed with 2.5 mg OTA/mg for three days, and 
sacrificed 24 hr after the last dose, showed diffuse changes including 
some disruption of the proximal tubular brush borders (Fig. 5.2.5A), in 
addition, interstitial cell proliferation was evident, particularly close 
to glomeruli and medullary rays in the corticomedullary junction (Fig. 
5.2.5B). Some glomeruli looked edematous, with wide interstitial spaces, 
and in some cases prominent PAS staining basement membrane was observed 
(Fig. 5.2.5C).
When the animals were sacrificed two weeks after the last dose, the 
proximal tubules and nuclei showed enlargement (Fig. 5.2.6), and some 
nuclei were displaced towards the luminal edge of the cell. There was also 
diffuse interstitial cell proliferation with basophilic nuclei. Some 
nuclei of distal tubules were also displaced to the centre luminal edge of 
the cell.
5.2.3 Repeated doses of ATB^.
The kidneys of animals dosed with 100 ug/kg showed slight microscopic 
changes, such as diffuse interstitial cell enlargement between proximal 
tubules. Some proximal tubules showed slight necrotic changes, with nuclei 
displaced towards the lumen. There was also disruption of the brush 
border, and a few mitotic figures were present in the proximal tubules 
(Fig. 5.2.7). In the distal tubules, nuclei were enlarged and rounded and 
displaced towards the centre of the tubules.
5.2.4 Repeated and combined administration of OTA and ATB^.
With the aim to study the effect of the interaction between OTA and ATB^, 
after simultaneous administration of repeated doses of both compounds, 
different doses of OTA (5, 2.5 and 0.5 mg/kg), were administered in
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Fig. 5.2.4
OTA 5 mg/kg for 3 days. Proximal tubular cytoplasmic disruption and extrusion of 
nuclei (arrow). Prominent interstitial cells (arrow head) adjacent to distal tubules 
and collecting ducts. H&E (xl72).
Fig. 5.2.5A
OTA 2.5 mg/kg for 3 days. PAS stained section showing disruption of brush border and 
vacuolation of cytoplasm (arrow). x!72.
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Fig. 5.2.5B
OTA 2.5 mg/kg for 3 days. Section showing interstitial cell proliferation. H&E 
(xl07).
Fig. 5.2.5C
OTA 2.5 mg/kg for 3 days. Edematous glomeruli with prominent PAS staining basement 
membrane (xl72).
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Fig. 5.2.6
OTA 2.5 mg/kg for 3 days. Enlarged nuclei within proximal tubules (arrow) after two 
weeks respite. PAS (x l72).
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Fig. 5.2.7
ATB^ 100 ug/kg for 3 days. Section of cortex showing extrusion o f proximal tubular 
nuclei also mitotic figures (arrow) and prominent interstitial cells (arrow). H&E 
(xl72). 145
combination with one low, dose of ATB^ (100 ug/kg).
The . kidneys of animals administered 5 mg OTA plus 100 ug of ATB^^/kg for 
three days, showed severe and extensive damage of proximal tubules, with 
swelling and necrosis.
The kidneys of animals dosed with 2.5 mg OTA plus 100 ug ATB^/kg for two 
days, showed generalized cytoplasmic swelling, with vacuolation and 
blebbing. The nuclei were dark and basophilic, and some were displaced 
towards the lumen. There were some casts within distal tubules'. The 
presence of monocytes, could be indicative of a necrotic change taking 
place within the tissue.
The kidneys of animals dosed with 2.5 mg OTA plus 100 ug ATB^/kg for 
three days, showed severe disruption of the Sg segment of the proximal 
tubule with cellular swelling, vacuolation of cytoplasm and necrosis (Fig. 
5.2.8A). The PAS staining of brush border was less intense than in the 
controls. Some glomeruli showed disruption of the general morphology (Fig. 
5.2.8B), including edematous appearance, intense and faint staining 
nuclei, and cytoplasmic vacuolation, possibly indicative of necrosis. 
Tubular and glomerular changes appeared to be more marked than with OTA 
(See Fig. 5.2.5A) or ATB^ alone.
The kidneys of animals dosed with 0.5 mg OTA plus 100 ug ATB/kg for three 
days, showed minimal changes, involving occasional cytoplasmic disruption 
and displaced nuclei in proximal tubules.
Discussion. In the present study in rats, repeated ip doses of OTA, 
induced microscopic renal changes that were dose related. The
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Fig. 5.2.8A
OTA 2.5 mg/kg and A T B j 100 mg/kg for 3 days. Section showing severe disruption o f 
the So segment o f the proximal tubule with cellular swelling, vacuolation o f 
cytoplasm and necrosis. Compare to Figs. 5.2.5A and B. PAS (xl07). Yellow colour is 
due to lack o f filte r during photographing.
Fig. 5.2.8B
OTA 2.5 mg/kg and AT B j  100 ug/kg for 3 days. Section o f glomerulus showing intense 
and faint staining nuclei and cytoplasmic vacuolation. H&E (x!72)
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nephrotoxicity of OTA is associated here mainly with proximal tubular 
damage, which is in agreement with previous studies (Suzuki et al, 1975). 
But most important, after routine histology, there is evidence of 
glomerular injury, such as edema and prominent PAS staining basement 
membrane, which has not been previously described in the literature, 
following such low doses of OTA. Damage to glomeruli has been reported in 
pigs fed the tpxin for three months (Krogh, 1976), and after the 
administration of massive single doses to rats (Albassam, 1987).
Repeated doses of ATB^ caused only slight microscopic renal changes.- Renal 
lesions have been previously described, only after relatively high doses 
of the mycotoxin were administered for several days (Madhavan and Rao, 
1967; Madhavan et al, 1965). But the most important feature in this work 
is the interactive effect that such low doses of ATB^ had when applied in 
combination with repetitive doses of OTA (2.5 mg/kg).
The combined administration of 2.5 mg OTA/kg and 100 ug/kg to rats for 3 
consecutive days, caused severe proximal tubular damage that was not seen 
with OTA or ATB^ alone. But a distinct feature is the glomerular injury 
detected in the form of oedema, general cellular derrangement and faint 
staining nuclei, possibly indicative of cell necrosis, which has not been 
described previously in the literature. There is a report in which the 
effect of simultaneous administration of OTA and ATB^ to rats during four 
months has been described as synergistic with degenerative changes, 
anaplasia and hyperchromatic nuclei in epithelial cells, not present when 
either toxin was administered alone (Rati et al, 1981) . In another report 
the effect of OTA and ATB^ in chickens fed both toxins simultaneously for 
three weeks was also described as synergistic, based on gross changes 
observed in kidney (Huff and Doerr, 1980). However acute effects due to
the combined administration of OTA and ATB^ have not been reported 
previously, neither in proximal tubules, nor in glomeruli of any species.
From the staining methods it is difficult to specify the type of
glomerular cell and change being undergone, therefore these data still 
need to be confirmed by high resolution microscopy, histochemistry,
immunohistochemistry and electron microscopy, in order to be able to 
describe these changes in greater detail.
5.3 Summary and conclusions
5.3.1 Summary
5.3.1.1 Biochemical parameters
1- Single low doses of OTA and ATB^ alone or in combination caused some 
changes on the excretion of urinary enzymes such as ALP, AAP, GGT and NAG.
2- Low repetitive doses of OTA (2.5 mg/kg) caused major elevations of
urinary enzymes such as ALP, AAP and GGT. ALP activity showed the highest
increase of all the enzymes (1752% on day 7) and AAP showed its maximum 
release at an earlier time point (432% on day 4).
3- Low repetitive doses of OTA (2.5 mg/kg) remarkably affected the 
excretion of glucose which reached a maximum value on day 6, which was 90- 
fold the control values. Protein and urinary volume were also increased 
(537% on day 4 and 276% on day 8 respectively).
4- There was great animal-to-animal variability in all biochemical 
parameters measured.
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5.3.1.2 Histopathological assessment
1- There were no detectable changes on the kidneys assessed 
histopathologically by H&E and PAS staining at the end of all experiments 
in which single doses of OTA and ATB^ either alone or in combination were 
administered to the rats.
2- Repeated ip doses of OTA, induced microscopic renal changes that were 
dose related. The nephrotoxicity of OTA is associated here with proximal 
tubular damage and glomerular changes.
3- Repeated doses of ATB^ caused only slight microscopic renal changes.
4- The histopathological changes observed after the combined 
administration of different doses of OTA and a fixed low dose of ATB^ for 
3 consecutive days were not dose-related.
5- The combined administration of 2.5 mg OTA/kg and 100 ug/kg to rats for 
3 consecutive days, caused severe proximal tubular damage that was not 
seen with OTA or ATB^ alone. Glomerular injury was also detected in the 
form of oedema, general cellular derrangement and faint staining nuclei, 
possible indicative of cell necrosis.
5.3.2 Conclusions
5.3.2.1 Biochemical parameters
1- The study of urinary enzymes such as ALP, AAP, GGT and NAG, over 24-hr 
period, after low single ip doses of OTA and ATB^ administered alone or 
simultaneouly is not a sensitive test, and does not give a dose related 
response.
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2- Although the histopathological changes were minimal when assessed on 
days 4 and 15, renal function was considerably disrupted, following the 
administration of three consecutive daily doses of 2.5 mg OTA/kg. The most 
sensitive parameters were glucose and ALP excretion.
3- The administered dose of OTA, was able to impair considerably the
mechanism of glucose reabsorption in the proximal tubule.
4- The findings on proteinuria mean either that protein macromolecules
were allowed to cross the glomerular barrier and therefore appeared 
excreted in urine, suggesting the possibility of glomerular involvement or 
that tubular reabsorption of low molecular weight proteins was impair. 
Both possibilities can also have occurred; however this needs further 
elucidation.
5.3.2.2 Histopathological assessment
1- The interactive effect observed between OTA and ATB^ after combined 
administration of both toxins seems to be synergistic.
2- The use of more sensitive techniques such as, high resolution
microscopy, histochemistry, immunohistochemistry and electron microscopy, 
might allow the detection of renal changes caused by low single doses of 
the mycotoxins assessed and would also help to confirm and describe the 
glomerular changes in greater detail.
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CHAPTER 6
IN VITRO STUDIES ON ISOLATED GLOMERULI AND PROXIMAL TUBULAR FRAGMENTS.
6.1 De novo protein synthesis
Because work was being done with isolated pig and rat glomeruli, at the 
time when these experiments were started, the same conditions were 
maintained (ie. incubation with Krebs and Tyrodes buffer respectively) for 
the initial experiments. However, in order to be able, to undertake further 
metabolic studies in isolated and cultured glomeruli, it was necessary to 
change the buffer system. Brendel and Meezan (1973) used Earles-HEPES to 
study glucose and fatty acid metabolism, and there was the need to set up 
similar experimental conditions, to establish the same reference point.
6.1.1 Amino acid incorporation into pig glomeruli incubated with Krebs 
buffer.
The incorporation of several different tritiated amino acids into isolated 
pig glomeruli was measured. The results are shown in Table 6.1.1 of the 
Appendix 2 and Figure 6.1.1. The levels of statistical significance 
are shown in Table 6.1.2 of Appendix 2. The results indicate that LEU had 
the highest rate of incorporation into macromolecules of all the amino 
acids tested. The rates of incorporation increased almost linearly with 
time. With the exception of the incorporations at 3 and 2 hr, the uptake 
of LEU was significantly different between each of the time points 
compared. PRO and HIS had very similar rates of incorporation at about 
50% of the rate of LEU and also followed a linear pattern. For both amino 
acids the incorporations were significantly different between all time
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points studied up to 2 hr of incubation, LYS showed a similar rate of
incorporation to PRO and HIS, after which it decreased. GLY was the
least well incorporated amino acid with very low rates up to 4 hr. There 
were significant differences in the uptake of the amino acid between most 
of the time points compared for GLY. At 4 and 3 hr of incubation the
incorporation of the different amino acids were significantly different
with the exception of PRO and HIS which showed very similar values. At 2
hr of incubation with the exception of PRO and LYS, PRO and HIS and LYS
and HIS, all other amino acids showed statistically significant
differences. At 1 hr of incubation there were statistically significant
differences in the incorporations between LEU and GLY (P < 0.05), LEU and 
LYS (P < 0.05), LEU and PRO (P < 0.05), LEU and HIS (P < 0.01) and HIS 
and PRO (P < 0.05). After 4 hr of incubation all five amino acids could be 
ranked according to the amount of amino acid incorporated as follows: LEU
»  PRO = HIS > LYS > GLY.
The time course of the incorporation of PRO between different experiments 
(Fig. 6.1.2, Table 6.1.3 Appendix 2) was very similar and, in most of
them, the maximum amino acid uptake (after 4 hr of incubation) was in the
range of 1-2 pmol/mg of protein. Only one experiment showed a higher PRO 
uptake at all time points, reaching 5.6 pmol/mg of protein at 4 hr of 
incubation. The rate of incorporation of PRO was statistically
significantly different for all time points studied for most of the
experiments (Table 6.1.4 Appendix 2).
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AMINO ACID INCORPORATION
INTO ISOLATED PIG GLOMERULI
GLY
LYS
HIS
PRO
LEU
0 1 2 3 4
Time (hr)
Fig. 6.1.1
Kinetics o f de novo protein synthesis by isolated pig glomeruli, incubated with Krebs 
buffer. 0.5 ml o f buffer containing 2.5 uCi o f each o f the 3H labelled amino acids (GLY, 
HIS, LEU, LYS, and PRO) was added separately at 0 time to 0.5ml o f the glomerular 
preparation. The ordinate represents specific activity incorporated into TCA-prccipitable 
labelled material. Each line corresponds to a different experiment and each time point is 
the result o f triplicate incubations.
Incorporation of proline
into isolated pig glomeruli
C 5' 
C l
D»
430 1 2
Time (hr)
Fig. 6.1.2
Time-course o f the incorporation of 3H-proline into total glomerular protein. 0.5 ml of 
buffer containing 2.5 uCi o f the labelled amino acid were added at time 0 to 0.5 ml 
aliquot o f pig glomerular suspension and incubated up to 4 hr. The ordinate represents 
specific activity incorporated into TCA-precipitable labelled material. Each line 
corresponds to a different experiment and each time point is the result o f triplicate 
incubations.'
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6.1.2 Comparison of the incorporation of PRO by isolated glomeruli
incubated with two different buffers.
6.1.2.1 Pig glomeruli.
Incubation with Krebs buffer (pH 7.4) gave a much lower incorporation of 
PRO than Earles-HEPES (pH 7.4) at all time points studied, as can be seen 
in Fig. 6.1.3 and Table 6.1.5 Appendix 2. At 2 hr of incubation with 
Krebs, the incorporation of PRO was significantly lower (P < 0.05) than 
with Earles-HEPES. After 4 hr of incubation in Earles-HEPES the 
incorporated PRO was 10 times more than in Krebs and the difference was 
highly significant (P <0.001).
6.1.2.2 Rat glomeruli.
A comparison was undertaken on the incorporation of PRO into isolated rat 
glomeruli incubated with Tyrodes and Earles-HEPES.
Fig. 6.1.4 and Table 6.1.6 Appendix 2 show the inorporation of PRO when 
rat glomeruli was incubated either with Tyrodes buffer or Earles-HEPES 
buffer. Incubation with Tyrodes gave a much lower incorporation of PRO 
than Earles-HEPES at all time points studied, and after 4 hr of 
incubation, the incorporation of the amino acid was twice higher with 
Earles-HEPES than with Tyrodes.
While the effects of chemicals on glomeruli in Krebs was studied in the 
early part of this work (Section 6.1.1), Earles-HEPES was then chosen as 
the incubation buffer for all further experiments (Sections 6.1.3-4).
Other conditions were also set up, as follows:
6.1.2.3 Influence of non-radioactive PRO on the incorporation of the 
labelled precursor into isolated pig glomeruli.
While some workers favour adding only the tracer molecule such as in the
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Incorporation o f proline into pig g lom eruli
incubated with two different buffers
4-i
2 4
Time (hr)
Earles-HEPES
Krebs
Fig. 6.1.3
Isolated pig glomeruli were suspended either in Krebs or Earles-HEPES buffers, and 
incubated with 0.5 ml of buffer containing 2.5 uCi 3H-proline at 0,2 and 4 hr.
INCORPORATION OF PROLINE INTO RAT GLOMERULI
INCUBATED WITH TWO DIFFERENT BUFFERS
Q.
1 2 3 4
Time (hr)
Fig. 6.1.4
Earles-HEPES
Tyrodes
Isolated rat glomeruli were suspended either in Tyrodes or Earles-HEPES buffers, and 
incubated with 0.5 ml of buffer containing 2.5 uCi 3H-proline at 0 ,1 ,2 ,3  and 4 hr.
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assay system used above, others have added carriers to saturate non­
specific binding sites. The effect of non-labelled precursor was therefore 
3assessed on H-PRO incorporation.
3When H-PRO incorporation was assessed in the presence of different 
concentrations of the non-labelled amino acid there were no variations at 
the minimum concentration used, in relation to the control (Figs. 6.1.5 
and Table 6.1.7 Appendix 2). However, as long as the concentration of 
non-label increased (100 - 1000 uM), there was a dose-related decrease in
3
the incorporation of H-PRO (to 69 - 55%). Only the incorporation of PRO 
in the presence of 1000 uM of the non-radioactive aminoacid • was 
significantly lower (P < 0.05) than the control.
6.1.2.4 Influence of non-radioactive analogues of PHE on the incorporation 
of this radiolabelled amino acid into isolated rat glomeruli.
The effect of different concentrations of non-labelled amino acids, and 
analogues of PHE on the incorporation of this one as glomerular protein 
was studied (Fig. 6.1.6 and Table 6.1.8 Appendix 2). Cold or non-labelled 
TYR and especially TRP, in the range of 0.025 - 2.5 mM, inhibited
radiolabelled PHE incorporation in a dose-related pattern. Low 
concentrations of non-labelled HIS (50 uM), caused a slight and non­
significant increase on PHE uptake, but at higher concentrations of the 
amino acid (ie. 0.5 and 2.5 mM), PHE incorporation was decreased 
significantly (P <0.05 and 0.01 respectively), with similar values to 
those obtained with non-labelled TRP.
6.1.3 Incorporation of PRO into pig glomeruli incubated with Earles- 
HEPES.
Thus a new set of experiments was started using optimized experimental
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Incorporation of proline into pig g lom eruli
incubated with the cold amino acid
100-
50-i
100
Cold PRO (uM)
1000
Fig. 6.1.5
0.5 ml aliquots of pig glomenili suspended in Earles-HEPES were incubated with 0.5 ml of 
buffer containing 2.5 uCi H-proline and different concentrations o f the "cold" amino acid
for 4 hrs.
EFFECT OF TYR, TRP AND HIS
ON THE GLOMERULAR INCORPORATION OF PHE
150 n
loo
50-
CN
TYR
TRP
HIS
DOSE (mM)
Fig. 6.1.6.
0.5 ml aliquots of rat glomeruli suspended in Earles-HEPES buffer were incubated with 0.5 
ml of buffer containing 2.5 uCi H-phcnylalanine and different concentrations o f "cold" 
HIS. TRP and TYR for 4 hrs.
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conditions such as incubation with Earles-HEPES buffer.
Incorporation of PRO into isolated pig glomeruli incubated with Earles- 
HEPES buffer was compared between different experiments (Fig. 6.1.7 and 
Table 6.1.9 Appendix 2). In most of the cases, the incorporation follows a 
similar pattern, with maximum values at 4 hr of incubation, ranging from
1.3 - 3 pmol/mg of protein. Two of the experiments had much higher
incorporation rates after 4 hr of incubation (5.1 and 7.6 pmol/mg 
protein). The incorporation of PRO showed statistically significant 
differences between all time points studied for each of 6 experiments 
(Table 6.1.10 Appendix 2), with the exception of one where the uptake of 
the amino acid did not show statistically significant differences between 
3 and 4 hr.
6.1.4 Amino acid incorporation into rat glomeruli using Earles-HEPES as 
the incubation buffer.
Radiolabelled PRO and PHE were incubated with rat glomeruli and Earles- 
HEPES buffer, and their incorporation into de novo synthesis of protein 
was compared (Fig. 6.1.8). The amino acids uptake was linear with time, 
but PHE rate of incorporation was twice that of PRO (Table 6.1.11 
Appendix 2).
In view of the differences found between PRO and PHE, it was decided to 
compare the incorporation of several other amino acids (Table 6.1.12 
Appendix 2 and Fig. 6.1.9A and B) into rat glomeruli. The highest rate of 
incorporation was that of TRP. After 4 hr of incubation, 117 - 134 pmol 
of amino acid/mg protein had been incorporated. This was 4 times higher 
(P < 0.01) than PHE which was ranked in second place with a range from 25 
- 26.3 pmol of amino acid/mg protein. PHE incorporation showed the best
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Incorporation of proline
Into Isolated pig glomeruli
CL
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2 3 410
Time (hr)
Fig. 6.1.7
Timc-course o f the incoiporation o f ^ H-proline into total glomerular protein. 0.5 ml o f 
Earles-HEPES buffer containing 2.5 uCi o f the labelled amino acid were added at time 0 to 
0.5 ml aliquots o f pig glomerular suspension and incubated up to 4 hr. The ordinate 
represents specific activity incorporated into TCA-precipitable labelled material. Each 
line corresponds to a different experiment and each dme point is the result o f triplicate 
incubations.
AMINO ACID INCORPORATION
INTO ISOLATED RAT GLOMERULI
30-i
23-
20-
15-
10-
Time (hr)
Fig. 6.1.8
Kinetics o f de novo protein synthesis by isolated rat glomeruli incubated with Earles- 
HEPES buffer. 0.5 ml o f buffer containing 2.5 uC: o f each o f the H-labelled amino acids 
(PHE and PRO) was added at 0 time to 0.5 ml o f the glomerular preparation. The ordinate 
represents specific activity incorporated into TCA-precipitable labelled material. Each 
time point is the result o f triplicate incubations.
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AMINO ACID INCORPORATION
INTO ISOLATED RAT GLOMERULI
150 ->
Q.
-0
Time (hr)
TRP
PHE
TYR
LEU
PRO
HIS
Fig. 6.1.9 A
Kinetics of de novo protein synthesis by isolated rat glomeruli, incubated with Earles- 
HEPES buffer. 0.5 ml of buffer containing 2.5 uCi o f each of the 3H-labelled amino acids 
(HIS, LEU, PHE, PRO, TRP and TYR) was added at 0 time. The ordinate represents specific 
activity incorporated into TCA-precipitable labelled material. Each time point is the 
result o f triplicate incubations.
AMINO ACID INCORPORATION
INTO ISOLATED RAT GLOMERULI
201
o 1 2 3 4
PHE
TYR
LEU
PRO
HIS
Time (hr)
Fig. 6.1.9B
Enlarged view of the incorporation of HIS, LEU, PHE, PRO and TYR from Fig. 6.1.9A.
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inter-experimental reproducibility with very small variance values at 
every time point that was studied for each of 4 experiments. The 
incorporation of this amino acid was significantly higher than LEU (P <
0.05) and the rest of the aminoacids (P < 0.01). LEU incorporation was
ranked third and PRO and TYR had similar incorporations after 4 hr. TYR
incorporation was significantly higher (P < 0.01) than HIS, and HIS was
the least actively incorporated. Despite the inter-experimental
variability in some of the cases (Figs. 5.1.1 - 6 of Appendix 2), the 
amino acid incorporation followed a similar, almost linear pattern. As can 
be seen from the tables, coefficients of variance were normally low.
6.1.5 Discussion.
Amino acid incorporation has been extensively used as a marker of de novo 
synthesis of protein. These data represents de novo protein synthesis
based on the fact that:
a- Macromolecules were TCA-precipitated and the TCA solution contained
small amounts of the respective cold amino acid, in order to avoid non­
specific adsortion.
b- There were differences in the rates of amino acid incorporation, 
c- The incorporation of a specific amino acid was inhibited by its 
analogues.
The data here show that isolated pig and rat glomeruli incorporate 
different amino acids, linearly for several hours, at different rates. 
This means that isolated glomeruli maintain their viability for a 
reasonable period of time (ie. > 4 hr), and also some of their biochemical 
properties, such as de novo synthesis of protein.
The effect of buffer on glomerular de novo protein synthesis. The
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incorporation of PRO into isolated pig and rat glomeruli was compared by
incubation with two different buffers (Earles-HEPES vs. Krebs for pig and
Earles-HEPES vs. Tyrodes for rat). The rate of amino acid incorporation
was greater when the incubation was performed with Earles-HEPES buffer for
both types of glomeruli, although in the assays with pig, the absolute
values of amino acid incorporation were far greater for Earles-HEPES than
was the case of rat glomeruli. This means that the amount of de novo
synthesised protein can vary with the composition of the incubating
media. It appears that Earles-HEPES buffer offers better control of pH
than Krebs and Tyrodes, the buffering properties of which relay on the
amount of bicarbonate present. Unless a constant supply of CO 2  is
provided, Tyrodes and Krebs loose their buffering capability with time.
Earles-HEPES seems to be especially appropriate for those studies
involving prolonged incubation out of a CC^-incubator and without constant
. 1 4  14supply of CC>2 r and also for trapping CO 2  from C labelled precursors 
and Earles-HEPES is also useful as the incubation buffer for cultured 
cells. Thus because CO2  gassing was not used in the previous experiments 
a non-gassing system was chosen.
Earles-HEPES was therefore chosen as the incubation buffer for all further 
experiments with isolated pig and rat glomeruli, and also for tubular 
fragments.
The effect of addition of non-labelled precursors to the incubation media.
Addition of increasing concentrations of non-radiolabelled PRO, decreased 
the incorporation of the radioactive amino acid. This is probably due to 
the "dilution" of the radiolabelled compound by competitive inhibition, 
therefore decreasing the chance of the labelled molecule been used as the
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only source of precursor for protein synthesis. In view of the observed 
effect of the non-radiolabelled PRO, it was decided not to add it to the 
incubation media, in order to get higher radioactive counts and therefore 
increased sensitivity of the method.
Incorporation of different radioactive amino acids. Pig glomeruli 
incorporated LEU at a much higher rate than PRO and the other amino acids. 
The order of incorporation being LEU »  PRO = HIS > LYS > GLY.
In rat glomeruli TRP was incorporated at the highest rate, with PHE and 
TYR ranking next. The ranking of incorporation was TRP »  PHE > TYR = LEU 
> PRO > HIS.
These data show that isolated rat glomeruli incorporate a high proportion 
of aromatic amino acids into protein and that this incorporation is at a 
higher rate than for PRO, which is a novel observation.
The incorporation of PRO and other different labelled amino acids into 
isolated piglet or rat glomeruli has been reported to be linear for 
several hours (Grant et al, 1975; Krisko and Walker, 1974), and when 
equimolar amounts of radioactive PRO and LYS, were added to isolated rat 
glomeruli, LYS was incorporated more than PRO (Krisko and Walker, 1976), 
which is in agreement with recent studies by Ahmed et al. (1987) who found 
the ranking of incorporation being LYS > PRO > HIS. However no comparison 
on the rates of incorporation between other different amino acids, nor 
interspecies comparison have previously been reported. Thus, the data 
presented in this thesis, appear to be the first that documents the 
incorporation of aromatic amino acids into isolated rat glomeruli and also 
shows differences in the basal de novo protein synthesis in pig and rat
glomeruli.
The data on PRO incorporation in Krebs buffer as compared between 
different experiments show that the amino acid is incorporated linearly 
over 4 hr with similar rates of incorporation for most of the cases. Only
one out of 6  experiments showed much higher rates of the PRO incorporation
which can be interpreted as a factor of individual variation within the 
different pigs, as discussed in section 6 .2 .2 .
The data on the incorporation of PRO into pig glomeruli incubated in 
Earles-HEPES buffer, show a pattern of incorporation similar to the one 
when Krebs buffer was used, was also linear and the rate of amino - acid 
incorporation increased with time. The values of the incorporation of PRO 
from Earles-HEPES, for several different experiments were distributed in 
three different populations with a total range going from 1.0 to 7.6
pmol/mg protein after 4 hr of incubation. This indicates a 7.6-fold
variability, which may reflect the individual differences existing in the 
pigs sampled, as suggested above.
From these studies on de novo synthesis of protein it is difficult to 
explain the specific fate of the different amino acids within either pig 
or rat glomeruli. Amino acids such as LEU are known to be present in all 
proteins, therefore its use does not allow differentiation between the 
synthesis of specific proteins of the glomerulus. PRO is incorporated into 
all proteins, but its subsequent hydroxylation occurs exclusively in GBM 
collagen, thus allowing differentiation between GBM and non-GBM protein 
metabolism. However our study did not distinguish whether the label once 
incorporated into macromolecules was present as PRO or OH-PRO. LYS is also 
used in GBM, and like PRO, it undergoes hydroxylation. Thus OH-LYS is also
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present in large amounts in GBM, being indicative of the presence of 
collagenous components. TYR is an amino acid present in small amounts in 
basement membranes. This amino acid together with TRP have been found to 
make part of the non-collagen GBM protein fibronectin, and localized in
folding regions, that seem to be important for adhesive activity and
cellular spreading (Yamada, 1983).
Although GLY appears to be a major constituent of GBM, in our study in
isolated pig glomeruli, it had the lowest incorporation into •total
glomerular protein. GLY incorporation has also been reported to be low in 
proximal tubular fragments (Kwizera and Bach 1987). GLY appears to be 
largely incorporated into GBM protein as it was shown by Hjelle et al 
(1979), who compared the incorporation of GLY, LYS and PRO and found GLY 
to be the most incorporated in rat GBM, being followed by LYS and then 
PRO. The fact that our study measured the incorporation of GLY into total 
glomerular protein and not into isolated GBM, does not allow to compare 
the proportion in which GLY was incorporated in these two different 
systems; furthermore, it has been shown above that the use of a different 
buffer can change the rate at which an amino acid is incorporated; this 
could also account for the differences in the incorporation of GLY into 
total glomerular protein and GBM. There are no previous reports on the 
incorporation of GLY into total glomerular protein.
Observations by Price and Spiro (1977), suggest that only a small 
proportion of the protein synthetic activity in the cells of glomeruli is 
dedicated to GBM synthesis. Therefore, a small proportion of amino acids 
incorporated into GBM-collagen, in these experiments with isolated 
glomeruli is expected. In studies involving total glomerular protein
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synthesis, the amino acids are more readily incorporated in either non­
collagen or non-GBM proteins which have a faster turnover within the 
glomerulus (ie. 9 days vs 100 days for GBM-collagen). Therefore is 
difficult to extrapolate from this data to de novo synthesis of GBM 
protein. However, indirect information can be obtained from the
biochemistry of the cells that produce and maintain this extracellular
matrix, assuming that changes in the biochemical functions of the cells 
which are in contact with the GBM, take place before or in parallel to any 
modification in the structure or composition of the GBM. On the other 
hand, the component of GBM that has been the focus of attention for 
studies in composition and turnover rate is the glycoprotein collagen 
(Kefalides et al, 1979), probably because of the difficulties in isolating 
non-collagenous material, with the traditional methods. However,
glomerular extracellular matrix is also composed of other non-collagenous 
proteins with higher turnover rates, which have been more recently 
detected (eg. fibronectin) and are not yet as well characterized
structurally and functionally within the glomeruli. Although fibronectin 
has been extensively studied in other cells and tissues, further studies 
are needed to characterize the properties of this protein in glomeruli.
6.1.6 Summary and conclusions.
6.1.6.1 Summary
1- Isolated pig and rat glomeruli incorporate different amino acids, 
linearly for several hours, at different rates.
2- Pig glomeruli incorporates LEU at a much higher rate than PRO and 
other amino acids. The order of incorporation being LEU »  PRO = HIS > LYS 
> GLY.
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3- In rat glomeruli TRP is incorporated at the highest rate, with PHE and 
TYR ranking next. The ranking of incorporation was TRP »  PHE > TYR = LEU 
> PRO > HIS.
4- Increasing concentrations of non-radiolabelled amino acids decrease 
the incorporation of the respective labelled precursor.
5- Increasing concentrations of non-labelled amino acids, such as 
HIS, TRP and TYR, decrease the incorporation of radiolabelled PHE.
6 - Incubation of isolated rat and pig glomeruli with Earles-HEPES buffer
increases the incorporation of PRO more than Tyrodes and Krebs.
6.1.6.2 Conclusions.
1- Isolated rat and pig glomeruli maintain their viability for a
reasonable period of time (ie. > 4 hr), and also some of their biochemical
properties, such as de novo synthesis of protein.
2- Isolated rat glomeruli incorporate a high proportion of aromatic 
amino acids into protein and that this incorporation is at a higher rate 
than for PRO, which is a novel observation.
3- The amount of de novo synthesised protein can vary with the 
composition of the incubating media.
4- Only a small proportion of the amino acids incorporated into total 
glomerular protein is expected to be incorporated into GBM-collagen.
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5- The fact that isolated rat glomeruli incorporate aromatic amino acids 
(ie. TRP and TYR) at higher rates than PRO/ suggests that a glomerular 
macromolecule other than GBM-collagen with a high turnover/ is being 
synthesised de novo .
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6.2 Effect of different chemicals on de novo protein synthesis.
6.2.1 Adriamycin (ADR)
6 .2.1.1 Effect of ADR on the incorporation of different amino acids by 
isolated pig glomeruli, using Krebs as the incubation buffer.
The effect of ADR assayed on de novo protein synthesis using different 
amino acids it is shown in Fig. 6.2.1 and Table 6.2.1 and 2 of Appendix 
2). PRO and LEU were similarly affected, with very close 
(Concentration of chemical that inhibits protein synthesis to 50% of the 
control values) (13 and 12.7 uM) as shown in Table 6.2.1, They showed a
dose-related response. The incorporation of the amino acids in the
presence of 7.8 uM of ADR, was significantly different from the control at 
P < 0.01 for LEU and P < 0.05 for PRO. Increasing concentrations of the 
drug caused an inhibitory effect on the incorporation of both LEU and PRO, 
which was significantly different from the respective controls (P < 0.01). 
Although the IC^q for HIS (15.6 uM) was slightly higher than those for PRO 
and LEU, there was a dose-related response. The incorporation of amino 
acid at ADR concentrations of 7.8 and 15.6 uM were significantly different 
from the control (P < 0.01) and higher concentrations depressed protein 
synthesis more (P < 0.001).
In spite of the low level of protein synthesis showed by GLY, in
comparison to the other amino acids, its incorporation was markedly 
affected by ADR, having an IC^g of 13.6 uM, and showed statistically 
significant reductions at all concentrations tested (P < 0.05 for
concentrations of 7.8, 15.6, and 31.2 uM, and P < 0.01 at 62.5 uM of ADR). 
However, this was hot a dose-related effect, since higher concentrations 
did not depress the synthesis of protein below 40% of control.
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Fig. 6.2.1
0.5 ml aliquots o f pig glomeruli suspended in Krebs buffer were incubated at 37°C with 0.5 
ml of buffer containing 2.5 uCi of various ’ H-amino acids (GLY.LYS, HIS, PRO and LEU), 
and different concentrations o f adriamycin, for 4 hr. The ordinate represents the proportion 
of incorporated amino acid calculated as a percentage of the total amino acid incorporation 
into isolated pig glomemli incubated without the chemical(control). Each point is the result 
o f triplicate incubations.
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TABLE 6.2.1
RELATIVE TOXICITY OF ADR ON THE INCORPORATION OF 
DIFFERENT AMINO ACIDS INTO ISOLATED PIG GLOMERULI
AMINOACID MAXIMUM INCORPORATION* IC5 0  (uM)
LEUCINE 3.7 + 0.38 12.7
PROLINE 2 . 0  + 0 . 2 13.0
HISTIDINE 2.0 ± 0.17 15.6
LYSINE 1 . 2  + 0 . 0 1 *
GLYCINE 0.5 ± 0.1 13.6
* pmol/mg protein
* LYSINE DID NOT REACH THE IC5Q POINT.
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From all amino acids studied, LYS was the least sensitive to ADR effect, 
none of the concentrations tested produced an inhibition of the 
incorporation that reached 50%. However, the reduction in the 
incorporation was significantly different (P < 0.01) from the control 
value at 7.8 and 15.6 uM of ADR, and highly significant (P < 0.001) at 
higher concentrations.
E f f e c t  o f  ADR on PRO in c o rp o ra t io n . The effect of different 
concentrations of ADR was assessed on the incorporation of PRO and
compared in several experiments. Fig. 6.2.2A shows the results as
percentage of control, it can be seen that the effect of ADR was
reproducible between experiments and very similar for all of them. In all 
of the experiments, the concentrations of ADR (7.8 - 250 uM) assayed
caused a statistically significant reduction on PRO incorporation. The 
degree of significances is shown in Table 6.2.3 of Appendix 2. The 
relative toxicity of the drug, presented as IC^q (Table 6.2.2) was in the 
range 11.7 - 27.3 uM which represents an inter-experimental variation of 
less than 3-fold. At the maximum incorporation of PRO, the dose of the 
compound needed to cause a 50% inhibition of amino acid incorporation was 
less than when the de novo synthesis of protein was lower. Fig. 6.2.2B
shows the general trend of ADR effect as an average of several 
experiments.
6 .2.1.2. Effect of ADR on PRO incorporation, using Earles-HEPES as the 
incubation buffer.
The effect of ADR on PRO incorporation into isolated pig glomeruli 
incubated with Earles-HEPES buffer was assessed in several experiments 
(Figs. 6.2.3A and 6.2.3B). All concentrations of ADR had a significant 
inhibitory effect on PRO incorporation, in all experiments, as can be seen
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Fig. 6.2 JA
0.5 ml aliquots o f isolated pig glomeruli suspended in Krebs buffer were incubated at 37°C 
with 0.5 ml of buffer containing 2.5 uCi 3H-proline and different concentrations of 
adriamycin for 4 hr. The ordinate represents the proportion of incorporated amino acid 
calculated as a percentage of the total incorporation of 3H-proline into isolated pig 
glomeruli incubated without the chemical (control). Each point is the result o f 
triplicate incubations.
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Fig. 6.2.2B
Data presented as the average o f five experiments.
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TABLE 6.2.2 
RELATIVE TOXICITY OF ADR ON PROLINE 
INCORPORATION INTO ISOLATED PIG GLOMERULI
EXPERIMENT MAXIMUM INCORPO RATIO N1" IC50 (uM)
1 2.10 18.7
2 1.4 20.3
3 1.1 27.3
4 5.6 11.7
5 2.0 13.0
+ pmol proline/mg protein
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Fig. 6.2 JA
0.5 ml aliquots of isolated pig glomeruli suspended in Earles-HEPES buffer were incubated 
at 37°C with 0.5 ml of buffer containing 2.5 uCi 3H-proline and different concentrations 
of adriamycin for 4 hr. The ordinate represents the proportion of incorporated amino acid 
calculated as a percentage of the total incorporation of •’H-proline into isolated pig 
glomeruli incubated without the chemical (control). Each point is the result of 
triplicate incubations.
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Fig. 6.2 JB
Data presented as the average of three experiments.
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in Table 6.2.4 Appendix 2. The estimated IC^q was < 26 uM.
These data show that PRO incorporation into glomeruli exposed to ADR, and 
assayed in Earles-HEPES buffer, was markedly inhibited as it was when 
Krebs buffer was used. There was little inter-experimental variability. 
Although no smaller concentrations than 31.2 uM were assessed, the 
estimated concentration to cause an inhibition of 50% relative to the 
control value, was very similar to the one obtained using Krebs buffer (26 
vs. 22 uM).
6.2.1.3 ADR effect on PRO incorporation into isolated rat glomeruli..
The effect of ADR on de novo protein synthesis into isolated rat glomeruli 
using PRO as the precursor is shown in Fig. 6.2.4A and B. All 
concentrations of the chemical caused significant inhibition on the 
incorporation of the amino acid. The degree of statistical significance is 
shown in Table 6.2.5 of Appendix 2.
6.2.1.4 Discussion.
The results on the effect of ADR on the incorporation of several amino 
acids into pig glomeruli, show that the drug depressed considerably the 
incorporation of all amino acids, with LEU and PRO, being the most 
sensitive and showing a similar effect, and LYS being the least sensitive. 
This means that de novo synthesis of glomerular protein from different 
amino acids on pig glomeruli is inhibited by ADR, and that some aminoacids 
(ie. LEU and PRO) are more affected than others (ie. GLY, HIS and LYS) .
The data on the inhibitory effect of ADR on PRO incorporation into 
glomeruli incubated in Krebs buffer, as compared in several different 
experiments are very similar and showed an inter-experimental variability
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Fig. 6.2.4A
0.5 ml aliquots o f isolated rat glomeruli suspended in Tyrodes buffer were incubated at 
37°C with 0.5 ml of buffer containing 2.5 uCi 3H-proline and different concentrations of 
adriamycin for 4 hr. The ordinate represents the proportion of incorporated amino acid 
calculated as a percentage o f the total incorporation o f 3H-proline into isolated pig 
glomeruli incubated without the chemical (control). Each point is the result o f 
triplicate incubations.
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125
Fig. 6.2.4B
Data presented as the average of two experiments. 
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of less than 3-fold, which is very small, considering that some 
characteristics of the sampled pigs, such as sub-strain, age, sex, diet, 
status of health, hydration, exposure to nephrotoxins, and time between 
slaughtering and harvesting the tissue can differ and account for 
individual variations in the different metabolic processes.
PRO incorporation was the most effectively inhibited parameter and is 
therefore considered to be a sensitive index of ADR glomerular 
cytotoxicity in pig glomeruli. This is in agreement with previous studies 
performed in glomeruli isolated from the rat (Ahmed et al., 1987).
The fact that ADR decreased considerably the incorporation of PRO (and 
other amino acids) into total glomerular protein, is consistent with the 
in vivo findings that ADR damages glomeruli in rats (Bertani et al, 1982), 
and can also be related to the fact that the drug causes nucleolar 
alterations in renal epithelial cells (Hayashi et al 1984), similar to 
those reported to occur in a variety of in vitro and in vivo cell systems, 
secondary to the action of various compounds such as actinomycin D, 4- 
nitroquinoline 1-oxide, Aflatoxin B^, amanitin and proflavin. All these 
compounds possess the biochemical property of forming complexes with DNA, 
suggesting that after interaction of ADR with DNA, transcription may 
rapidly be inhibited, with subsequent inhibition of translation. 
Inhibition of glomerular protein synthesis in vitro may be related to the 
changes produced by the toxin on GBM-collagen synthesis by glomerular 
epithelial cells; the target cell in vivo (Bertani et al, 1982) .
Although it has been reported previously that ADR inhibit synthesis of 
protein in isolated rat glomeruli (Ahmed et al., 1987), no data has so far 
shown the effect of the drug in the synthesis of protein by isolated pig
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glomeruli. Therefore, these data presented above appear to be the first 
reporting such in vitro effect on glomeruli from pigs. The extrapolation 
of these in vitro data to the whole animal seems likely.
The information on the in vivo toxicity of ADR in pigs is scarce, so far
there is only one report (Van Fleet et al, 1979), where renal microscopic 
lesions in tubules and glomeruli were observed, after chronic iv
administration of the drug, but no data on the clinical chemistry was 
provided.
For further experiments, PRO was chosen as a sensitive index with which to 
study glomerular toxicity for several reasons:
i- It is regarded as a very important constituent of GBM, being part of 
the collagen-like regions, as such, and also in the hydroxylated form 
(Kefalides et al, 1979). GBM is .of considerable physiological and
pathological interest because of its role as the main filter in the
filtration process, and its apparent modification in a variety of 
degenerative renal conditions (Glassock, 1978) .
ii- PRO incorporation into rat glomerular protein has been previously
reported to be a sensitive parameter of glomerular toxicity caused by ADR 
(Ahmed et al., 1987) which has also been confirmed by this work.
iii- The good performance of PRO between the different experiments, such
as linearity, and low inter-experimental variability.
6.2.2 Puromycin aminonucleoside (PAN).
6 .2.2.1. Effect of PAN on PRO incorporation into pig glomeruli incubated 
with Krebs buffer.
Having shown that protein synthesis from PRO is a sensitive indicator of
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ADR glomerular cytoxicity, the effect of other compounds on the 
incorporation of the amino acid into pig glomeruli was investigated. Fig. 
6.2.5A shows the effect of PAN on the incorporation of PRO as a percentage 
of the control and Fig. 6.2.5B as an average of several experiments.
There was a certain degree of inter-experimental variation at the lower 
concentrations assayed, for most of the experiments, PAN caused an 50% 
inhibitory effect at high concentrations (> 2.5 mM). The degree and level 
of statistical significance is shown in Table 6.2.6 Appendix 2.
6 .2.2.2 Effect of PAN on PRO incorporation with Earles-HEPES as the 
incubation buffer.
Fig. 6.2.6 A shows the effect of PAN on the incorporation of PRO as 
percentage of control. There is a certain degree of inter-experimental 
variation at the lowest concentration assayed. The average IC^q estimated 
for the drug was 1 mM (Table 6.2.3). The degree and level of statistical 
significance is shown in Table 6.2.7 Appendix 2. Fig. 6.2.6 B shows the 
data as an average of several experiments.
6 .2.2.3 PAN effect on PRO incorporation into isolated rat glomeruli using 
Tyrodes as the incubation buffer.
Fig. 6.2.7A and B show the effect on PAN on the incorporation of PRO as a 
percentage of the control and average of two experiments respectively. 
For both experiments, low doses of PAN caused an increase in the 
incorporation of PRO, and the dose of the compound needed to cause a 50% 
inhibition in the amino acid incorporation was greater than 2.5 mM. Table 
6.2.8 Appendix 2 shows the degree of statistical significance.
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Fig. 6.2.5A
0.5 ml aliquots of isolated pig glomeruli suspended in Krebs buffer, were incubated at 37°C 
with 0.5 ml of buffer containing 2.5 uCi 3H-proline and different concentrations of 
puromycin for 4 hr. The ordinate represents the proportion of incorporated amino acid 
calculated as a percentage o f the total incorporation o f 3H-proline into isolated pig 
glomeruli incubated without the chemical (control). Each point is the result o f 
triplicate incubations.
PAN e ffec t on proline incorporation
into isolated pig glomeruli
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Fig. 6.2.5B
Data presented as the average o f four experiments.
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Fig. 6.2.6A
0.5 ml aliquots of isolated pig glomeruli suspended in Earles-HEPES buffer were incubated 
at 37°C with 0.5 ml of buffer containing 2.5 uCi 3H-proline and different concentrations 
of puromycin for 4 hr. The ordinate represents the proportion o f incorporated amino acid 
calculated as a percentage of the total incorporation of 3H-proline into isolated pig 
glomeruli incubated without the chemical (control). Each point is the result of 
triplicate incubations.
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Fig. 6.2.6B
Data presented as the average o f two experiments.
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Fig. 6.2.7 A
0.5 ml aliquots of isolated rat glomeruli suspended in Tyrodes buffer were incubated at 
37°C with 0.5 ml o f buffer containing 2.5 uG 2.5 uCi 3H-proline and different 
concentrations o f puromycin for 4 hr. The ordinate represents the proportion of 
incorporated amino acid calculated as a percentage of the total incorporation of 3H- 
proline into isolated pig glomeruli incubated without the chemical (control). Each point 
is the result o f triplicate incubations.
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Fig. 6.2.7B
Data presented as the average of two experiments.
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TABLE 6.2.3 Relative toxicity (IC^q) of different chemicals
on PRO incorporation into isolated pig and
rat glomeruli incubated with different buffers.
Buffer
Species
CHEMICAL
Krebs
Pig
Tyrodes
Rat
IC5Q (mM )
Earles-HEPES 
Pig Rat
ADR 0.022 <7.8 uM
**
0.026
PAN > 2.5 >2.5
STR < 0.5 <0.5 0.5
ETA 0.05
BEA >10 10 < 1
FA >10
OTA >3 <19 uM
PBN <0.125 <0.125
* -3M x 10
* *
M x 10 D
a Target for glomeruli
k Target for proximal tubule
c Target for papilla
^ Target for distal tubule 
e Least nephrotoxic of the aminoglycosides 
^ Therapeutic agent without known nephrotoxic properties 
- No data
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6.2.2.4 Discussion.
When Krebs was used as the incubation buffer, PAN affected PRO 
incorporation only at high concentrations (1C5q > 2 . 5  mM), but when the 
amino acid and glomeruli were incubated with Earles-HEPES buffer, the 
concentration of the drug that decreased the amino acid incorporation to 
50% of the control was lower (ImM) than when the mixture was incubated 
with Krebs. This suggest the possibility of an increase in the sensitivity 
of the test, perhaps due to the increase of the rate of the incorporation 
of the amino acid, can account for this difference. However, the trend 
that PAN is not as potent in vitro glomerulotoxin as ADR, is maintained. 
This means that de novo synthesis of protein from PRO into isolated pig 
glomeruli exposed to the compound, is not as sensitive as it was for ADR, 
and in spite of the fact that PAN is regarded as a potent glomerulotoxin 
in vivo (Kreisberg and Karnovsky, 1983). The compound did not show the 
effect that would be expected in vitro, despite the fact that PAN shows a 
similar histopathological lesion to that caused by ADR. There was also a 
certain degree of inter-experimental variability that was not seen with 
the ADR studies in vitro.
When isolated rat glomeruli exposed to PAN was incubated with Tyrodes 
buffer, a moderate effect on PRO incorporation is obtained at high
concentrations (IC5 0  = 2 . 5  mM) of the chemical. This is consistent with
the observations in pig glomeruli, using Krebs as the incubation buffer. 
In previous studies (Norgaard, 1979), PAN did not show a potent effect 
when the morphology of isolated pig glomeruli exposed to the drug was
examined, the compound did not have an acute effect on the epithelial
cells, as shown by the staining with colloidal iron which was not altered 
by a short term exposure to PAN. The author suggested that the influence 
of PAN on glomerular morphology may be due to a long term effect of the
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compound, but in our case it is more likely that it is not the compound
per se, but a metabolite that exerts the effect in vivo or that a
different biochemical mechanism is affected. PRO incorporation into
glomeruli of rats that had been treated with PAN was reported to have
decreased (Krisko and Walker, 1976), although the degree to which PRO was
deppressed was not stated in the report. Studies on amino acid
3incorporation into GBM, have shown that the rate of incorporation of H- 
PRO and its conversion to OH-PRO was increased in PAN treated animals 
(Blau and Michael, 1971). According to another report, however, the GBM in 
PAN-nephrotic rats showed decreased amounts of OH-PRO, OH-LYS and GLY 
(Kefalides and Forsell-Knott, 1970). At this stage it is not possible to 
relate these findings with those in the literature, because detailed 
studies of GBM were not performed. On the other hand, most of the 
observations on the effects of PAN on glomerular metabolism, have been 
undertaken on isolated glomeruli from nephrotic rats, this is generally 
done several days after PAN treatment, therefore the renal degenerative 
effect has been caused in vivo most likely by a metabolite, and not by the 
parent compound. By contrast glomeruli isolated from normal rats and 
subsequently exposed to PAN, appear to lack the metabolic components for 
activation or bioconversion. Regarding the in vitro effect of PAN on 
protein synthesis, so far there is a report where LEU incorporation into 
cultured glomerular epithelial cells was transiently decreased (Fishman 
and Karnovsky, 1985), after either a brief or continuous exposure. 
Although our findings are consistent, in so far as there was a decrease in 
the incorporation of PRO, at this stage it is not clear whether there was 
an earlier and greater decrease, followed by a recovery, and therefore the 
low inhibition produced. Further studies should be conducted to elucidate 
the effect of PAN metabolites on isolated glomeruli.
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6.2.3 Streptomycin (STR).
6 .2.3.1 Effect of STR on protein synthesis in isolated pig glomeruli 
incubated with Krebs buffer.
PRO incorporation into isolated pig glomeruli exposed to STR and incubated 
with Krebs is significantly decreased (P < 0.01) at all concentrations 
tested. The lowest concentration of the chemical (0.5 mM) depressed de 
novo synthesis of protein to 19% of the control values (Table 6.2.9 
Appendix 2; Fig 6.2.8). The concentration of the drug required to produce 
a 50% inhibition from the control value was less than 0.5 mM.
PRO incorporation into isolated pig glomeruli exposed to STR is decreased 
at all concentrations tested, Fig. 6.2.9A and B. The results and levels 
of statistical significance are shown in Table 6.2.10 of Appendix 2. The 
concentration of the drug required to produce a 50% inhibition from the 
control value, was between 0.5 and 1.0 mM. The inter-experimental 
variability is only of 2 -fold.
6 .2.3.3 Effect of STR on protein synthesis into isolated rat glomeruli 
incubated with Tyrodes.
STR caused a remarkable and significant decrease (P < 0.01) at all
concentrations tested. The lowest concentration assessed, inhibited 
protein synthesis from PRO almost completely (by 94% of the control). 
Table 6.2.11 Appendix 2 and Fig. 6.2.10).
6 .2.3.4 Discussion
The data on STR effect on PRO incorporation into isolated pig glomeruli, 
using Krebs as the incubation buffer show a greater effect than in Earles- 
HEPES. In rat glomeruli, the effect of the drug on the incorporation of
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Fig. 6.2.8
0.5 ml aliquots of isolated pig glomeruli suspended in Krebs buffer were incubated at 37°C 
with 0.5 ml of buffer containing 2.5 uCi H-proline and different concentrations of 
streptomycin for 4 hr. The ordinate represents the proportion o f incorporated amino acid 
calculated as a percentage of the total incorporation of 3H-proline into isolated pig 
glomeruli incubated without the chemical (control). Each point is the result of 
triplicate incubations.
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Fig. 6.2.9 A
0.5 ml aliquots of isolated pig glomeruli suspended in Earles-HEPES buffer were incubated 
at 37°C with 0.5 ml of buffer containing 2.5 uCi 3H-proline and different concentrations 
of streptomycin for 4 hr. The ordinate represents the proportion of incorporated amino 
acid calculated as a percentage of the total incorporation of 3H-proline into isolated pig 
glomeruli incubated without the chemical (control). Each point is the result o f 
triplicate incubations.
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into isolated pig glomeruli
100
80-
60-
40-
20-
0 .25 1 2
Dose (mM)
Fig. 6.2.9B
Data presented as the average of two experiments.
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Fig. 6.2.10
0.5 ml aliquots of isolated rat glomeruli suspended in Tyrodes buffer were incubated at 
37°C with 0.5 ml o f buffer containing 2.5 uCi 3H-proline and different concentrations of 
streptomycin for 4 hr. The ordinate represents the proportion o f incorporated amino acid 
calculated as a percentage of the total incorporation of 3H-proline into isolated pig 
glomeruli incubated without the chemical (control). Each point is the result o f 
triplicate incubadons.
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the amino acid incubating with Tyrodes, was similar to that on pig 
glomeruli using Krebs. At this stage it is difficult to draw any 
conclusion from these data, and more work need to be done on STR toxicity 
on isolated glomeruli in order to obtain a proper and more consistent 
dose-response relationship.
6.2.4 Ethacrynic acid (ETA).
6.2.4.1 Effect of ETA on protein synthesis into isolated pig glomeruli 
incubated with Earles-HEPES.
PRO incorporation was strongly inhibited (P < 0.001) by increasing
concentrations of ETA, as shown in Table 6.2.12 of Appendix 2 and Fig. 
6.2 .11.
6.2.4.2 Discussion
These data show that PRO incorporation was markedly depressed by the 
lowest concentration (0.1 mM) assayed. This means that ETA is a potent 
inhibitor of de novo synthesis of glomerular protein and the 
concentrations required to produce this effect are comparable to those for 
ADR. ETA is known to interact strongly with sulfhydryl groups of protein 
(Duggan and Noll, 1965), and the strong inhibition shown by the compound 
on in vitro protein synthesis by pig glomeruli may be related to this 
interaction.
ETA effects on fatty acid and glucose metabolism have been previously 
shown in isolated rat glomeruli by Meezan and Brendel (1973) . However, 
there appear to be no previous reports on the effect of the compound on 
protein synthesis by isolated pig glomeruli, therefore this appears to be 
a novel finding.
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Fig. 6.2.11
0.5 ml aliquots of isolated pig glomeruli suspended in Earles-HEPES buffer were incubated 
at 37°C with 0.5 ml of buffer containing 2.5 uCi 3H-proline and different concentrations 
of ethaciynic acid for 4 hr. The ordinate represents the proportion of incorporated amino 
acid calculated as a percentage of the total incorporation of 3H-proline into isolated pig 
glomeruli incubated without the chemical (control). Each point is the result of 
triplicate incubations.
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In view of the potent effect of the compound on glomerular protein 
synthesis and oxidative metabolism, and the fact that ETA has not been 
considered a toxic drug, several questions are raised, such as the 
importance of ETA effects on glomerular metabolism in vitro, as related to 
glomerular function in vivo. Whether the inhibition of protein synthesis 
is a secondary effect, or a direct effect. Possible GBM structural and 
compositional changes caused by ETA. Studies with ETA-related compounds 
and metabolites such as the saturated derivatives on in vitro glomerular 
protein synthesis may help to elucidate the mechanism of action.
6.2.5 2-Bromoethanamine (BEA)
6 .2.5.1 Incorporation of PRO into isolated pig glomeruli exposed to BEA 
and incubated with Krebs.
At the maximum concentration tested of 10 mM (Figs. 6.2.12) BEA effect on 
PRO incorporation did not reach an IC^q . Table 6.2.13 of Appendix 2 shows 
the degree of statistical significance.
6 .2.5.2 Incorporation of PRO into isolated pig glomeruli exposed to BEA 
and incubated with Earles-HEPES.
The effect of BEA on PRO incorporation is shown in Table 6.2.14 Appendix 2 
and Figs. 6.2.13A and B. At the lower concentration tested (ImM), the
amino acid incorporation was reduced significantly to 1 0 % of the control
value, and at increasing concentrations of the drug this was practically
nil.
6 .2.5.3 Incorporation of PRO into isolated.rat glomeruli exposed to BEA 
and incubated with Tyrodes.
Low concentrations of this compound caused a slight and not significant
increase on PRO incorporation. The dose of the compound needed to cause a
194
% 
of 
C
on
tr
ol
BEA e ffe c t on p ro line  in co rp o ra tio n
into isolated pig glomeruli
100
80-
60-
40-
20-
0 1 5 10
Dose (mM)
Fig. 6.2.12
0.5 ml aliquots of isolated pig glomeruli suspended in Krebs buffer were incubated at 37°C 
with 0.5 ml of buffer containing 2.5 uCi -H-proline and different concentrations of 2- 
bromoethanamine for 4 hr. The ordinate represents the proportion of incorporated amino 
acid calculated as a percentage of the total incorporation of 3H-proline into isolated pig 
glomeruli incubated without the chemical (control). Each point is the result of 
triplicate incubations.
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Fig. 6.2.13A
0.5 ml aliquots of isolated pig glomeruli suspended in Earles-HEPES buffer were incubated 
at 37°C with 0.5 ml of buffer containing 2.5 uCi 3H-proline and different concentrations 
of 2-bromoethanamine for 4 hr. The ordinate represents the proportion of incorporated 
amino acid calculated as a percentage of the total incorporation of 3H-proline into 
isolated pig glomeruli incubated without the chemical (control). Each point is the result 
of triplicate incubations.
BEA e ffe c t on proline incorpora tion
into Isolated pig glomeruli
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Fig. 6.2.13B
Data presented as the average of three experiments.
196
50% inhibitory effect (P < 0.05) was near 10 mM, under the conditions of 
this experiment (Fig. 6.2.14 and Table 6.2.15 Appendix 2)
6 .2.5.4 Discussion.
The data on BEA effect on PRO incorporation using Krebs as the incubation 
buffer show that even at large concentrations (10 mM) BEA failed to cause 
an inhibition of 50% on the incorporation of PRO. However, the data on PRO 
incorporation using Earles-HEPES as the incubation buffer, show that 1 mM 
BEA depressed PRO incorporation to 10% of the control value. This 
variation in the behavior of the compound can be due to an increase in 
sensitivity with the second buffer. As no concentrations lower than ImM 
of the compound were assessed, it is difficult to draw conclusions and 
compare this effect with the glomerular cytotoxicity of ADR and ETA. To 
estimate an IC^q value it is necessary to perform a dose-response curve, 
with concentrations below 1 mM. Due to the selective papillotoxicity shown 
by the drug in vivo# a strong effect of the drug on glomeruli would not 
be expected. However, BEA is regarded as a potential alkylating agent 
(Dermer and Ham, 1969), and therefore inhibition of protein synthesis 
could occur as a secondary effect.
6 . 2 . 6  O th e r to x in s .
6.2.6.1 Folic acid
Folic acid caused a dose-related decrease on PRO incorporation into 
isolated pig glomeruli, when incubated with Krebs, which reached the IC5 Q 
at 5mM (Fig. 6.2.15; Table 6.2.16 Appendix 2). At 1 mM, there was a 
significant reduction (P < 0.01) from the control value by 25%, higher 
concentrations produced a highly significant reduction (P < 0.001) from
the control value.
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Fig. 6.2.14
0.5 ml aliquots of isolated rat glomeruli suspended in Tyrodes buffer were incubated at 
37°C with 0.5 ml of buffer containing 2.5 uCi 3H-proline and different concentrations of 
2-bromoethanamine for 4 hr. The ordinate represents the proportion of incorporated amino 
acid calculated as a percentage of the total incorporation of 3H-proline into isolated pig 
glomeruli incubated without the chemical (control). Each point is the result of 
triplicate incubations.
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Low concentrations of folic acid only caused little effect on PRO 
incorporation by isolated rat glomeruli when incubated with Tyrodes (Fig. 
6.2.16; Table 6.2.17 Appendix 2), which even did not reach a IC^g at the 
highest concentration tested (10 mM).
6.2.6.1.1 Discussion.
PRO incorporation into isolated pig glomeruli exposed to folic acid is 
reduced to 50% of the control by higher concentrations of the compound 
than in the case of ADR or even PAN. The in vitro effect of folic acid 
seems to correlate with the fact that it is another part of the nephron 
the one that is affected by this compound - i.e. distal tubule -.
The data on rat glomeruli show that de novo synthesis of protein is 
slightly inhibited by large concentrations of folic acid, and from the 
data on pig glomeruli it can be assumed that rat glomeruli are less 
sensitive to the effect of the compound. However, it is necessary to 
confirm this using the same buffer system (ie. Earles-HEPES) for both 
types of glomeruli.
6.2.6.2 Ochratoxin A (OTA).
The effect of ochratoxin A on PRO incorporation into isolated pig 
glomeruli was assayed at two concentrations (Table 6.2.18 Appendix 2 and 
Figs. 6.2.17) and neither caused an inhibitory effect of 50% on the amino 
acid incorporation. The reduction in de novo protein synthesis caused by
3.2 mM OTA, was significantly different from the control value (P < 0.01) .
6.2.6.2.1 Discussion.
The data on the effect of OTA show that none of the concentrations tested 
caused a reduction of 50% on the incorporation of PRO. This means that
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OTA, a mycotoxin regarded as targeting for proximal tubule, does not have 
a selective inhibitory effect on de novo synthesis of protein when 
glomeruli have been exposed to it in the present in vitro system.
6.2.6.3 Polybrene.
All concentrations of polybrene, assayed on isolated pig and rat 
glomeruli, significantly depressed PRO incorporation as can be seen in 
Figs. 6.2.18 and 6.2.19A and B and Tables 6.2.19 and 20 of Appendix 2.
6.2.6.3.1 Discussion.
These data show polybrene as being a strong inhibitor of de novo synthesis 
of protein in isolated rat glomeruli. This confirms previous observations 
under the same experimental conditions (Ahmed et al., 1987). The effect of 
this compound on glomerular protein synthesis may be in connection to the 
changes in GBM and glomerular epithelial cells after the administration of 
the compound in vivo (Hunsicker et al, 1981).
It is necessary to perform a dose-response curve for polybrene, with a 
lower range of concentrations, in order to estimate the IC^q value.
6.2.7 Summary and conclusions
6 .2.7.1 Summary.
1- ADR considerably depressed the incorporation of all amino acids into 
isolated pig glomeruli, with LEU and PRO, being the most sensitive and 
showing a similar effect, and LYS being the least sensitive.
2- PAN and STR affected PRO incorporation into isolated glomeruli only at 
high concentrations (IC5 Q > anc* > 0 . 5  respectively) as can be seen in 
Fig. 6.2.20.
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Fig. 6.2.15
0.5 ml aliquots of isolated pig glomeruli suspended in Krebs buffer were incubated at 37°C 
with 0.5 ml of buffer containing 2.5 uCi 3H-proline and different concentrations of folic 
acid for 4 hr. The ordinate represents the proportion of incorporated amino acid 
calculated as a percentage of the total incorporation of 3H-proline into isolated pig 
glomeruli incubated without the chemical (control). Each point is the result of 
triplicate incubations.
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Fig. 6.2.16
0.5 ml aliquots of isolated rat glomeruli suspended in Tyrodes buffer were incubated at 
37°C with 0.5 ml of buffer containing 2.5 uCi 3H-proline and different concentrations of 
folic acid for 4 hr. The ordinate represents the proportion of incorporated amino acid 
calculated as a percentage of the total incorporation of 3H-proline into isolated pig 
glomeruli incubated without the chemical (control). Each point is the result of 
triplicate incubations.
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Fig. 6.2.17
0.5 ml aliquots o f isolated pig glomeruli suspended in Krebs buffer were incubated at 37°C 
with 0.5 ml of buffer containing 2.5 uCi 3H-proline and different concentrations of 
ochratoxin A for 4 hr. The ordinate represents the proportion of incorporated amino acid 
calculated as a percentage of the total incorporation of 3H-proline into isolated pig 
glomeruli incubated without the chemical (control). Each point is the result of 
triplicate incubations.
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Fig. 6.2.18
0.5 ml aliquots of isolated pig glomeruli suspended in Krebs buffer were incubated at 37°C 
with 0.5 ml of buffer containing 2.5 uCi 3H-proline and different concentrations of 
polybrene for 4 hr. The ordinate represents the proportion of incorporated amino acid 
calculated as a percentage of the total incorporation of 3H-proline into isolated pig 
glomeruli incubated without the chemical (control). Each point is the result of 
triplicate incubations.
3- PRO incorporation into isolated pig glomeruli was markedly depressed 
by ETA (IC5 0  = 0 .05 mM).
4- The effect of STR and BEA on PRO incorporation into isolated pig 
glomeruli incubated with different buffers varies (IC^q with Earles-HEPES 
= 0.5 mM for STR and < ImM for BEA; with Krebs «  0.5 for STR and > 10 mM 
for BEA).
6 .2.7.2 Conclusions.
1- De novo synthesis of glomerular protein from different amino acids in 
pig glomeruli is inhibited by ADR; some amino acids (ie. LEU and PRO) are 
more affected than others (ie. GLY, HIS and LYS).
2- From the amino acids assessed, PRO incorporation appeared to be the 
most sensitive index of cytotoxicity in pig glomeruli caused by ADR, as 
has already been shown in rat.
3- De novo synthesis of protein from PRO into isolated pig glomeruli 
exposed to PAN, is not as sensitive as it was for ADR, and in spite of the 
fact that PAN is regarded as a potent glomerulotoxin in vivo.
4- STR and BEA effect on protein synthesis needs further elucidation.
5- ETA is a potent inhibitor of de novo synthesis of glomerular protein 
and the concentrations required to produce this effect seem comparable to 
those for ADR.
7- ETA effect on protein synthesis by isolated pig glomeruli appears to 
be a novel finding.
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Fig. 6.2.19 A
0.5 ml aliquots of isolated rat glomeruli suspended in Tyrodes buffer were incubated at 
37°C with 0.5 ml of buffer containing 2.5 uCi 3H-proline and different concentrations of 
polybrene for 4 hr. The ordinate represents the proportion of incoiporated amino acid 
calculated as a percentage of the total incorporation of 3H-proline into isolated pig 
glomeruli incubated without the chemical (control). Each point is the result of 
triplicate incubations.
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Fig. 6.2.19B
Data presented as the average of three experiments.
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Fig. 6.2.20
Dosc-rcsponsc of proline incorporation into isolated pig glomeruli exposed to different 
chemicals. 0.5 ml aliquots of glomeruli suspended in Earles-HEPES were incubated at 37°C 
with 0.5 ml of buffer containing 2.5 uCi of ^ H-proline and different concentrations of 
the chemical. The ordinate represents the proportion of incorporated amino acid calculated 
as a percentage of the activity incorporated into isolated pig glomeruli incubated without 
the chemical (control). Each time point is the result of triplicate incubations.
6.3 Oxidative Metabolism.
6.3.1 Setting of the conditions to perform oxidative metabolism
6 .3.1.1 Influence of non-radioactive substrates on the metabolism of the 
labelled substrate.
For the study of oxidative metabolism by isolated pig glomeruli the effect
of non-radioactive glucose, linolenic and oleic acid when incubated
14together with the respective labelled substrates on the release of CO 2  
is shown in Figs. 6.3.1 and Table 6.3.1 Appendix 2. Low concentrations of 
glucose (10 - 100 uM) did not cause an effect but at 1000 uM there. was 
a highly significant decrease (P < 0.001) to 76% of the control. On the 
other hand all concentrations of the non-labelled linolenic acid caused a 
dose-related inhibitory effect on the metabolism of the radioactive 
compound, which was highly significantly different (P < 0.001) from the 
control. A similar effect was shown by increasing concentrations of non­
radioactive oleic acid on the labelled substrate. At concentrations of 10 
uM of non-radioactive oleic acid, the metabolism was significantly lower 
(P < 0.05) than the control. At 100 uM the metabolism was significantly 
reduced (P <0.01) by 49% relative to the control, and at 1000 uM the 
reduction was highly significantly different from the control (P < 0.001), 
by 85%.
6 .3.1.2 Effect of shaking.
The effect of shaking during incubation of glomeruli on the oxidative 
metabolism of glucose, linolenic acid and oleic acid was tested (Fig.
6.3.2 and Table 6.3.2 Appendix 2). Linolenic and oleic acid release of 
1 4 CC> 2 under shaking conditions ( 1 2 0  oscillations/min) was highly
significantly higher (P < 0.001) than when the samples were not agitated,
14 . .while glucose values of CO 2  release under shaking conditions were
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Lttect ot "cold" substrates
on oxidative metabolism
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Fig. 6.3.1
0.5 ml aliquots of pig glomeruli suspended in Earles-HEPES buffer were incubated with 0.5 
ml of buffer containing either 14C- glucose (2.0 uCi) or linolenic or oleic acid (50 
nCi), and different concentrations of each of the respective "cold" substrates for 4 hrs.
The heights of the bars represents the proportion of C02 released, calculated as a 
percentage of the total 14C02 released by isolated glomeruli incubated only with the 
radiolabelled substrate (control). .
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Fig. 6.3.2
0.5 ml aliquots of pig glomeruli suspended in Earles-HEPES buffer were incubated with 0.5 ml of 
buffer containing either 14C- glucose (2.0 uCi) or linolenic or oleic acid (50 nCi), and 
C02 release assessed with and without agitation during incubation. The heights of the 
bars represents the proportion of 14C02 released.
significantly different from the non-agitated samples at the 5% level.
6.3.2 Glucose
6 .3.2.1 Isolated pig glomeruli.
14 14 .The generation of CO 2  from C-glucose oxidation, using glomeruli
incubated in Earles-HEPES buffer, was compared between several
14 .experiments. In most of the cases CC> 2 release followed a linear pattern
with time (Fig. 6.3.3, Table 6.3.3 Appendix 2) and the values ranged from
63 - 83 pmol CC^/mg protein.
14Two out of seven experiments had much higher CO 2  generated at all time 
points. After 4 h of incubation the values were 127 and 189 pmol CC^/nig 
protein. In most cases the inter-experimental variability was low, with 
coefficient of variance < 10%. The CO2  release from glucose showed
statistically significant differences within all time points studied in 
each experiment as can be seen in Table 6.3.4 of Appendix 2, with the 
exception of one in which there were no significant differences between 
CO2  release at 3 and 4 hr.
6 .3.2.2 Isolated rat glomeruli.
The rate of release from labelled glucose was found to be linear
when incubated for the first 3 hr, and at 4 hr, the rate of oxidation was 
the same as that at 3 hr (Fig. 6.3.4). The rate of CO2  formation is shown 
in Table 6.3.5 Appendix 2.
6 .3.2.3 Discussion.
The effect of shaking and addition of non-labelled substrates to the 
incubation media. The data on the comparison on the effect of shaking on 
oxidative metabolism show that it increases with agitation, supposedly
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Fig. 6.3.3
Kinetics of glucose oxidation by isolated pig glomeruli. 0.5 ml of Earles-HEPES buffer 
containing 2 uCi of 14C-glucose was incubated with 0.5 ml of the glomerular preparation 
for up to 4 hr. The ordinate represents specific activity o f1 C02 trapped into NaOH. 
Each line corresponds to a different experiment and each time point is the result of 
triplicate incubadons.
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Fig. 6 .3.4
Kinetics of glucose oxidation by isolated rat glomeruli. 0.5 ml of Earles-HEPES buffer 
containing 2 uCi of C-glucose was incubated with 0.5 ml of the glomerular preparauon 
for up to 4 hr. The ordinate represents specific activity of C02 trapped into NaOH. 
Each time point is the result of triplicate incubations.
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because the the composition of the mixture is maintained homogeneous and 
also because aggregation of glomeruli is avoided, increasing in this way 
the surface that is exposed to the incubation mixture.
Addition of increasing concentrations of the non-radiolabelled precursor, 
decreased the respective radioactive yield, of oxidative metabolism. This 
is probably due to the "dilution" o f . the radiolabelled compound by 
competitive inhibition, therefore decreasing the chance of the labelled 
molecule being used as the only source of substrate for oxidative 
metabolism. In view of the observed effect of the non-radiolabelled 
substrates, it was decided not to add them to their respective incubation
media, in order to get higher radioactive counts and therefore increased
sensitivity of the method.
Glucose metabolism. Isolated pig glomeruli glucose metabolism was linear
over 4 hr of incubation. The values of CC> 2 release fell into two different
populations, one having higher values after 4 hr of incubation (119 - 189
pmol ^CC^/mg protein). However, most of the experiments fell in the lower
14values (63 - 83 pmol CC^). The differences with the other one can be
explained by the different origin of the pigs sampled.
Isolated rat glomeruli glucose oxidation seemed to begin to decrease the
14 . .release of co2 ' after 3 hr. The possibility that may account for this
effect, is a decrease in the viability of the glomerular preparation, and
not a species difference, since the findings by Meezan and Brendel (1973),
show a linear increase of the rate of glucose oxidation in their
glomerular preparation.
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6.3.3. Fatty acid metabolism
6 .3.3.1 Metabolism of linolenic acid.
Pig glomeruli. A comparison on the release of CO2  between different
experiments was performed. In most of the cases there was a linear
release of CO 2  with time (Fig. 6.3.5, Table 6.3.6 Appendix 2). Although 
there was a high inter-experimental variability, the variability within 
experiments and triplicates was low (<10%). Table 6.3.7 Appendix 2 shows 
the level of statistical significance between different.time points for 
each experiment.
Linolenic acid metabolism by isolated rat glomeruli. Oxidative metabolism
14of labelled linolenic acid was measured by the release of CO 2  over 4 hr, 
which was linear during the first 3 hr (Fig. 6.3.6, Table 6.3.8 Appendix
2) and presented a decrease at 4 hr.
6 .3.3.2 Oleic acid metabolism by isolated pig glomeruli. For most of the
cases the oxidative metabolism of oleic acid followed a very similar
14pattern to that of linolenic acid. CO 2  release was linear with time
(Fig. 6.3.7, Table 6.3.9 Appendix 2) as for linolenic acid. The
variability within triplicates performed in the same sample was around 1 0 %
in most cases. 1 4 C0 2  release from linolenic and oleic acid showed
statistically significant differences between all time points studied for
each experiment (Table 6.3.10 Appendix 2). Only in one experiment, there
14were not a significant difference between the release of CO 2  at 3 and 4 
hr and in another one at 1  and 2  hr.
6 .3.3.3 Discussion.
These data show that isolated pig glomeruli metabolize oleic and linolenic 
acid linearly over a period of 4 hr. The maintenance of good rates of
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Fig. 6.3 J
Kinetics of linolenic acid oxidation by isolated pig glomeruli. 0.5 ml of Earles-HEPES 
buffer containing 50 nCi o f1 C-linolenic acid was incubated with 0.5 ml of the glomerular 
preparation for up to 4 hr. The ordinate represents specific activity of C02 trapped 
into NaOH. Each line corresponds to a different experiment and each time point is the 
result of triplicate incubations.
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Fig. 6.3.6
Kinetics of linolenic acid oxidation by isolated rat glomeruli. 0.5 ml of Earles-HEPES 
' buffer containing 50 nCi of  ^ C-linolenic acid was incubated with 0.5 ml of the glomerular 
preparation for up to 4 hr. The ordinate represents specific activity o f1 C02 trapped 
into NaOH. Each time point is die result of triplicate incubations.
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Fig. 6.3.7
Kinetics of oleic acid oxidation by isolated pig glomeruli. 0.5 ml of Earles-HEPES buffer 
containing 50 nCi of C-oleic acid was incubated with 0.5 ml of the glomerular 
preparation for up to 4 hr. The ordinate represents specific activity of* C02 trapped 
into NaOH. Each line corresponds to a different experiment and each time point is the 
result of triplicate incubations.
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oxidation of fatty acids, for several hours is another indication of the 
viability of isolated pig glomeruli.
Fatty acid oxidation is performed mainly by the beta-oxidative system, 
which takes place in the mitochondria and is a major source of energy for 
the cell, this energy is generated as ATP by means of the oxidative 
phosphorylation. The oxidation of fatty acids is an important source of 
energy in the kidney (Hohenegger, 1976), being higher in the cortex than 
in the medulla.
There is also beta-oxidation in the peroxisome, a subcellular organelle, 
capable of respiration. The function of peroxisomal beta-oxidation is 
still poorly understood and its contribution to fatty acid oxidation is 
still controversial. Although peroxisomes of the kidney have not been 
comprehensively studied, they have been histochemically identified in some 
renal regions with the exception of glomeruli (Novikoff and Goldfisher, 
1969) , but catalase activity has been found in this part of the nephron, 
suggesting the presence of functional peroxisomes (Beard et al, 1985).
Further studies are necessary to confirm the presence of peroxisomes in 
glomeruli, and to establish the contribution made by peroxisomal beta- 
oxidation to fatty acid oxidation in glomeruli and tubules.
6.3.4 Summary and conclusions.
6 .3.4.1 Summary.
1- This research has shown that pig glomeruli metabolize glucose and fatty 
acids (linolenic and oleic acid) linearly for several hours.
2- Glucose oxidative metabolism is much lower than fatty acid oxidation 
for both species assessed.
2 1 2
3- Glucose metabolism is lower in rat than in pig glomeruli.
4- Oleic acid rate of oxidation is lower than linolenic acid.
6.3.4.2 Conclusions.
1- Isolated rat and pig glomeruli have the ability to oxidize
14radiolabelled glucose and fatty acids (oleic and linolenic acid) to CO2 •
14 .2- The higher rates of CO2  production from fatty acids than glucose, 
suggests that fatty acids are a more important source of energy in 
glomeruli.
3- The maintenance of good rates of oxidation of glucose, linolenic and 
oleic acid shows the metabolic integrity of the glomerular preparation in 
isolated pig glomeruli.
4- Further studies are necessary to find out whether the lower rates of 
rat glomerular oxidative metabolism in comparison to pig glomeruli, 
corresponds to a species differences or loss of the viability of the 
glomerular preparation.
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6.4 Effect of different chemicals on oxidative metabolism by isolated pig
glomeruli.
6.4.1 Effect of ADR on glucose and fatty acid metabolism.
6 .4.1.1 Glucose
When the effect of several concentrations of ADR (0.031 - 1 mM) was
14 .assessed on the release of CO 2  from glucose, the highest concentration
of the drug (0.25 and 1 mM), caused a significant inhibition, as can be
seen in Table 6.4.1 of Appendix 2 and in Figs. 6.4.1 and B.
6 . 4.2.2 Fatty acids
a)- Linolenic acid. All concentrations of ADR (0.031 - 1 mM), reduced
14significantly the release of CO2  from linolenic acid (Table 6.4.2
Appendix 2), with the exception of 0.031 mM which caused a slight, but not
significant decrease in one of the experiments. Figs. 6.4.2A and B show 
14the release of CO2  as percentage of the control and as an average of 2  
experiments.
b)- Oleic acid. Oleic acid metabolism was markedly depressed by all
concentrations of ADR assessed (0.031 - 1 mM). The reduction was highly
significantly different (P < 0.001) from the control values as is shown
14
in Table 6.4.3 Appendix 2. co2 release as percentage of the control, is 
shown in Fig. 6.4.3.
6 . 4.1.3 Discussion
Effect of ADR on glucose oxidation. The data show that ADR inhibited 
1 4 C0 2  release from glucose to a certain extent, however this inhibition is 
not as marked as in the case of protein synthesis in which the 
concentration required to cause a 50% inhibition is 3-fold lower than for 
inhibition glomerular glucose metabolism. Glucose oxidative metabolism is
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Fig. 6.4.1A
Dose-response of glucose oxidation by isolated pig glomeruli exposed to adriamycin. 0.5 ml 
aliquots of glomeruli suspended in Earles-HEPES were incubated at 37°C with 0.5 ml of 
buffer containing 2 uCi of C glucose an different concentrations of the chemical. The 
ordinate represents the proportion of 14CO_2 calculated as a percentage of the total 14C02 
released from 1 C-glucose incubated with isolated pig glomeruli without the chemical 
(control). Each line corresponds to a different experiment and each time point is the 
result of triplicate incubations.
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Fig. 6.4.1B
Data presented as the average of two experiments.
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Fig. 6.4.2A
Dose-responsc of linolenic acid oxidation by isolated pig glomeruli exposed to adriamycin. 
0.5 ml aliquots of glomeruli suspended in Earles-HEPES were incubated at 37°C with 0.5 ml 
of buffer containing 50 nCi of C-linolenic acid and different concentrations of the 
chemical. The ordinate represents the proportion of CO, calculated as a percentage of 
the total C02 released from 14C-linolenic acid incubated with isolated pig glomeruli 
without the chemical (control). Each point is the result of triplicate incubations.
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Fig. 6.4.2 B
Data presented as the average of two experiments.
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Fig. 6.4 3
Dose-responsc of oleic acid oxidation by isolated pig glomeruli exposed to adriamycin.
0.5 ml aliquots of glomeruli suspended in Earles-HEPES were incubated at 37°C with 0.5 ml 
of buffer containing 50 nCi of C-oleic acid and different concentrations of the 
chemical. The ordinate represents the proportion of CXX calculated as a percentage of 
the total C02 released from 14C-oleic acid incubated with isolated pig glomeruli without 
the chemical (control). Each point is the result of triplicate incubations.
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also less sensitive to ADR than fatty acid metabolism.
Effect of ADR on fatty acids. These data show that ADR markedly inhibited 
the oxidative metabolism of oleic acid (IC^q < 31.5 uM) and although 
linolenic acid was inhibited in a dose related fashion, this effect was 
only moderate (IC^q = 0.21 mM). There are no previous observations on the 
effect of ADR on fatty acid metabolism of isolated glomeruli of any
species. These findings are however consistent with observations of the
inhibition of the oxidation of palmitic acid to CO2  by renal mitochondria 
of ADR treated (Bizzi et al, 1983), although the type of cell responsible 
for this effect was not specified in this report.
A dose-response curve is needed to follow the effect of ADR on oleic acid
oxidation at concentrations lower than 31.2 uM.
ADR effect on glucose and fatty acid metabolism may be of importance in 
connection with the degenerative changes described in renal mitochondria 
in vivo, using ultrastructural methods (Bertani et al, 1982) .
6.4.2 Effect of PAN on oxidative metabolism.
6 . 4.2.1 Glucose.
The effect of PAN on glucose metabolism is shown in Figs. 6.4.4A and B 
Although the compound did not show a strong effect on glucose metabolism, 
this was decreased significantly at all concentrations tested as can be 
seen in Table 6.4.4 of Appendix 2, but the highest concentration (2.5 mM) 
did not reduced glucose metabolism below 48% of control.
6 . 4.2.2 Linolenic acid.
As is shown in Figs. 6.4.5A and B and Table 6.4.5 of Appendix 2, PAN
218
PAN e ffe c t on g lucose m etabo lism
by Isolated pig glomeruli
100
O * 80
CM 10
8  2 3CD
o
Dose (mM)
Fig. 6.4.4A
Dose-responsc of glucose oxidation by isolated pig glomeruli exposed to puromycin. 0.5 ml 
aliquots of glomeruli suspended in Krebs buffer were incubated at 37°C with 0.5 ml of 
buffer containing 2 uCi of 1 C-glucose and different concentrations of the chemical. The 
ordinate represents the proportion of 1 C02 calculated as a percentage of the total 14C02 
released from 1 C-glucose incubated with isolated pig glomeruli without the chemical 
(control). Each point is the result of triplicate incubations.
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Fig. 6.4.4B
Data presented as the average of two experiments.
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Fig. 6.4 .5A
Dose-responsc of linolenic acid oxidation by isolated pig glomeruli exposed to puromycin 
aminonucleoside. 0.5 ml aliquots of glomeruli suspended in Earles-HEPES were incubated at 
37°C with 0.5 ml of buffer containing 50 nCi o f1 C-linolenic acid and different 
concentrations of the chemical. The ordinate represents the proportion o f1 C02 
calculated as a percentage of the total1 C02 released from ‘4C-linolenic acid incubated 
with isolated pig glomeruli without the chemical (control). Each point is the result of 
triplicate incubations.
PAN e ffec t on linolenic acid m etabolism
by isolated pig glomeruli
100
80-
80-
40-
20-
m
<4aNtoo
Dose (mM)
Fig. 6.4SB
Data presented as the average of two experiments.
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moderately but significantly decreased oxidative metabolism of linolenic 
acid. As there was a high degree of inter-experimental variability, it 
its difficult to draw conclusions about the effect of the drug on the 
oxidative metabolism of linolenic acid. However, in general terms it can
be said that high doses of PAN such as 2.5 mM, did not decrease the
14 . .release of CC> 2 from this fatty acid, below 46% of the control.
6 .4.2.3 Oleic acid.
The lowest concentration of PAN assessed (0.062 mM) caused a significant
14 .decrease to the CO2  release from oleic acid, to 36% relative to the
control value (Table 6.4.6 Appendix 2; Fig. 6.4.6). Increasing
concentrations of the drug, did not produce a dose-related effect, and the
highest concentration tested (2.5 mM), depressed oleic acid metabolism
significantly to 26% of the control.
6 . 4.2.4 Discussion.
PAN inhibited glucose metabolism by pig glomeruli reproducibly for the two 
different experiments, but this was not a very strong effect, since the 
concentration of the drug needed to cause a 50% inhibition was slightly 
lower than the highest concentration assayed (2.5 mM). The utilization of 
glucose by PAN-nephrotic rat glomeruli has been reported to have 
progresively decreased to 50% of the control, between 1 and 7 days of the 
treatment (Kaplan et al, 1974). Although this research is in agreement in 
that there was a decrease in glucose metabolism of isolated glomeruli 
exposed to PAN, it is not possible to establish a comparison because of 
the difference between Kaplan's studies, where the chemical was applied in 
vivo, and this experiments, where glomeruli were exposed to PAN in vitro.
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Fig. 6.4.6
Dose-responsc of oleic acid oxidation by isolated pig glomeruli exposed to puromycin 
aminonucleoside. 0.5 ml aliquots of glomeruli suspended in Earles-HEPES were incubated at 
37°C with 0.5 ml of buffer containing 50 nCi o f1 C-oleic acid and different 
concentrations of the chemical. The ordinate represents the proportion of C02 
calculated as a percentage of the total1 CX)  ^released from r C-oleic acid incubated with 
isolated pig glomeruli without the chemical (control). Each point is the result of 
triplicate incubations.
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Fatty acids. Due to the variability shown between experiments/ in the 
case of linolenic acid metabolism, it is difficult to draw any conclusion. 
Therefore it is also difficult to conclude from the data of a single 
experiment using oleic acid.
6.4.3 STR effect on oxidative metabolism
6 .4.3.1 Glucose.
Figs. 6.4.7A and B show the effect of STR on. glucose oxidation by isolated 
glomeruli. The results and statistical analysis are shown in Table 6.4.7 
Appendix 2.
6 .4.3.2 Linolenic acid.
Fig. 6.4.8 and Table 6.4.8 Appendix 2 show the effect of STR on linolenic
acid metabolism. There was low inter-experimental variability. The results
on linolenic acid metabolism show that only the highest concentration of
14STR tested (2 mM), decreased the release of CC> 2 from the fatty acid, to 
50% of the control value. This means that although the aminoglycoside 
inhibited linolenic acid metabolism significantly, at various 
concentrations tested ( 1 - 2  mM), it had little effect on linolenic acid 
metabolism compared to other chemicals such as ADR and ETA.
6 .4.3.3 Oleic acid.
Fig. 6.4.9 and Table 6.4.9 Appendix 2, show that none of the
. . . . .  14concentrations of STR inhibited significantly the release of CO 2  from
the fatty acid below 80% of the control value. This means that STR effect 
on oleic acid oxidation, was minimal.
6 .4.3.4 Discussion.
These data show that STR had little effect on the oxidative metabolism 
compared to ADR and ETA. In the case of glucose oxidation, although the 
results from the two experiments show some degree of variability, none of
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Fig. 6.4.7A
Dose-responsc of glucose oxidation by isolated pig glomeruli exposed to streptomycin. 0.5 
ml aliquots of glomeruli suspended in Earles-HEPES were incubated at 37°C with 0.5 ml of 
buffer containing 2 uCi of 1 C-glucose and different concentrations of the chemical. The 
ordinate represents the proportion o f1 C02 calculated as a percentage of the total 14C02 
released from C-glucose incubated with isolated pig glomeruli without the chemical 
(control). Each line corresponds to a different experiment and each point is the result 
of triplicate incubations.
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Fig. 6.4.7B
Data presented as the average of two experiments.
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Fig. 6.4.8A
Dose-response of linolenic acid oxidation by isolated pig glomeruli exposed to 
streptomycin. 0.5 ml aliquots of glomeruli suspended in Earles-HEPES were incubated at 
37°C with 0.5 .ml of buffer containing 50 nCi of 14C-linolenic acid and different 
concentrations of the chemical. The ordinate represents the proportion of CO2 calculated 
as a percentage of the total1 C02 released from 14C-linolenic acid incubated with 
isolated pig glomeruli without the chemical (control). Each point is the result of 
triplicate incubations.
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Fig. 6.4.8B
Data presented as the average of two experiments.
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Fig. 6.4.9
Dose-responsc o f oleic acid oxidation by isolated pig glomeruli exposed to streptomycin.
0.5 ml aliquots o f glomemli suspended in Earles-HEPES were incubated at 3 7 C  with 0.5 ml 
o f buffer containing 50 nCi o f 1 C-oleic acid and different concentrations o f the 
chemical. The ordinate represents the proportion o f CO, calculated as a percentage o f 
the total l4C02 released from 1 C-oleic acid incubated with isolated pig glomeruli without 
the chemical (control). Each point is the result o f triplicate incubations.
ETA effect on glucose oxidation
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Fig. (.4.10
Dose-response o f glucose oxidation by isolated pig glomeruli exposed to ethacrynic acid.
0.5 ml aliquots o f glomeruli suspended in Earles-HEPES were incubated at 37°C with 0.5 ml 
o f buffer containing 2 uCi o f 1 C-glucose y d  different concentrations o f the chemical.
The ordinate represents the proportion o f 1 CO, calculated as a percentage o f the total 
C02 released from 14C-glucose incubated with isolated pig glomeruli without the chemical 
(control). Each point is the result o f triplicate incubations.
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the concentrations assessed, caused an inhibition below 60% of the control
value.
The little effect seen on the oxidative metabolism of glucose and fatty 
acids, is also consistent with the fact that STR is not considered as a 
potent nephrotoxin, and that the aminoglycoside have shown little effect 
on cortical mitochondria respiration in vitro (Weinberg et al, 1980).
6.4.4 ETA effect on oxidative metabolism
6 .4.4.1 Glucose
Fig. 6.4.10 and Table 6.4.10 Appendix 2 show the effect of ETA on glucose 
metabolism. The highest dose of ETA assessed (0.5 mM) depressed glucose 
oxidation no more than 47% of the control (P < 0.01).
6 .4.4.2 Linolenic and oleic acid.
The effect of ETA on the oxidative metabolism of linolenic and oleic acid 
is shown in Figs. 6.4.11 and 6.4.12 and Tables 6.4.11 and 6.4.12 of 
Appendix 2). There was a highly significant inhibition (P < 0.001) on the 
metabolism of both fatty acids at all concentrations tested, and with 
0.5mM ETA oleic acid metabolism was depressed completely.
6 .4.4.3 Discussion.
14Glucose. The effect of ETA on the CO2  release from glucose is not 
strong, and the concentration that causes an inhibition of 50% in 
relation to the control is about 1 0 -fold the dose required to inhibit the 
protein synthesis to the same extent. The effect of ETA on the pig 
glomerular metabolism of glucose in this study is in agreement with 
previous observations on rat glomeruli (Meezan and Brendel, 1973) . The 
inhibition of glycolysis by ETA has also been reported in kidney slices
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Fie. 6.4.11
Dose-responsc o f linolenic acid oxidation by isolated pig glomeruli exposed to ethacrynic 
acid. 0.5 m l aliquots o f glomeruli suspended in Earles-HEPES were incubated at 37°C with 
0.5 ml o f buffer containing 50 nCi o f 1 C-linoIenic acid and different concentrations o f 
the chemiad. The ordinate represents the proportion o f 1 CO* calculated as a percentage 
o f the to ta l1 C02 released from 1 C-linolenic acid incubatedwith isolated pig glomeruli 
without the chemical (control). Each point is the result o f triplicate incubations.
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Fig. 6.4.12
Dose-response o f oleic acid oxidation by isolated pig glomeruli exposed to ethacrynic 
acid. 05 ml aliquots o f glomeruli suspended in Earles-HEPES were incubated at 37°C with 
0.5 ml of buffer containing 50 nCi of l4C-oleic arid and different concentrations o f the 
chemical. The ordinate represents the proportion o f 14CO, calculated as a percentage of 
the total COj released from C-oleic arid incubated with isolated pig glomeruli without 
the chemical (control). Each point is the result o f triplicate incubations.
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(Jones and Landon, 1967).
Fatty acids. The data on the effect of ETA on linolenic and oleic acid 
metabolism show that the compound markedly inhibited the metabolism of the 
two fatty acids, at the lowest concentration tested (0.1 mM). This means 
that ETA is a potent inhibitor of fatty acid metabolism in pig glomeruli, 
although the effect on protein synthesis is greater. This finding is in 
agreement with studies on isolated rat glomeruli by Brendel and Meezan 
(1973), who reported a marked inhibition of oleic acid oxidation in 
isolated glomeruli from rat kidney at ETA concentrations of 0.1 mM and 
greater. They suggested that an essential feature in the inhibitory 
effect of oxidative metabolism of glomerular cells is the presence of the 
double bond in the ETA molecule which determines it sulphydryl reactivity 
with proteins and enzymes. Previous studies had reported inhibition of 
respiration in kidney cortical slices, and rat kidney mitochondria (Jones 
and Landon, 1967; Poat et al, 1970; Landon and Fitzpatrick, 1972) .
6.4.5 BEA effect on oxidative metabolism
6 .4.5.1 Glucose.
The effect of BEA on glucose metabolism is shown in Fig. 6.4.13A and B and 
Table 6.4.13. All concentrations asessed (1, 5 and 10 mM) enhanced
significantly the glomerular metabolism of glucose.
6 .4.5.2 Linolenic and oleic acid.
The effect of BEA on linolenic and oleic acid is shown in Figs. 6.4.14 and 
6.4.15 and Table 6.4.14 and 15 of Appendix 2. Fatty acid metabolism by 
glomeruli exposed to BEA show a high degree of inter-experimental 
variability for both linolenic and oleic acid.
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Fig. 6.4.13A
Dose-responsc of glucose oxidation by isolated pig glomeruli exposed to bromoethanamine. 
0.5 ml aliquots of glomeruli suspended in Earles-HEPES were incubated at 37°C with 0.5 ml 
of buffer containing 2 uCi of C-glucose and different concentrations of the chemical.
The ordinate represents the proportion of CO, calculated as a percentage of the total 
1 C02 released from 1 C-glucose incubated with isolated pig glomeruli without the chemical 
(control). Each line corresponds to a different experiment and each point is the result 
of triplicate incubations.
BEA e ffec t on glucose m etabolism
by isolated pig glomeruli
200 n
150-
o>
100
50-
100 1 5
Dose (mM)
Fig. 6.4.13B
Data presented as the average of three experiments.
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Fig. 6.4.14
Dose-response of linolenic acid oxidation by isolated pig glomeruli exposed to 2- 
bromoethanamine. 0.5 ml aliquots o f glomeruli suspended in Earles-HEPES were incubated at 
JiFC with 0.5 ml o f buffer containing 50 nCi o f C-linolenic acid and different 
concentrations o f the chemical. The ordinate represents the proportion o f * C 02 
calculated as a percentage o f the to ta l* C02 released from ‘ C-linolenic acid incubated 
with isolated pig glomeruli without the chemical (control). Each line corresponds to a 
different experiment and each point is the result o f triplicate incubations.
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Fig. 6.4.15
Dose-responsc o f oleic acid oxidation by isolated pig glomeruli exposed to 2- 
bromoethanamine. 0.5 ml aliquots o f glomeruli suspended in Earles-HEPES were incubated at 
37°C with 0.5 ml o f buffer containing 50 nCi o f 1 C-oleic acid and different 
concentrations o f the chemical. The ordinate represents the proportion o f ' C 02 calculated 
as a percentage of the to ta l1 C02 released from 1 C-oleic acid incubated with isolated 
pig glomeruli without the chemical (control). Each line corresponds to a different 
experiment and each point is the result o f triplicate incubations.
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6.4.5.3 Discussion.
The data on glucose metabolism show that BEA increases the 1 4 C 0 2  release 
from glucose at all concentrations tested. This means that BEA had a 
stimulating effect on glomerular oxidative metabolism of glucose. This 
effect is unexpected and was considered to be beyond the scope of this 
research project and still needs to be elucidated.
Due to the high degree of inter-experimental variability seen when the 
effect of BEA was assessed on fatty acid metabolism, it is difficult to 
draw any conclusion or to allow any comparison, and more experiments need 
to be done.
6.4.6 Summary and conclusions.
6.4.6.1 Summary.
1- Figs. 6.4.16 - 18 summarize the results on oxidative metabolism by 
isolated pig glomeruli.
2- ADR markedly inhibited the oxidative metabolism of fatty acids, such as
14linolenic and oleic acid (IC5 Q = 0.21 mM), but it only inhibited CO 2  
release from glucose moderately (IC5 0  = 0.75 mM).
3- PAN had only a slight effect on glucose and linolenic acid metabolism 
by pig glomeruli. The concentration of the drug needed to cause a 50% 
inhibition on the metabolism of linolenic acid is higher than the highest 
concentration assayed (2.5 mM). The effect on oleic acid metabolism was 
more pronounced with an estimated IC^q = 62 uM.
4- STR had little effect on the oxidative metabolism of glucose ^ ^ 5 0  > 
2mM) and oleic and linolenic acid UCjq < 2 mM).
5- The effect of ETA on the 1 4 C0 2  release from glucose is moderate ( * £ 5 0  = 
0.46 mM)).
6 - ETA markedly inhibited linolenic and oleic acid metabolism at the
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Dose-response of glucose oxidation by isolated pig glomeruli exposed to different 
chemicals. 0.S ml aliquots of glomeruli suspended in Earles-HEPES were incubated at 37°C 
with 0.5 ml of buffer containing 2 uCi of C glucose and different concentrations of the 
chemical. The ordinate represents the proportion of 14C02 calculated as a percentage of 
the total 14C02 released from 14C-glucose incubated with isolated pig glomeruli without 
the chemical (control). Each time point is the result of triplicate incubations.
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Fig. 6.4.17
Dose-response of linolenic acid oxidation by isolated pig glomeruli exposed to different 
chemicals. 0.5 ml aliquots of glomeruli suspended in Earles-HEPES were incubated at 37°C 
with 0.5 ml of buffer containing 50 nG of 14C linolenic acid and different concentrations 
of the chemical. The onhnate represents the proportion of C02 calculated as a 
percentage of the total C02 released from *4C-glucose incubated with isolated pig 
glomeruli without the chemical (control). Each time point is the result of triplicate 
incubations.
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Fig. 6.4.18
Dose-response of oleic acid oxidation by isolated pig glomeruli exposed to different 
chemicals. 0.5 ml aliquots of glomeruli suspended in Earles-HEPES were incubated at 37°C 
with 0.5 ml of buffer containing 50 nCi of ,4C oleic acid and different concentrations of 
the chemical. The ordinate represents the proportion o f1 C02 calculated as a percentage 
of the total *C 0 2 released from 14C-glucose incubated with isolated pig glomeruli without 
the chemical (control). Each time point is the result of triplicate incubations.
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lowest concentration tested (0.1 mM).
147- BEA stimulated the CC> 2 release from glucose oxidation at all 
concentrations tested.
6 .4.6 .2 Conclusions.
- Glucose oxidative metabolism is less sensitive to ADR than fatty acids.
- Of all compounds assessed for glucose and fatty acid metabolism, PAN 
and STR had the least inhibitory effect.'
ETA is a potent inhibitor of fatty acid metabolism by isolated pig 
glomeruli.
The stimulating effect of BEA on glomerular oxidative metabolism of 
glucose is unexpected and needs further elucidation.
- Due to the high degree of inter-experimental variability seen when the 
effect of BEA was assessed on fatty acid metabolism, it is not possible to 
draw any conclusion or to allow any comparison, and more experiments need 
to be done.
The ability of isolated pig and rat glomeruli to perform the different 
biochemical reactions leading to the oxidation of subtrates to CO 2  offers 
a useful metabolic system with which to study target selective toxicity.
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6.5 Isolated glomeruli as an in vitro system for the study of OTA toxicity
6.5.1 Effect of OTA on amino acid incorporation into isolated rat 
glomeruli
The effect of OTA on the incorporation of several different amino acids 
into isolated rat glomeruli, was assessed over 4 hr. OTA markedly
inhibited the incorporation of all the amino acids tested. The lowest
concentration of the toxin assayed (10 uM) significantly decreased protein 
synthesis from LEU and TYR to 28% (P < 0.01 and 0.001 respectively), as is 
shown in Table 6.5.1 and 2 of Appendix 2, and Fig. 6.5.1, with an 
estimated IC5 Q of 5 uM. PHE incorporation was also decreased significantly
(P < 0.05) to 44% (IC5Q = 7.8), and TRP to 50% (IC5Q = 10). Although the
least affected amino acid was HIS, this showed a significant decrease of 
protein synthesis to 62% of the control. Higher concentrations of the 
OTA caused further decreases in protein synthesis, all statistically 
significant in relation to the control. Table 6.5.1. shows the relative 
toxicity of OTA on amino acid incorporation.
Discussion
These data show that OTA markedly depressed the incorporation of all amino 
acids, with very small doses of the toxin (ranging from 4.7 to 25 uM) 
required to decrease it to 50% of the control. This means that de novo 
protein synthesis from different amino acids, is strongly inhibited and 
that LEU and the aromatic amino acids are the most sensitive. The effect 
of OTA on protein synthesis has been previously reported in other in vitro 
systems such as cultured hepatoma cells (Creppy et al, 1979a), in which 90 
uM of the toxin inhibited the incorporation of LEU by 60% and MDCK cells 
in which this parameter was inhibited to 50% with 15 uM OTA (Creppy et al,
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Fig. 6.5.1
0.5 ml aliquots o f isolated rat glomeruli suspended in Earles-HEPES buffer were incubated 
at 37°C with 0.5 m l o f buffer containing 2.5 uCi o f various 3H-amino acids (HIS, LEU, PRO, 
PHE, TRP and TYR) and different concentrations o f ochratoxin A , for 4 hr. The ordinate 
represents the proportion o f incorporated amino acid calculated as a percentage o f the 
total amino acid incorporation into isolated rat glomeruli incubated without the chemical 
(control). Each point is the result o f triplicate incubations.
OTA EFFECT ON GLUCOSE OXIDATIVE METABOLISM
BY ISOLATED RAT GLOMERULI
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Fig. 6.5.2
Dose-response o f glucose oxidation by isolated rat glomeruli exposed to ochratoxin A. 0.5 
ml aliquots o f glomeruli suspended in Earles-HEPES were incubated at 37°C with 0.5 ml of 
buffer containing 2 uCi o f 14C-glucose and different concentrations o f the chemical. The 
ordinate represents the proportion o f CO, calculated as a percentage o f the to ta l1 C02 
released from ,4C-gIucose incubated with uie glomerular suspension without the chemical 
(control). Each point is the result o f triplicate incubations.
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TABLE 6.5.1
RELATIVE TOXICITY OF OCA ON THE INCORPORATION OF SEVERAL AMINO ACIDS
INTO ISOLATED RAT GLOMERULI
AMINO ACID IC50* (uM)
HIS 25.0
PRO 19.0
TRP 10.0
PHE 7.8
TYR 5.0
LEU 4.7
* Estimated concentration that inhibits protein synthesis to 50! 
of the control value.
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198 6 ). There are also reports on the reduction of in vivo renal protein 
synthesis from PHE and LEU by 30 - 40% in rats fed the toxin (Meisner and 
Meisner, 1981).
OTA has been also reported to decrease protein in liver and kidney of mice 
that had been administered the toxin (Creppy et al., 1984). In the case of 
these investigations, OTA inhibited more the incorporation of PHE than PRO 
and HIS.
The sensitivity of the aromatic amino acids compared to PRO, suggests the 
involvement of non-collagen components of the glomerular extracellular 
matrices, but to confirm this further studies with GBM, need to be.done. 
There are no other reports on the incorporation on PHE and other amino 
acids into glomerular protein, but a protective effect of PHE against OTA 
toxicity has been reported in vitro and in vivo (Creppy et al, 1979a; 
1984); and OTA inhibition of protein synthesis has been attributed to the 
competition between the drug and PHE for the binding site on the 
phenylalanyl-tRNA synthetase (Creppy et al, 1983).
The relevance of this findings in relation to the in vivo lesion produced 
by OTA is not yet known.
The different behaviour shown in the previous experiments with isolated 
pig glomeruli exposed to OTA incubated in Krebs buffer (Section 6 .2.6 .2), 
where large concentrations of the toxin (3.2 mM) did not produce a 50% 
inhibition relative to the control, could be due to a species difference, 
but it is more likely due to the different buffering system used. This 
still needs further elucidation using the same conditions as for rat 
glomeruli to allow a better comparison between the two species.
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From this work, several questions have been raised, such as the 
relationship between OTA effect on glomerular protein to GBM structure and 
composition. Electrophoretic and autoradiographic studies on glomerular 
protein synthesised from different amino acids as affected by OTA, will 
allow one to follow the fate of the precursors, and the effect of the 
mycotoxin on the composition of glomerular protein (see Chapter 7).
6.5.2 Effect of OTA on the oxidative metabolism of glucose and 
linolenic acid
6.5.2.1 Glucose
CO2  release from glucose was enhanced significantly (P < 0.001) up to 345% 
by low concentrations of OTA (10 - 100 uM) as can be seen in Fig. 6.5.2 
and Table 6.5.3 of Appendix 2. On the other hand, higher concentrations 
of the toxin (ie. 1000 uM), inhibited significantly (P < 0.001) glucose 
metabolism to 59%.
Discussion
These data show that small concentrations of OTA stimulated considerably 
glucose metabolism. The interpretation of this effect is difficult, and at 
this stage it is not possible to say if the enhanced production of CO 2  
from glucose was due to an stimulation either of the complete oxidation of 
the carbohydrate to CO2  or the pentose phosphate pathway activities or 
both, although the first possibility does not fit with findings from 
previous studies where small concentrations of OTA are reported to inhibit 
mitochondrial respiration in the isolated rat liver mitochondria (Moore 
and Truelove, 1970; Meisner and Chan, 1974; Wei et al, 1985). However, 
the metabolism of glucose in glomeruli exposed to OTA has not been focus
241
of any previous published studies. More data on this topic needs to be 
obtained to be able to reach definite conclusions.
6.5.2.2. Linolenic acid
CC> 2 release from linolenic acid showed a slight increase at OTA 
concentrations between 10 - 100 uM (Table 6.5.4 of Appendix 2 and Fig. 
6.5.3), by 17% and 19% of the control respectively, which was 
significantly different (P < 0.05). However, 1000 uM of the toxin markedly 
depressed it, to 7.5% of the control (P < 0.001).
Discussion.
These data show that low concentrations of OTA caused a small, but 
definite stimulation of linolenic acid oxidation. A stimulatory effect on 
fatty acid metabolism in isolated glomeruli, could be linked to the 
observations of Elling and coworkers (1985) who found enhanced levels of 
peroxisomal beta-oxidation in soluble fractions of subcellular components 
of pig kidney, after in vivo short-term exposure to OTA.
The fact that 1000 uM OTA reduced remarkably fatty acid metabolism, may be 
in connection with the deteriorative changes of the mitochondria, and 
decreased respiration that have been reported to be caused by the toxin in 
vitro.
There are no previous reports on the study of fatty acid metabolism in 
isolated glomeruli of any species, exposed to OTA.
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Fig. 6.5 J
Dose-response of linolenic acid oxidation by isolated rat glomeruli exposed to ochratoxin 
A. 0.5 ml aliquots of glomeruli suspended in Earles-HEPES were incubated at 37°C with 0.5 
ml of buffer containing 50 nCi o f1 C-linolenic acid and different concentrations of the 
chemical. The ordinate represents the proportion o f1 CO, calculated as a percentage of 
the total 14(X>2 released from ^C-linolenic acid incubated with the glomerular suspension 
without the chemical (control). Each point is the result of triplicate incubations.
2 4 3
6.5.3. Summary and Conclusions
6 .5 .3 .1. Summary
1- OTA markedly inhibited de novo synthesis of protein by isolated rat 
glomeruli from different amino acids.
2- The relative toxicity of OTA on the incorporation of several amino 
acids into isolated rat glomeruli ranked as follows:
LEU > TYR > PHE > TRP »  PRO > HIS.
3- Low concentrations of OTA (10 and 100 uM) enhanced glucose metabolism 
to CO2 .
4- Only high concentrations of OTA (1000 uM) caused significant inhibition 
on linolenic acid metabolism.
6 . 5 . 3 . 2 .  C onclusions
1- Protein synthesis from aromatic amino acids such as PHE and TYR appears 
to be a sensitive parameter of OTA toxicity.
2- The sensitivity of the aromatic amino acids to the effect of OTA 
(compared to proline) suggests that a glomerular macro-molecule other than 
GBM-collagen may be affected. This could be other functional and 
structural proteins of the glomeruli.
3- The inhibition of the incorporation of aromatic amino acids into 
glomerular macromolecules by OTA suggests that the synthesis of specific 
proteins may be central to the mechanism of target selective toxicity
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towards the kidney.
4- The stimulation of glomerular glucose metabolism 
clear.
5- The findings on OTA toxicity may be relevant 
nephropathy and to the human condition BEN.
by OTA is still not
to porcine endemic
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6.6. Metabolic studies on isolated rat proximal tubular fragments.
With the aim to compare some metabolic characteristics between rat 
isolated glomeruli and proximal tubular fragments, studies on the latter 
were carried out. '
6.6.1 Amino acid incorporation into isolated rat tubules.
6.6.1.1 Comparison on the incorporation of PRO incubated with two 
different buffers.
Incubation with Earles-HEPES buffer gave a significantly higher 
incorporation of the amino acid than Tyrodes at all time points studied 
(Fig. 6.6.1; Table 6.6.1 Appendix 2), and after 4 hr of incubation the 
values for Earles-HEPES were three times higher (P < 0.01), therefore this 
buffer was also chosen for all experiments performed with proximal tubular 
fragments.
6.6.1.2 Incorporation of different amino acids.
The incorporation of several tritiated amino acids into rat proximal 
tubular fragments was measured. The highest rate of incorporation was 
shown by TRP (Fig. 6.6.2A; Table 6.6.2, Appendix 2). After 4 hr of 
incubation 18 - 26 pmol of amino acid/mg of protein were incorporated
(Fig. 6.6.2 of Appendix 2), seven times higher (P < 0.001) than PRO whose 
incorporation was ranked second (2.7 pmol/mg of protein). Although TYR 
and PHE had similar values of incorporation after 4 hr of incubation 
(1.3 and 1.2 pmol/mg of protein), they were significantly different (P < 
0.05). HIS and LEU were the least incorporated of all amino acids tested 
( 0.9 and 0.7 pmol/mg protein), as can be seen in Fig. 6.6.2B). Although 
the pattern of amino acid incorporation was almost linear in all cases, 
there was a certain degree of variability when the amino acid
246
In
co
rp
or
at
io
n 
(p
m
ol
 
PR
O
/m
g 
pr
ot
)
INCORPORATION OF PROLINE INTO RAT TUBULES
INCUBATED WITH TWO DIFFERENT BUFFERS
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Fig. 6.6.1
Isolated rat proximal tubular fragments were suspended either in Tyrodes or Earles-HEPES 
buffers, and incubated with 0.5 ml of buffer containing 2.5 uCi 3H-proline for 0,1,2,3 
and 4 hr.
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Fig. 6.6.2A
Kinetics of de novo protein synthesis by isolated rat proximal tubular fragments, 
incubated with Earles-HEPES buffer. 0.5 ml of buffer containing 2.5 uCi of each of the 
3H-Iabelled amino acids (HIS, LEU, PHE, PRO, TRP and TYR) was added at 0 time. The 
ordinate represents specific activity incorporated into TCA-precipitable labelled 
material. Each time point is the result o f triplicate incubations.
AMINO ACID INCORPORATION INTO RAT PT FRAGMENTS
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Fig. 6.6.2B
Enlarged view of the incorporation of HIS, LEU, PHE, PRO and TYR from Fig. 6.6.4A.
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incorporation was tested in different experiments. PHE showed a 5-fold 
inter-experimental variability in its uptake having values ranging between 
(1.2 - 6  pmol/mg protein) as can be seen in Fig. 6.6.1 of Appendix 2. The 
other amino acids also presented some degree of inter-experimental 
variability (Figs. 6.6.3 - 6 .6 . 6  Appendix 2). Standard deviations were 
normally low. The degree of statistical significance between different 
time points for each amino acid is shown in Table 6.6.3 Appendix 2, and 
for the different amino acids at the same time point in Table 6.6.4 
Appendix 2.
6 .6.1.3 Discussion
These data show that the incorporation of amino acids such as proline into 
rat proximal tubular fragments can vary with the composition of the 
incubating media in a similar way to isolated rat glomeruli, and the 
possible reasons for these differences are discussed in section 6.1.5. 
Proximal tubular fragments also incorporate different amino acids linearly 
for several hours, at different rates. The pattern of incorporation is 
similar to that seen for isolated glomeruli, but when the rate of 
incorporation was calculated per mg of protein, this is 1 0 -fold lower for 
the proximal tubular fragments than for glomeruli (Table 6.6.1), 
suggesting that glomeruli have a higher metabolic rate for the synthesis 
of protein than tubules. This is consistent with the fact that glomerular 
cells have to produce and maintain the extracellular matrices such as GBM 
and other structural and functional proteins, therefore requiring higher 
activities of protein synthesis.
The incoporation of PRO and other different amino acids has been reported
to be linear for several hours (Kwizera and Bach, 1987) but no comparison has bee:
performed between the incorporation of different aromatic amino acids nor
2 4 9
TABLE 6 . 6 . 1 .
RATE OF INCORPORATION OF SEVERAL AMINO ACIDS 
INTO ISOLATED RAT GLOMERULI (G) AND TUBULES (T)
AMINO ACID INCORPORATION RATE (pmol/mg prot/hr)
G T
TRP 27.3 3.20
PHE 4.7 0.67
TYR 3.7 0.33
LEU. 3.5 0.31
PRO 2.4 0.27
HIS 2.5 0.21
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between their rates of incorporation into isolated glomeruli.and proximal 
tubules.
6.6.2 Oxidative metabolism
6.6.2.1 Glucose oxidative metabolism into isolated rat proximal
tubular fragments
14The rate of CO 2  release from labelled glucose was linear for 2 hr, after 
which it levelled off (Fig. 6.6.3; Table 6.6.5 Appendix 2). The degree of 
statistical significance between different time points is shown in Table 
6.6.7 Appendix 2
6. 6.2.2 Fatty acid metabolism into isolated rat proximal tubular 
fragments
A comparison of the time course of the oxidative metabolism of various
14 .C-labelled fatty acids was performed. Oxidation of linolenic acid was
the highest (Fig. 6.6.4; Table 6 .6 . 6  Appendix 2), followed by oleic.
Metabolism of stearic and palmitic acid was the lowest, and the blanks
without tubules gave half of the counts that were obtained when tubular
fragments were present. Mevalonic acid which was also assessed, did not
undergo metabolism under the conditions of this experiment. The degree of
statistical significance between different time points of each fatty acid
is shown in Table 6 .6 . 8  of Appendix 2.
6.6.3 Effect of Ochratoxin A
6.6.3.1 Effect of OTA on amino acid incorporation into isolated rat 
tubules
OTA markedly inhibited the incorporation of all the amino acids tested
(Fig. 6.6.5; Table 6.6.9 Appendix 2). The lowest concentration of the
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Fig. 6.6.3
Kinetics of glucose oxidation by isolated rat proximal tubular (PT) fragments. 0.5 ml of 
Earles-HEPES buffer containing 2 uCi of 14C-glucose was incubated with 0.5 ml of the PT 
preparation for up to 4 hr. The ordinate represents specific activity of 14CO, trapped 
into NaOH. Each line corresponds to a different experiment and each time point is the 
result o f triplicate incubations.
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Fig. 6.6.4
Comparison of the time-course o f the oxidative metabolism of various 14C-labclIed fatty 
acids by isolated rat proximal tubular (PT) fragment. 0.5 ml of Earles-HEPES buffer 
containing 50 nCi of either radiolabel was incubated with 0.5 ml of the PT preparation for 
up to 4 hr. The ordinate represents specific activity o f C02 trapped into NaOH. Each 
time point is the result of triplicate incubations.
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Fig. 6.6.5
0.5 ml aliquots o f rat proximal tubular fragments (PTF) suspended in Earles-HEPES buffer 
were incubated at 37 C with 0.5 ml of buffer containing 2.5 uCi of various 3H-amino acids 
(HIS, LEU, PRO, PHE, TRP and TYR) and different concentrations o f ochratoxin A, for 4 hr. 
The ordinate represents the proportion of incorporated amino acid calculated as a 
percentage o f the total amino acid incorporation into isolated PTF incubated without the 
chemical (control). Each point is the result o f triplicate incubations.
OTA EFFECT ON GLUCOSE OXIDATIVE METABOLISM
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Fig. 6.6.6
Dose-response of glucose oxidation by isolated rat proximal tubular fragments (PTF) 
exposed to ochratoxin A. 0.5 ml aliquots of PTF suspended in Earles-HEPES were incubated 
at 37°C with 0.5 ml of buffer containing 2 uCi of ,4C-glucose and different concentrations 
of the chemical. The ordinate represents the Droportion of CO2 calculated as a 
percentage of the total 14CO, released from r4C-glucose incubated with isolated PTF 
without die chemical (control). Each point is the result o f triplicate incubations.
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toxin assayed (10 mM) decreased significantly (P < 0.001) protein
synthesis from HIS to 34%, PRO to 41%, LEU, TRP and TYR to 47%, and PHE to 
53% (Table 6.6.10 Appendix 2). Higher concentrations of OTA caused further 
significant decreases (P < 0.001) relative to the control values. Although 
the estimated IC^q values were very close for most of the amino acids, HIS 
appeared to be the most sensitive (IC5 Q = 5.8 uM) and PHE the least (IC5 o 
= 2 1  uM) as can be seen in Table 6.6.2.
Discussion
As in isolated glomeruli, OTA remarkably decreased de novo protein 
synthesis by isolated tubular fragments, but this time the ranking of OTA 
toxicicity towards the different amino acids was different from isolated 
glomeruli with PHE appearing as the less sensitive and HIS as the most. It 
is necessary to extend the range of concentrations between 0 - 100 uM to 
see if greater differences between the amino acids can be picked up.
6.6.3.2. Effect of OTA on the oxidative metabolism of glucose
Glucose metabolism was enhanced significantly (P < 0.001 and 0.01
respectively) to 270 and 224% of the control by 10 and 100 uM of OTA (Fig. 
6 .6 .6 ; Table 6.6.10). On the other hand, . higher concentrations of the 
toxin (ie. 1000 uM), inhibited glucose metabolism to 72%.
Discussion
These data show that OTA at low doses (10 and 100 uM) stimulates 
glucose oxidation by isolated rat proximal tubular fragments. The 
pattern of interaction is similar to that shown by isolated glomeruli. 
Therefore the interpretation of those results (Section 6 .5.2.1.) also 
applies for these findings on proximal tubular fragments.
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TABLE 6.6.2.
RELATIVE TOXICITY OF OCA ON THE INCORPORATION OF SEVERAL AMINO ACIDS 
INTO ISOLATED RAT GLOMERULI (G) AND TUBULES (T)
AMINO ACID IC50* (uM)
G T
HIS 25.0 5.8
PRO 19.0 7.2
TRP 1 0 . 0 8 . 6
PHE 7.8 2 1 . 0
TYR 5.0 9.2
LEU 4.7 8 . 6
* Estimated concentration that inhibits protein synthesis to 50% 
of the control value.
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6.6.3.3. Effect of OTA on the oxidative metabolism of linolenic acid
Linolenic acid metabolism was increased significantly (P < 0.01 and 0.05 
respectively) by 43 and 33% at OTA concentrations of 10 and 100 uM 
respectively (Fig. 6.6.7; Table 6.6.11 Appendix 2). Higher concentrations 
of the toxin markedly depressed it (P < 0.001), to 11% of the control.
Discussion
These data show that low concentrations of OTA also increased moderately 
but significantly the oxidative metabolism of linolenic acid. The
interaction is again similar to that seen for isolated glomeruli (Section 
6 .5.2 .2 ) and the same interpretation applies.
In all two oxidative pathways assessed, it is necessary to extend the 
range of concentrations between 0-100 uM, for a proper dose-response 
relationship.
6.6.4 Summary and Conclusions 
6.6.4.1 Summary
6.6.4.1.1. Proximal Tubular Metabolism
1- Isolated rat proximal tubules incorporate different amino acids, at 
different rates. The order of incorporation being the same as in
glomeruli TRP »  PHE > TYR > LEU > PRO > HIS. However, . the rates of
incorporation were 1 0 -fold lower for the proximal tubular fragments.
2- Incubation of isolated rat proximal tubules with Earles-HEPES buffer 
increases the incorporation of PRO more than Tyrodes and Krebs.
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Fig. 6.6.7 ‘
Dose-response of linolenic acid oxidation by isolated rat proximal tubular fragments (PTF) 
exposed to ochratoxin A. 0.5 ml aliquots of PTF suspended in Earles-HEPES were incubated 
at 37°C with 0.5 ml o f buffer containing 50 nCi o f1 C-linolenic acid and different 
concentrations of the chemical. The ordinate represents the proportion o f * C02 
calculated as a percentage o f the total C02 released from *4C-linolenic acid incubated 
with isolated PTF without the chemical (control). Each point is the result o f triplicate 
incubations.
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14 143- Isolated rat proximal tubular fragments metabolize C-glucose and C-
14fatty acids (linolenic, oleic, palmitic and stearic) to C 2  linearly for 
two hours.
4- Glucose oxidative metabolism is much lower than fatty acid oxidation, 
in proximal tubular fragments, as in isolated glomeruli.
5- Among the fatty acids linolenic showed the highest oxidation rate.
6 - The rate of fatty acids oxidative metabolism is much lower for isolated 
rat proximal tubular fragments when calculated per mg of protein.
7- Rat proximal tubular fragments glucose oxidative rate is similar to 
that in isolated rat glomeruli.
6 .6 .4.1.2. OTA Toxicity
1- OTA markedly inhibited de novo synthesis of protein by isolated 
proximal tubular fragments from different amino acids.
2- The relative toxicity on OTA on the incorporation of several amino 
acids into isolated proximal tubules ranked as follows:
HIS > PRO > LEU > TYR »  PHE.
3- Low concentrations of OTA (10 and 100 uM) enhanced glucose metabolism 
to CO 2  by isolated rat proximal tubular fragments, similarly to isolated 
rat glomeruli.
4- Only high concentrations of OTA (1000 uM) caused significant inhibition
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on linolenic acid metabolism.
6 .6 .4.2. Conclusions
1- Isolated proximal tubular fragments maintain their viability for
several hours as manifested for the maintenance of linear rates of amino 
acid incorporation.
2- The metabolic activity of isolated proximal tubular fragments per mg of 
protein (de novo protein synthesis, and oxidative metabolism) appears to 
be lower than in isolated glomeruli..
3- The amount of de novo synthesized protein can vary with the composition
of the incubating media, similarly to isolated glomeruli.
4- Contrary to isolated rat glomeruli, PHE appears to be the least
sensitive amino acid, and HIS the most sensitive (I5 Q 21 vs. 5.8 uM, 
respectively) to the toxicity of OTA.
5- OTA effect on glucose and fatty acid oxidative metabolism by isolated 
proximal tubular fragments is still not clear.
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CHAPTER 7.
FINAL DISCUSSION
The problems associated with assessing the real role of mycotoxins in 
clinically relevant nephropathies are extensive, and there needs to be a 
number of problems resolved before this question can be answered.
In the first place, end stage renal disease is a long-term consequence of 
multifactorial events, it may be impossible to identify the initiating 
event. Secondly, when mycotoxins appear to be involved, it is difficult to 
determine the levels of exposure, because it_will depend on the seasonal 
variation and whether it has been a pulse dose rather than a continuous 
exposure, or a combination of both. The nephropathies associated with 
mycotoxins may also involve more than one compound, with the possibility 
of interactions between them. The mycotoxins OTA and aflatoxin (ATB^)
have been detected in a great diversity of agricultural products, they can 
also occur simultaneously, due either to the growing of more than one 
species of mould on the same commodity or to the mixtures of various food 
or feed supplies. The combined ingestion of OTA and ATB^ may be 
synergistic, with nephropathy as the primary effect. The possibility of 
interactions between a mycotoxin and other nephrotoxicant bring about 
further complications.
In addition, the target cell within the kidney needs to be defined 
accurately. In the case of OTA, the target has been identified as the 
proximal tubule, but there is evidence to suggest early glomerular
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involvement. In the case of BEN, the clinical signs of the disease appear 
too late to have an accurate picture of the cascade of early degenerative 
events that lead to this condition.
This thesis has attempted to address some of these problems. First of all, 
the in vivo work aimed to study early renal clinical and morphological 
changes, caused by the administration of different repetitive doses of 
ochratoxin A alone or in combination with small doses of aflatoxin and 
tried to identify the extent of glomerular involvement.
Using clinical biochemistry, features relating to proximal tubular damage, 
such as enzymuria, glucosuria and polyuria, were observed. Most important, 
a proteinuria which could have been of glomerular origin was found. 
Routine histology showed besides the tubular lesion, morphological changes 
in glomeruli of animals treated with repeated doses of OTA, such as 
edema and prominent PAS staining, suggesting thickening of basement 
membrane. On the other hand repeated doses of OTA and ATB^, applied 
simultaneously, appeared to have a synergistic effect, characterized by 
severe disruption of proximal tubules, but most important, a general 
morphological derangement of the glomerulus was seen involving intense and 
faint staining nuclei (possibly indicative of cell necrosis) and 
cytoplasmic vacuolation, which was not seen with either toxin alone. These 
findings have not been previously described in the literature, following 
such low dose regime of OTA alone or in combination with ATB^. These in 
vivo data need to be confirmed by high resolution microscopy, 
histochemistry, immunohistochemistry and electron microscopy, in order to 
describe these changes in greater detail and follow the time-course at the 
ultrastructural level, to help understand molecular changes.
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Due to the findings of early glomerular changes after exposure of the 
animals to small repetitive doses of OTA, as well as the relative high 
cost and time-consuming task of the in vivo experimentation, it was 
decided to focus studies on the use of in vitro techniques (ie. isolated 
glomeruli). The complex and highly organized structure of the kidney makes 
it difficult to study the various specialized functions separately in the 
intact organ. Therefore, studies on. isolated glomeruli offer several 
advantages over both the intact animal and other in vitro techniques such 
as perfusion, slices and isolated cells. Glomeruli are easily isolated 
from the rest of the nephron in an intact form. More important, their 
anatomical characteristics are such that they can not be confused with 
other regions of the nephron. The preparation of isolated glomeruli is a 
relatively simple and quick procedure, with no need of sophisticated or 
expensive apparatus, and the glomerular preparation maintain many of 
their metabolic functions for several hours. Contrary to in vivo studies, 
considerable information can be obtained with the use of small number of 
rats. Several different parameters can be assessed from the same tissue, 
allowing comparison .of data, while minimizing tissue variability. Isolated 
glomeruli allow the study of glomerular characteristics, or functions as 
well as metabolic properties, under controlled conditions and independent 
of haemodynamic changes and other renal or extrarenal factors; this 
facilitates the differentiation of direct and indirect effects and allows 
an assessment of a precise dose-effect and time-concentration relationship 
of a specific chemical.
The disadvantages of studying isolated glomeruli are mainly those inherent 
to most in vitro systems, such as the short viability which restricts the 
study of morphological and biochemical effects to the investigation of
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short responses such as acute changes following a toxic insult. 
Furthermore, due to the cellular heterogeneity, it is not possible to 
correlate the observations with a specific cell type within the glomeruli. 
Other disadvantage is that opposite to the in vivo situation, a chemical 
is presented to the glomeruli from outside the blood supply, it is not 
plasma bound, and it is not under pharmacokinetic changes in 
concentration. Therefore, the interpretation and extrapolation of data 
derived from observations performed on isolated glomeruli may require 
some care. However, most of the knowledge on glomerular biochemistry and 
metabolism has been obtained from studies in isolated glomeruli.
Useful information on the properties of the glomerular basement membrane 
(GBM) can also be obtained from observations in isolated glomeruli and 
therefore, after toxic injury the assessment of changes in the biochemical 
functions of the cells which produce and maintain this extracellular 
matrix can also be performed, based on the supposition that they take 
place before or in parallel with any modification in the structure or 
composition of the GBM. It is possible that some of these changes can be 
measured by studying selected parameters of glomerular metabolism. 
Isolated glomeruli also provide a suitable system to study the mechanism 
of action of nephrotoxic compounds either from one compound alone, its 
metabolites or after multichemical exposure, and also has the potential to 
help the -development of a reliable in vitro system for the screening of 
chemicals for glomerular toxicity. The method can be applied to the study 
of different species such as rat, pig and man, allowing interspecies 
comparison. The work with human tissue does, however present a number of 
difficulties because of the fibrous nature of human kidney available from 
nephrectomies and cadavers, interindividual variability and association 
with biohazard risks such as hepatitis and AIDS. In addition, human
kidneys are not conveniently available from cadaver material (where the 
biohazard risk is more difficult to assess) and although surgical 
nephrectomy material provides a better basis for studies and easier 
biohazard assessment, the kidney may have, of necessity, pathological 
changes. In contrast, the pig kidney is amply available from abattoirs, 
which provides a source of disease-free tissue from an organ that is 
anatomically almost identical to that from man. One pig kidney provides a 
considerable amount of tissue, equivalent to that of more than 25, 150g
rats.
In this thesis, de novo synthesis of protein has been studied using a 
variety of radiolabelled amino acids as precursors and extending the area 
of biochemical assessment by following the oxidative metabolism of glucose 
and linolenic acid, by isolated rat and pig glomeruli. In addition, the 
changes in the metabolism of isolated glomeruli (ie. protein synthesis and 
oxidative metabolism) have been investigated, after exposure to different 
chemicals (ie. Adriamycin, Puromycin aminonucleoside and Streptomycin), 
some of which are known to damage this part of the nephron in vivo. These 
effects were also compared to those compounds that target specifically for 
other parts of the nephron, such as Ethacryn'ic acid, 2-Bromoethanamine and 
Folic acid. Studies on the effect of OTA on de novo synthesis of protein 
and oxidative metabolism by isolated rat glomeruli and tubules were also 
carried out. The data presented in this thesis, appear to be the first 
that document differences in the pig and rat glomerular metabolism.
Isolated pig and rat glomeruli and rat tubules incorporated different 
amino acids linearly for several hours, at different rates. Pig glomeruli 
incorporated leucine at a much higher rate than the other amino acids,
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and proline was ranked second. The order of incorporation being leucine 
»  proline = histidine > lysine > glycine. In rat glomeruli tryptophan 
was incorporated at the highest rate, with phenylalanine and tyrosine 
ranked next. The order of incorporation was tryptophan »  phenylalanine > 
tyrosine = leucine > proline > histidine. The rate of incorporation of 
amino acids into rat glomeruli was higher than that in tubules, however 
the same pattern of amino acid incorporation was followed.
Proline and the aromatic amino acids were chosen to assess de novo
synthesis of protein because they are believed to play an important role 
as structural constituents of some GBM proteins. Proline is regarded as a 
major constituent of the collagen-like structure, and its conversion to 
the hydroxylated amino acid takes place specifically in GBM. This
structural integrity seems to play an important role in the cell-matrix 
interactions. Fibronectin, a non-collagen GBM protein, is thought to be 
formed by floppy, asymetric molecules with localized regions of folding in 
which aromatic amino terminals (ie. the TRP and TYR terminals) appear to 
have the function of keeping this structural characteristic which seems 
to be important for intercellular adhesion and to promote cellular
spreading.
It is important to point out the higher rate of incorporation of the
aromatic amino acids into rat glomeruli, compared to proline, suggesting a 
higher turnover in glomerular proteins other than GBM-collagen (ie. 
fibronectin). This is consistent with previous observations in vivo in 
which the turnover rate of GBM-collagen was found to be about 100 days, 
while the turnover of non-collagen glomerular proteins took about 9 days 
only (Price and Spiro, 1977) .
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Isolated pig and rat glomeruli and rat tubules metabolized glucose to CO 2  
linearly for several hours. In both species, the glucose oxidative 
glomerular metabolism, was much lower than fatty acid oxidation. Rat 
glomeruli metabolized glucose at a higher rate than tubules. Isolated pig 
and rat glomeruli and rat tubules also oxidize fatty acids to CO 2
linearly, for several hours.
When various chemicals that target in vivp: for different parts of the
nephron were assessed, Adriamycin exerted a strong inhibition on de novo 
synthesis of protein, from proline, in isolated pig glomeruli. Although it 
has been reported previously that Adriamycin inhibits synthesis of protein 
in isolated rat glomeruli (Ahmed et al., 1987), no data has shown the 
effect of the drug in the synthesis of protein by isolated pig glomeruli.
Therefore, the data presented above appear to be the first reporting such
effect in this species in vitro. .
Adriamycin markedly inhibited the oxidative metabolism of fatty acids, 
such as linolenic and oleic acid. There are no previous observations on 
the effect of Adriamycin on fatty acid metabolism of isolated glomeruli of 
any species. The findings reported in this thesis are however consistent 
with observations on the inhibition of the oxidation of palmitic acid to 
CC> 2 by renal mitochondria following Adriamycin treatment to rats (Bizzi 
et al, 1983), although the type of cell responsible for this effect could 
not be specified in this paper, as it used whole renal homogenates.
Adriamycin also inhibited the oxidative metabolism of glucose but to a 
lesser degree than fatty acids.
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Puromycin aminonucleoside effects on de novo synthesis of protein and 
oxidative metabolism of isolated pig glomeruli, are weak compared to 
Adriamycin, suggesting that either it is not the compound per se, but a 
metabolite that may exert the toxic effect, or that de novo synthesis of 
protein is not sensitive and a different biochemical pathway is affected 
as part of the mechanism of injury.
Although moderate, the inhibition of glucose metabolism is consistent with 
observations on isolated glomeruli of Puromycin aminonucleoside nephrotic 
rats, where there was a decrease in glucose metabolism.
Ethacrynic acid showed the strongest inhibitory effect on de novo protein 
synthesis in isolated pig glomeruli but fatty acid and glucose metabolism 
were also remarkably decreased. The effect of the drug on fatty acid and 
glucose metabolism has been previously shown in isolated rat glomeruli by 
Meezan and Brendel (1973). However, there appear to be no reports on the 
effects of ethacrynic acid on glomerular synthesis of protein by isolated 
pig glomeruli.
2-Bromoethanamine showed a moderate inhibitory effect on protein synthesis 
of isolated pig glomeruli. Although, due to the selectivity of the 
compound for the renal papilla, a lesser effect on glomeruli would be 
expected, its potential alkylating properties may have been responsible 
for the inhibitory effect on protein synthesis.
2-Bromoethanamine also enhanced glucose oxidative metabolism in isolated 
pig glomeruli, at all concentrations tested.
267
OTA
The mycotoxin remarkably decreased de novo protein synthesis by isolated
rat glomeruli and tubules. This is consistent with findings that OTA
inhibited the synthesis of protein in several in vivo and in vitro
systems. However, no one has ever looked at the biochemical processes 
taking place in glomeruli exposed to the action of OTA in vitro.
Although OTA showed a remarkable generalized depression on the
incorporation of the six amino acids tested, there were differences in 
their sensitivity to OTA effect. All three aromatic amino acids, 
phenylalanine, tyrosine and tryptophan were more sensitive to the effects 
of OTA than proline, suggesting a great involvement of GBM non-collagen 
proteins in OTA toxicity in isolated rat glomeruli.
Small doses of OTA stimulates glucose oxidative metabolism. This can be 
due to an increase in either glycolysis or pentose phosphate shunt. There 
appears to be no report in the literature about the effect of OTA on this 
metabolic pathway in isolated glomeruli or other systems.
Low concentrations of OTA also increase moderately the oxidative 
metabolism of linolenic acid. This can be due to an increase in either 
mitochondrial Beta-oxidation or peroxisomal Beta-oxidation. This is 
consistent with findings of enhancement of peroxisomal Beta-oxidation in 
cortex of pig kidney after administration of OTA, although the type of 
cell responsible for this effect, was not specified.
In conclusion the experiments detailed above have highlighted:
1- The use of isolated glomeruli a)- as a system which allows the study of 
characteristics that are difficult to study in the intact organ.
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b)- For screening of chemicals for glomerular toxicity.
c)- To study the mechanism of action of nephrotoxic compounds.
2- The differences in pig and rat glomerular metabolism.
3- The glomerular effects of OTA in vivo and in vitro.
4- The potential role of glomeruli in the toxic lesion caused by 
neprotoxicants.
Conclusions:
The following conclusions can be drawn from the present data:
1- Isolated rat and pig glomeruli maintain a range of metabolic fuctions 
(protein synthesis, glucose and fatty acid oxidation) for several hours.
2- The incorporation of a high proportion of aromatic amino acids into 
isolated rat glomeruli macromolecules is a novel observation.
3- From the metabolic pathways assessed in isolated pig glomeruli, proline 
incorporation appeared to be the most sensitive index of glomerular 
cytotoxicity caused by Adriamycin.
4- Protein synthesis from aromatic amino acids such as phenylalanine and 
tyrosine appears to be a sensitive parameter of OTA toxicity.
5- The sensitivity of the aromatic aminoacids to the effect of OTA 
(compared to proline) suggests that glomerular macromolecules other than 
GBM-collagen may be affected. These could include other functional and
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structural proteins.
6 - The inhibition on the incorporation of aromatic amino acids into 
glomerular macromolecules by OTA suggests that the synthesis of specific 
proteins may be central, to the mechanism of target selective toxicity of 
OTA towards the kidney.
7- The findings on OTA toxicity may be relevant to porcine endemic 
nephropathy and to the human condition BEN.
8 - The ability of isolated pig and rat glomeruli to synthesise protein and 
to perform different biochemical reactions involved in the oxidation of 
substrates to CC^, offers a series of useful metabolic systems with which 
to study target selective toxicity.
Future research directions:
In common with most other research, some questions have remained 
unanswered and a score of vital questions has been opened:
- It is necessary to relate proline behaviour, in protein synthesis to GBM 
structural and chemical changes after toxic injury. Studies, on the 
incorporation of proline into GBM, as well as its conversion to OH-proline 
will provide more specific information on GBM changes.
The findings on the high incorporation of aromatic amino acids into 
glomerular protein, have raised the question on the possible role of other 
constituents (ie. aromatic amino acids vs. proline) of the glomerular 
extracellular matrix as related to glomerular injury, and the possibility 
that they can be used as sensitive indices of toxicity.
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It is necessary to follow the fate of the precursors within the 
different glomerular proteins and also to identify changes on the 
composition of specific glomerular proteins.
The weak effects shown by Puromycin aminonucleoside on isolated 
glomeruli, raise the question of how and why this chemical is such a 
potent glomerulotoxin in vivo, but has only a moderate effect when 
incubated with glomeruli in vitro. One attractive hypothesis is that 
puromycin aminonucleoside is not the proximate toxin.
Further studies are necessary to elucidate the in vivo - in vitro effect, 
on the incorporation of proline in animals treated with puromycin 
aminonucleoside at early and different time points. It is also necessary 
to compare the effect of the parent compound and its metabolites on 
protein synthesis and other metabolic pathways.
In view of the potent effect of ethacrynic acid on glomerular protein 
synthesis and oxidative metabolism, and the fact that this compound is a 
widely used drug considered to have few nephrotoxic effects, several 
questions are raised. These include the importance of ethacrynic acid 
effects on glomerular metabolism in vitro, as related to glomerular 
function in vivo. Whether the inhibition of protein synthesis is a 
secondary effect, or is it a direct effect. What are the possible GBM 
structural and compositional changes caused by the compound. Studies with 
ethacrynic acid-related compounds and metabolites such as the saturated 
derivative on in vitro glomerular protein synthesis will help to elucidate 
the mechanism of action and the relevance, if any, of the glomerular 
effect to the pharmacological action of the drug.
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- It is necessary to establish a dose-response for 2-Bromoethanamine with 
a lower range of concentrations ( 0 - 1  mM), for protein synthesis, and to 
elucidate the mechanism responsible for the inhibitory effect. The effect 
of 2 -bromoethanamine on glucose metabolism is unexpected and it is 
necessary to determine which of the glucose metabolic pathways is 
enhanced by the compound: glycolysis or pentose phosphate shunt, and the
site of enhancement.
With regard to OTA, expanding the range of OTA concentrations between 
0 - 100 uM, will establish if greater differences in the rate of
incorporation between the different amino acids can be identified at lower 
concentrations than the ones assessed in these studies.
It is also necessary to establish which is the route of glucose 
metabolism enhanced by OTA. Is it the pentose phosphate shunt or 
glycolysis and which of the beta- oxidative pathways (mitochondrial or 
peroxisomal) is affected by OTA. This should be measured over the range of 
concentrations between 0 - 100 uM, in order to obtain a dose response 
relationship.
The relationship between the in vivo and in vitro effect of OTA on
glomerular proteins needs to be related to GBM structure and composition. 
Electrophoretic and autoradiographic studies of glomerular protein 
synthesised from different labelled amino acids in the presence and
absence of OTA, could help follow the fate of the precursors and the
effect of the mycotoxin on the composition of glomerular protein. It 
would also be useful to establish where different labelled amino acids 
(especially the aromatic compounds) are distributed in glomeruli using
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autoradiography at the light and electron microscopy levels.
- In vivo studies such as micropuncture of individual nephrons, will 
allow to distinguish between tubular and glomerular changes following 
toxic insult with OTA, and also to correlate functional with metabolic in 
vitro changes, but this techniques can only be undertaken with specialised 
equipment.
It has been shown that glomeruli are vulnerable to the effect of OTA, 
but because of their cellular heterogeneity, from the observations on 
isolated glomeruli, the changes detected can be assessed as specific for 
glomeruli (in relation to other renal structures), but not specific for
the various populations of glomerular epithelial and mesangial cells. The
application of cell culture of glomerular cells will offer a unique means 
of assessing their individual response to the toxic injury such as changes 
in their metabolic properties and morphology.
- The fact that glomeruli from superficial and juxtamedullary zones of the 
kidney differ, has led our group to start studying the sensitivity of 
these two different populations of glomeruli. This is based on using 
isolated glomerular fragments that have been obtained from surgically 
separated superficial and juxtamedullary regions of the rat kidney
respectively. The two populations of glomeruli are then exposed to
adriamycin and have been shown to be different. The same approach could 
also be used to assess whether there are metabolic differences in the 
response of isolated superficial and juxtamedullary glomeruli from rats, 
the pig and man exposed to OTA.
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Immunohistochemical techniques at a light microscopy and electron 
microscopy will allow early glomerular changes taking place over the time 
course following administration of OTA, to be highlighted. These might no 
have been seen when general non-specific histopathological methods were 
used.
It will be important to assess the effect of simultaneous exposure to 
more than one mycotoxin on isolated glomeruli.
The relationship between the biochemical effects on isolated glomeruli 
and the pathology of OTA .lesion still needs to be investigated.
These questions offer an interesting challenge to find out more about the 
role of glomeruli in nephrotoxicity and how mycotoxins may affect the 
kidney in animals and man exposed to these environmental chemicals with so 
much potential to cause major diseases.
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APPENDIX 1
APPENDIX 1
TABLE 5..1.1
URINARY ALP ACTIVITY AFTER 
IP ADMINISTRATION OF OTA TO RATS (1 mg/kg)
ACTIVITY
nmol/ 24 hr % OF CONTROL
DAYS OF TREATMENT CONTROL TREATMENT
0 119 ± 74 119 ± 7 4 100
1 141 ± 30 90 ± 46 64
2 160 ± 55 75 ± 26 100
3 105 ± 20 160 ± 80 152
4 7 7 + 2 0 211 + 46*. 272
* Significantly different from control at P < 0.05 (n=3)
TABLE 5,.1.2
URINARY AAP ACTIVITY AFTER IP
ADMINISTRATION OF OTA TO RATS (1 mg/kg)
ACTIVITY
nmol/ 24 hr % OF CONTROL
DAYS OF TREATMENT CONTROL TREATMENT
0 1027 + 619 1027 ± 619 100
1 1554 ± 93 967 ± 422 62
2 2268 ± 234 1289 ± 115 * 57
3 2683 ± 464 2626 ± 987 98
4 2395 ± 808 3433 + 1147 143
* Significantly different from control at P <0. 05 (n=3)
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TABLE 5.1.3
URINARY GGT ACTIVITY AFTER
IP ADMINISTRATION OF OTA TO RATS (1 mg/kg)
ACTIVITY
Units/ 24 hr % OF CONTROL
DAYS OF TREATMENT CONTROL TREATMENT
0 451 ± 251 451 + 251 100
1 289 ± 73 250 + 104 87
2 457 + 156 271 + 57 59
3 425 + 146 394 + 179 93
4 345 ± 126 532 + 155 154
n=3 n=3
TABLE 5.1.4
URINARY NAG ACTIVITY AFTER
IP ADMINISTRATION OF OTA TO RATS (1 mg/kg)
ACTIVITY
nmol/ 24 hr % OF CONTROL
DAYS OF TREATMENT CONTROL TREATMENT
0 35 ± 16 35 ± 16 100
1 67 + 19 45 ± 20 68
2 56 ± 14 56 + 20 101
3 56 ± 11 66 ± 20 119
4 43 ± 22 59 ± 24 138
n=3 n=3
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TABLE 5.1.5
URINARY VOLUME AFTER IP
ADMINISTRATION OF OTA TO RATS (1 mg/kg)
VOLUME
ml/24 hr % OF CONTROL
DAYS OF TREATMENT CONTROL TREATMENT
0 5.8 ± 2.9 5.8 ± 2.9 100
1 7.0 ± 2 . 6 5.6 ± 2.5 80
2 9.3 ± 3.0 5.0 ± 1.0 54
3 8.0 ± 2.0 5.6 ± 1.5 70
4 7.0 ± 3.6 6.6 ± 1.1 94
n=3
TABLE 5,.1.6
OTA
URINARY ALP ACTIVITY AFTER 
ADMINISTRATION TO RATS (5 mg/kg)
ACTIVITY
nmol/ 24 hr % OF CONTROL
DAYS OF TREATMENT CONTROL TREATMENT
0 340 ± 100 340 ± 100 100
1 225 ± 50 305 ± 100 135
2 480 + 160 500 ± 200 222
3 370 ± 120 600 ± 200 162
4 385 ± 5 0  
n=4
600
n
±
l=5
100 156
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TABLE 5.1.7
URINARY AAP ACTIVITY AFTER
OTA ADMINISTRATION TO RATS (5 mg/kg)
ACTIVITY
nmol/ 24 hr % OF CONTROL
DAYS OF TREATMENT CONTROL TREATMENT
0 1600 ± 625 1600 ± 625 100
1 1491 ± 426 1605 ± 588 108
2 2133 ± 341 2715 ±  1142 151
3 1936 ± 654 4050 ± 973* 209
4 1956 ± 455 3843 ± 857* 196
n=4 n=5
* Significantly different from control at P < 0.05
TABLE 5.1.8
URINARY NAG ACTIVITY AFTER 
IP ADMINISTRATION OF OTA TO RATS (5 mg/kg)
ACTIVITY
nmol/ 24 hr % OF CONTROL
TREATMENT CONTROL TREATMENT
0 32.5 ± 12 32.5 ± 12 . 100
1 27.8 ± 7 24.8 ± 6 89
2 38.0 ± 5 38.2 ± 12 100
3 48.5 ± 14 79.5 ± 13 164
4 53.4 ± 1 1 98.1 ± 22* 184
n=4 n=5
* Significantly different from control at P <0.05
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TABLE 5.1.9
URINARY GGT ACTIVITY AFTER
IP ADMINISTRATION OF OTA TO RATS (5 mg/kg)
ACTIVITY
Units/ 24 hr % OF CONTR<
DAYS OF TREATMENT CONTROL TREATMENT
0 947 ± 297 947 + 297 100
1 859 ± 195 830 ± 297 97
2 1257 + 72 1246 + 611 99
3 1327 + 476 1947 + 775 147
4 1436 + 378 1611 ± 347 112
n=4 n=5
TABLE 5..1.10
URINARY VOLUME AFTER IP
ADMINISTRATION OF OTA TO RATS (5 mg/kg)
VOLUME
ml/24 hr % OF CONTROL
DAYS OF TREATMENT CONTROL TREATMENT
0 5.2 + 1.7 5.2 + 1.7 100
1 5.2 + 1.9 4.8 + 1.8 92
2 7.5 + 2.4 7.6 ± 4.0 101
3 6.2 + 1.7 10.0 ± 1 . 6 161
4 7.7 ± 1 . 7 8.2 + 1.2 106
n=4 n=5
* Significantly difference from control at P < 0.05.
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TABLE 5.1.11
URINARY AAP ACTIVITY AFTER
IP ADMINISTRATION OF ATB^ TO RATS (100 ug/kg)
ACTIVITY
nmol/ 24 hr % OF CONTROL
TREATMENT CONTROL TREATMENT
0 1066 + 442 1066 + 442 100
1 1640 + 257 2037 + 772 124
2 132 6 + 265 1903 + 318 143
3 1911 + 256 1885 + 170 99
4 2029 + 132 1586 + 191* 78
* Significantly different from control at P < 0.05 (n=3) 
TABLE 5.1.12
URINARY GGT ACTIVITY AFTER 
IP ADMINISTRATION OF ATB^ TO RATS (100 ug/kg)
ACTIVITY
Units/ '24 hr % OF CONTROL
DAYS OF TREATMENT CONTROL TREATMENT
o 405 + 95 405 + 95 100
1 476 + 103 445 + 87 94
2 343 + 46 620 + 222 181
3 531 + 64 411 + 105 77
4 456 + 28 304 + 61* 67
* Significantly different from control at P < 0.05 (n=3)
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TABLE 5.1.13
URINARY NAG ACTIVITY AFTER
IP ATBX ADMINISTRATION TO RATS (100 ug/kg)
ACTIVITY
nmol/ . 24 hr % OF CONTROL
TREATMENT CONTROL TREATMENT
0 70 + 30 70 ± 30 100
1 69 + 2 59 ± 3* 85
2 49 + 4 89 ± 3** 182
3 67 + 10 76 + 4 113
4 63 + 10 61 + 16 97
* Significantly different from control at P < 0.05 (n=3) 
** Significantly different from control at P < 0.01 (n=3)
TABLE 5.1.14
URINARY ALP ACTIVITY AFTER 
IP ADMINISTRATION OF ATB^ TO RATS (100 ug/kg)
ACTIVITY
nmol/ 24 hr % OF CONTROL
DAYS OF TREATMENT CONTROL TREATMENT
0 225 ± 76 225 ± 76 100
1 187 ± 26 223 ± 46 119
2 140 ± 4 4 202 + 31 144
3 210 + 37 182 ± 6 86
4 209 ± 11 207 ± 55 99
n=3 n=3
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TABLE 5.1.15
URINARY VOLUME AFTER IP
ADMINISTRATION OF ATBX TO RATS (100 ug/kg)
VOLUME
ml/24 hr % OF CONTROL
DAYS OF TREATMENT CONTROL TREATMENT
0 7.5 + 1.0 7 . 5 + 1 . 0  100
1 10.3 + 1.1 9.3 + 1.1 90
2 9.0 ± 3.6 10.0 ± 3.0 111
3 9.0 + 1.7 8.6 ± 2.3 95
4 8 . 0 + 0  5.7 + 2.5 71
(n=3)
TABLE 5.1.16
URINARY ALP ACTIVITY AFTER COMBINED ADMINISTRATION 
OF 1 mg OTA AND 100 ug ATB1/kg
ACTIVITY
nmol/ 24 hr % OF CONTROL
DAYS OF TREATMENT CONTROL TREATMENT
0 105 + 38 105 + 38 100
1 95 + 12 96 + 41 115
2 116 + 14 154 + 33 133
3 117 + 13 242 + 43* 208
4 160 + 22 .335 + 150 210
* Significantly different from control at P < 0.05 (n=3)
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TABLE 5.1.17
URINARY GGT ACTIVITY AFTER COMBINED ADMINISTRATION
OF 1 mg OTA AND 100 ug ATB^/kg TO RATS
ACTIVITY
Units/ 24 hr % OF CONTROL
DAYS OF TREATMENT CONTROL TREATMENT
0 847 ± 440 847 + 440 100
1 593 ± 345 858 + 199 145
2 1244 + 170 960 + 384 77
3 990 ± 160 1320 + !* 133
4 1336 ± 163 1182 + 206 88
* Significantly different from control at P <0.05 (n=3) 
TABLE 5.1.18
URINARY NAG ACTIVITY AFTER COMBINED ADMINISTRATION 
OF 1 mg OTA AND 100 ug ATB^/kg
ACTIVITY
nmol/ 24 :hr % OF CONTROL
DAYS OF TREATMENT CONTROL TREATMENT
0 47 + 10 47 + 10 100
1 35 + 9 56 + 6* 161
2 45 i 3 45 + 2 101
3 39 + 5 58 + 1* 149
4 46 + 3 62 + 10 133
* Significantly different from control at P <0.05 (n=3)
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TABLE 5.1.19
URINARY AAP ACTIVITY AFTER COMBINED ADMINISTRATION OF
1 mg OTA AND 100 ug ABT^kg TO RATS
ACTIVITY
nmol/ 24 hr % OF CONTROL
DAYS OF TREATMENT CONTROL TREATMENT
0 1672 + 440 1672 + 440 100
1 1918 + 869 1787 + 1649 93
2 2199 + 464 2175 ± 525 99
3 3262 + 511 4743 + 1024 145
4 4524 + 505 4955 ± 150 109
(n=3)
TABLE 5..1.20
URINARY VOLUME AFTER COMBINED
ADMINISTRATION OF 1 mg OTA and 100 ug ATB1/kg
VOLUME
ml/24 hr % OF CONTROL
DAYS OF TREATMENT CONTROL TREATMENT
0 7.7 + 1.5 7.7 + 1.5 100
1 6.8 + 2.9 6.5 ± 2.5 95
2 9.0 ± 1.0 6.0 + 3.4 67
3 9.0 + 1.0 11.0 + 0.0* 122
4 11.3 ± 0.6 10.3 ± 0.6 91
* Significantly different from control at P < 0.05 (n=3)
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TABLE 5.1.21
URINARY ALP ACTIVITY AFTER COMBINED ADMINISTRATION OF
5 mg OTA AND 100 ug ATB^/kg
ACTIVITY
nmol/ 24 hr % OF CONTROL
DAYS OF TREATMENT CONTROL TREATMENT
0 143 ± 52 143 ± 52 100
1 225 + 56 128 ± 52** 71
2 203 ± 67 252 + 143 124
3 224 ± 112 486 ± 131* 217
4 235 + 66 385 ± 129 163
3 ii n=5
* Significantly different from control at P < 0.05 
** Significantly different from control at P < 0.01
TABLE 5.1.22
URINARY GGT ACTIVITY AFTER COMBINED ADMINISTRATION
OF 5 mg OTA and 100 ug ATB^/Jcg
ACTIVITY
Units/ 24 hr % OF CONTROL
DAYS OF TREATMENT CONTROL TREATMENT
0 926 + 235 926 ± 235 100
1 1407 ± 510 890 ± 281* 63
2 1695 ± 978 1226 ± 757 72
3 2152 ± 1014 2080 + 856 96
4 2097 ± 610 1682 ± 216 80
nc n=5
* Significantly different from control at P < 0.05.
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TABLE 5.1.23
URINARY AAP ACTIVITY AFTER COMBINED ADMINISTRATION
OF 5 mg OTA AND 100 ug ATB^/kg
ACTIVITY
nmol/ 24 hr % OF CONTROL
DAYS OF TREATMENT CONTROL TREATMENT
0 1720 ± 486 1720 ± 486 100
1 2634 ± 698 1987 ± 1136 75
2 3379 ± 1248 2590 ± 1547 77
3 3412 + 989 3853 ± 1703 113
4 4036 ± 1515 3761 ± 694 93
n=4 n=5
TABLE 5.1.24
URINARY NAG ACTIVITY AFTER COMBINED ADMINISTRATION 
OF 5 mg OTA AND 100 ug ATB^kg
ACTIVITY
nmol/ 24 hr % OF CONTROL
DAYS OF TREATMENT CONTROL TREATMENT
0 50 + 7.6 50 + 7.6 100
1 59 + 2.8 45 + 12.2 75
2 69 + 27.0 79 + 42.0 115
3 25 + 4.6 30 + 12.7 119
4 29 Hr, 3.0 48 + 6.1 163
n=4 n=5
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TABLE 5.1.25
URINARY VOLUME AFTER COMBINED 
ADMINISTRATION OF 5 mg OTA and 100 ug ATB^/kg
VOLUME
ml/24 hr % OF CONTROL
TREATMENT . CONTROL TREATMENT
0
oCO + 4.2 CO ° + 4.2 100
1 9.5 + 0.6 00 o + 4.5 84
2 10.2 + i.9 7.4 + 7. 6 72
3 9.7 + 2.4 00 o + 4.5 82
4 10.2 + 2.4 8.2 + 2.2 80
n=4 n=5
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TABLE 5.1.26
URINARY ACTIVITY OF ALP AFTER 3 IP DAILY ADMINISTRATION
OF OTA (2.5 mg/kg) TO RATS
ACTIVITY
nmol/ 18 hr % OF CONTROL
TIME CONTROL TREATMENT
0 56 + 32 56 ± 32 100
1 78 + 35 142 + 73 182
2 116 + 60 102 + 70 88
3 50 + 35 237 + 340 474
4 50 + 50 211 + 190 527
5 54 + 30 243 + 160 714
6 74 + 35 1196 + 1740 1616
7 119 + 83 1367 + 1350 1752
8 78 + 46 263 + 50** 337
9 134 + 70 272 + 129 203
10 263 + 90 367 + 110 139
11 218 + 130 298 + 110 137
12 277 + 60 479 + 58 173
13 638 + 610 120 + 77 18
14 307 + 300 176 + 20 57
15 65 + 50 153 + 60 306
** SIGNIFICANTLY DIFFERENT AT P < 0.01 (n=5)
TABLE 5.1.27
URINARY ACTIVITY OF GGT AFTER 3 IP DAILY ADMINISTRATION
OF OTA (2.5 mg/kg) TO RATS
ACTIVITY
Units/ . 18 hr % OF CONTROL
TIME
(DAYS) CONTROL TREATMENT
0 816 + 318 816 + 318 100
1 1017 + 209 821 + 370 80
2 919 + 266 1058 + 243 115
3 791 + 288 1007 + 362 127
4 775 + 171 1423 + 160* 184
5 513 + 175 1006 + 258* 196
6 687 + 322 1107 + 301 161
7 573 + 144 1067 + 510 186
8 667 + 228 980 + 314 147
9 793 + 272 741 + 211 93
10 721 + 197 471 + 141 65
11 976 + 421 577 + 165 59
12 891 + 216 911 + 176 102
13 878 + 318 921 + 156 105
14 1049 + 312 961 + 169 92
15 1063 + 379 1070 + 276 101
* SIGNIFICANTLY DIFFERENT FROM CONTROL AT P < 0.05 (n=5)
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TABLE 5.1.28
URINARY ACTIVITY OF AAP AFTER 3 IP DAILY ADMINISTRATION
OF OTA (2.5 ml/kg) TO RATS
ACTIVITY
TIME (DAYS)
nmol/
CONTROL
18 hr
TREATMENT
% OF CONTROL
0 1120 + 520 1120 + 520 100
1 1140 + 340 1232 + 300 107
2 1440 + 480 1680 + 920 116
3 794 + 440 1520 + 1000 191
4 500 + 176 2160 + 600* 432
5 370 + 140 1480 + 500* 400
6 508 + 220 1020 + 220* 201
7 628 + 220 1420 + 760 226
8 928 + 340 2260 + 620* 243
9 1230 + 540 2120 + 1140 172
10 1540 + 320 1640 + 460 106
11 1140 + 540 720 + 280 63
12 620 + 240 940 + 200 151
13 640 320 1160 + 200 181
14 960 + 460 1540 + 480 160
15 1120 + 540 1700 + 660 152
* SIGNIFICANTLY DIFFERENT FROM CONTROL AT P < 0.05 (n=5)
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TABLE 5.1.29
URINARY GLUCOSE AFTER ADMINISTRATION OF 3 IP REPETITIVE
DOSES OF OTA (2.5 mg/kg) TO RATS
GLUCOSE
mmoles/ 18h % CONTROL
TIME
(DAYS) CONTROL TREATMENT
0 3.9 + 1.8 3.9 + 1.8 100
1 6.2 + 1.2 3.5 + 3.0 56
2 9.8 + 7.0 11. 9 + 5.0 121
3 5.5 + 1.5 2.5 + 5.0 45
4 5.3 + 2.0 3.3 + 3.6 62
5 6.5 + 2.4 218 .0 + 234.0 3354
6 5.7 + 2.0 501.0 + 187.0* 8789
7 4.4 + 2.6 261.0 + 129.0* 5932
8 6.6 + 2.2 62.0 + 70.0 939
10 6.3 + 1.0 3.9 + 1. 0** 61
11 5.3 + 2.3 5.4 + 3.0 102
12 6.0 + 1.5 6.0 + 1.0 100
13 5.3 + 2.0 4.7 + 1.0 89
14 6.0 + 1.0 2.4 + 2 .0** 40
15 5.6 + 2.0 5.0 + 2.6 89
* SIGNIFICANTLY DIFFERENT FROM CONTROL AT P < 0.05 (n=5)
** SIGNIFICANTLY DIFFERENT FROM CONTROL AT P < 0.01 (n=5)
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TABLE 5.1.30
TIME
URINARY PROTEIN AFTER 3 IP DAILY ADMINISTRATION
OF OTA (2.5 mg/kg) TO RATS
PROTEIN
mg/18h % CONTROL
(DAYS) CONTROL TREATMENT
0 '8.0 + 3.1 8.0 + 3.1 100
1 10.4 + 3.3 15.7 + 5.2 151
2 10.8 + 2.2 21.6 + 6.4* 200
3 12.1 + 3.4 18.0 + 5.4 14 9
4 14.3 + 5.6 75.2 + 34.6* 537
5 44.5 + 32.8 88.5 + 29.0 199
6 44 .5 + 39.3 78 .4 + 21.2 17 6
7 37 .1 + 19.0 62.9 + 11.5 169
8 76.7 + 32.5 50.1 + 25.0 65
10 48 .4 + 47 .4 29.0 + 7.8 14
• 11 33.9 + 16.0 26.2 + 1.5 77
12 77 .8 + 50.9 65.1 + 63.0 84
13 50.3 + 29.9 40 .2 + 23.5 80
14 51. 4 + 47.3 32.8 + 8.6 64
* SIGNIFICANTLY DIFFERENT FROM CONTROL AT P < 0.05 (n=5)
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TABLE 5.1.31
URINARY VOLUME AFTER 3 IP DAILY DOSES OF OTA (2.5 mg/kg)
VOLUME
ml/18h % OF CONTROL
TIME (DAYS) CONTROL TREATMENT
0 3.5 + 1.4 3.5 + 1.4 100
1 3.6 + 2.0 4.2 + 2.5 218
2 3.8 + 1.5 4.9 + 2.6 129
3 • 3.6 + 1.3 3.8 + 2.1 105
4 3.8 + 1.0 6.6 + 3.0 174
5 3.6 + 1.0 . 7.8 + 2.1* 216
6 4.5 + 1.5 10.0 + 3.0* 222
7 4.4 + i.o 12.0 + 3.8* 273
8 4.6 + 1.3 12.7 + 3.2* 276
9 6.3 + 2.2 9.6 + 3.4. 152
10 5.7 + 1.3 8.0 + 2.1 140
11 5.5 + 1.7 7.7 + 2.5 140
12 6.1 + 1.1 7.4 + 2.6 121
13 5.9 + 0.8 8.6 + 2.1 146
14 6.5 + 2.0 10.3 + 2.4 158
15 4.8 + 1.4 9.0 + 3.0 187
* SIGNIFICANTLY DIFFERENT FROM CONTROL AT P < 0.05 (n=5)
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APPENDIX 2
TABLE 6.1.2 T VALUES AT LEVELS OF 5%-0.1% OF PROBABILITY FOR THE 
INCORPORATION OF DIFFERENT LABELLED AMINO ACIDS INTO 
ISOLATED PIG GLOMERULI INCLUBATED WITH KREBS BUFFER 
AT VARIOUS TIME POINTS
AFTER 4 HR OF INCUBATION
GLY LYS PRO LEU
LYS 12.7*** -
PRO 11.8*** 6 .8 ** -
LEU 14.2*** 11.3*** 6 .8 ** -
HIS 13.4*** 8 .0 ** 0 7.0**
AFTER 3 HR OF INCUBATION
GLY LYS PRO LEU
GLY -
LYS 1 0 .0 *** -
PRO 26.0*** 5.1** -
LEU 13.5*** 8 .0 *** 7.3** -
HIS 16.0*** 5.3** 1.9 6 .1 **
AFTER 2 HR OF INCUBATION
'j
GLY LYS PRO LEU
GLY -
LYS 54.8 *** -
PRO 18.0*** 2 . 1 -
LEU 13.3*** 8.7*** 7.7** -
HIS 9 # g*** 1.7
IT)
O
6.7**
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APPENDIX 2
TABLE 6 . 1 . 2  (CONTINUED) 
AFTER 1 HR OF INCUBATION
GLY LYS PRO LEU
GLY -
LYS 1 .3 -
PRO 2 . 1 2 .5 -
LEU 3 . 1 * 4 .2 3 . 4 * -
HIS ! .  4 0.16 4 . 0 * 4 . 9 * *
* P<0 .5  
* *  P<0.1
* * *  P<0.01
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TABLE 6.1.3
EXPERIMENT 1
EXPERIMENT 2
EXPERIMENT 3
EXPERIMENT 4
EXPERIMENT 5
INCORPORATION OF 3H-PROLINE INTO ISOLATED PIG GLOMERULI 
INCUBATED WITH KREBS BUFFER.
TIME (Hr) INCORPORATION
(pmol/mg PROTEIN)
0 0
2.5 0.8 ± 0.07
4 2 . 1 + 0 . 2 7
0 0
1 0.18 ± 0.02
2 0.51 ±  0.05
3 0.90 ± 0.07
4 1.4 ± 0.2
0 0
1 0.32 ±  0.03
2 0.68 ± 0.02
3 1.03 ±0 .1 6
4 1.1 ±  0.16
0 0
1 f . 0.73 ±  0.10
2 1.5 ± 0.07
3 2.8 ±0. 12
4 5.6 ± 0.4
0 0
1 0.5 ± 0.012
2 0.9 ±  0.07
3 1.1 ± 0.05-
4 2.0 + 0.2
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TABLE 6.1.4 T VALUES AT LEVELS OF 5%-0.1% OF PROBABILITY FOR THE
INCORPORATION OF 3H-PROLINE INTO ISOLATED PIG GLOMERULI 
INCUBATED WITH KREBS BUFFER AT VARIOUS TIME POINTS IN 
DIFFERENT EXPERIMENTS
Hr of
Incubation 1 2 3
1 -
2 10.6*** -
3 17.1*** 7.8** -
4 10.5*** 7.5** 4.1*
Hr of
Incubation 1 2 3
1 -
2 17.3*** -
3 7.5** 3.7* -
4 8.3** 4.5** 0.12
Hr of
Incubation 1 2 3
1 -
2 10.9 *** -
3 22.9*** 16.2*** -
4 20.4*** 17.5*** 11.6***
* P<0.5
** P<0.1
*** P<0.01
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TABLE 6.1.5
INCORPORATION OF 3H-PROLINE INTO PIG GLOMERULI 
INCUBATED WITH TWO DIFFERENT BUFFERS+
TIME INCORPORATION (pmol/mg prot)
(Hr) EARLE S-HEPES* KREBS+
0 0 0
2 0.93 + 0.1* 0.3 + 0.03
4 4.00 + 0.7*** 0.42 + 0.074
*
***
Significantly different from control at P<0.05 
Significantly different from control at P<0.001
TABLE 6.1.6
INCORPORATION OF 3H-PROLINE INTO RAT GLOMERULI 
INCUBATED WITH TWO DIFFERENT BUFFERS4"
TIME INCORPORATION (pmol/mg prot)
(Hr) EARLES-HEPES+ TYRODES4*
1 2.0 + 0.10 0.20 + 0.04
2 5.5 + 0.03 0.40 + 0.04
3 8.0 + 0.50 0.75 ±0.08
4 10.0 ± 1.00 1.10 ± 0.10
TABLE 6.1.7
EFFECT OF DIFFERENT CONCENTRATIONS OF NON-RADIOACTIVE PROLINE 
ON THE INCORPORATION OF 3H-PROLINE INTO ISOLATED PIG GLOMERULI
NON RADIOACTIVE PROLINE INCORPORATION % OF CONTROL
(uM) (pmol /mg prot)
0 4.2 + 0.74 100
10 4.3 + 0.14 102
100 2.9 ± 0.8 69
1000 2.3 ± 0.5* 55
* SIGNIFICANTLY DIFFERENT FROM CONTROL AT P<0.05
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TABLE 6.1.9 INCORPORATION OF 3H-PROLINE INTO ISOLATED PIG GLOMERULI
INCUBATED WITH EARLES-HEPES BUFFER
INCORPORATION OF PROLINE 
(pmol/mg protein)
2
4
EXPERIMENT 2:
0.15 ± 0.02 
0.8 . + 0.06 
1.8 ± 0 .09
3.0 ±0. 07
EXPERIMENT 3:
1
2
3
4
0.1 ± 0.004 
0.5 ± 0.04 
1.2 ± 0.08 
2.6 + 0.05
1
2
3
4
0.23 ± 0.084 
1.5 + 0.140
EXPERIMENT 1:
TIME
(Hr)
EXPERIMENT 4:
1
2
3
4
EXPERIMENT 5:
1
2
3
4
EXPERIMENT 6:
0
0.2 ± 0.02 
0.7 ± 0.07 
2.0 ± 0.2 
5.1 ± 0.6
EXPERIMENT 7:
0
0.3 ± 0.06 
1.2 ± 0.2 
5.1 ± 0.5 
7.6 ± 2
0
1
2
3
4
0
1
2
3
4
0.03 ± 0.008 
0.2 ± 0.014
0.7 ± 0.090
1.3 + 0.193
0.035 ± 0.004
0.2 ± 0.03
0.6 ± 0.014
1.0 + 0.184
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TABLE 6.1.10
EXPERIMENT 1:
1
2
3
4
EXPERIMENT 2:
1
2
3
4
EXPERIMENT 3:
1
2
3
4
EXPERIMENT 4:
1
2
3
4
EXPERIMENT 5:
T VALUES AT LEVELS OF 5%-0.1% OF PROBABILITY FOR 
THE INCORPORATION OF 3H-PROLINE INTO ISOLATED PIG 
GLOMERULI INCUBATED WITH EARLES-HEPES BUFFER AT 
VARIOUS TIME POINTS, IN DIFFERENT EXPERIMENTS
17.8***
31.0***
67.8***
17.2*** 
23.8*** 
86.3***
5.7** 
23.1*** 
9.1* * *
18.3***
12.8***
11.4***
16.0*** - 67.8***
41.3*** 18.2***
13.5***
56.8***
20.9***
7.4**
9.5***
9.8***
25.7***
3.7*
4.9
10.5***
15.5***
14.1***
10.4*** 
12.6*** 8.5**
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TABLE 6.1.10 (CONTINUED) 
EXPERIMENT 6 :
1
1
2 7.5**
3 16.5***
4 6.3**
* P<0.5
** P<0.1
***  p<0.01
12
5
3
5***
5** 2.1
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TABLE 6.1.11 TIME-COURSE OF PRO AND PHE INCORPORATION 
INTO ISOLATED RAT GLOMERULI
TIME INCORPORATION (pmol/mg protein)
(Hr) PRO PHE
1 0.6 ± 0.07 4.6 ± 0.3
2 3.8 ± 0.40 8.6 ± 0.5
3 6.6 ± 0.87 15.2 ± 1.3
4 13.5 ± 2.00 25.1 ± 3.0
TABLE 6.1.12
AMINO ACID INCORPORATION INTO ISOLATED RAT GLOMERULI
Incorporation 
(pmol/mg protein)-
Time
(Hr)
TRP PHE TYR LEU PRO HIS
1 26 ± 4.0 4.6 ± 0.8 4 ± 0.3 3 ± 0.6 2.0 ± 0.10 1.5 ± 0.1
2 40 ± 0.9 8.0 + 2.0 6 ± 1.0 7 + 0.9 5.5 + 0.03 2.5 ± 0.2
3 91 ± 1.0 17.0 ± 0.8 12 ± 0.5 11 ± 1 . 5 8.0 ± 0.50 4.0 ± 0.4
4 120 ± 19.0 19.0 ± 2.0 15 ± 1.0 14 ± 1.5 10.0 + 1.00 6.0 ± 0.7
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TABLE 6.1.13
T values at levels of 5% - 0.1% of probability for the time-course of 
the incorporation of different amino acids into isolated rat glomeruli.
INCORPORATION OF TRP INTO ISOLATED RAT GLOMERULI
1 2 3
1 -
2 5.6** - ;
3 26.5*** 5.7*** -
4 2.0 0.22
•kick
9.2
INCORPORATION OF PHE INTO ISOLATED RAT GLOMERULI
1 2 3
1 -
2 2.8* -
k k k **
3 18.2 7 _
**
4 4.7 1.5 5.1
INCORPORATION OF TYR INTO ISOLATED RAT GLOMERULI
1 2 3
1 -
2 2.5 -
3
***
23.8 6.9** -
4
**
6.9 4.6*
* * *
28.8
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INCORPORATION OF LEU INTO ISOLATED RAT GLOMERULI
1 2 3
1 -
**
2 6.2
★
3 8.2 3.8 **
4 3* 1.5 4.5
INCORPORATION OF PRO INTO ISOLATED RAT GLOMERULI
1 2 3
1 -
2
***
53.1 -
3
***
19.4 8.6 -
4 0.68
***
10.4
***
13.5
INCORPORATION OF HIS INTO ISOLATED RAT GLOMERULI
1 2 3
1 -
2
**
7.3 -
3
***
15.5
***
14.2 -
4 2.2
**
9.5
***
15.8
* P<0.5
** P<0.1
*** PC0.01
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TABLE 6.1.14
T values at levels of 5% - 0.1% of probability for the 
incorporation of different amino acids into isolated rat 
glomeruli, at various times.
AFTER 4 HR OF INCUBATION
. TRP PHE TYR LEU PRO
PHE
* ★
4 . 7 -
TYR 6.2** 6.9** -
LEU 5.5** 3.4*
*
4.4 -
PRO
**
6.1
**
6.7 0.3 < 4.1* -
HIS
★ ★
6.4
**
7.9
**
6.1 < 6**
*
< 4.1
AFTER 3 HR OF INCUBATION
TRP PHE TYR LEU PRO
PHE 83.2** -
TYR 98.7***
**
8.4 -
LEU
***
70.2
**
5.9 1.2 -
PRO
_ ★ ★ *
103.8
***
15.6 10
★
3.3 -
HIS
***
70.1 3* 2.3 2.6
**
7.1
AFTER 2 HR OF INCUBATION
TRP PHE TYR LEU PRO
PHE 24.7** -
TYR
* * *
34.5 1.3 -
LEU 43.8** 0.7 1 -
PRO 65.2*** 2.2 0.9 3.3* -
HIS 69.3***
* ★
4.8 4.5* 8.8***
***
25.7
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TABLE 6.1.14 (CONTINUED) 
AFTER 1 HR OF INCUBATION
*
**
***
TRP PHE TYR LEU PRO
PHE 8.7 - .
TYR 9.1 1 -
LEU
* * *
9.4 2.2 2.1 -
PRO « «*** 9.9
**
4.9 « «*** 9.8 2.8* -
H IS
***
10.2
**
6.6
* * *
13.8 5.1**
**
8.4
P<0.5 
P<0.1 
P<0.01
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Tryptophan incorporation
into isolated rat glomeruli
so-
0 1 2 3 4
Time (hr)
Fts.6.M
Time-course o f the incorpora non o f ^ H-tryptophan into total glomerular protein. 0.5 m l o f 
Earfes-HEPES buffer containing U  oQ  o f the labelled amino acid were added at time 0  to 
0.S m l aliquot! o f rat glomerular suspension and incubated up to 4 hr. The onfiaate 
represents specific activity incorporated into TCA-prccipitabie labelled material. Each 
line corresponds to a different experiment and each rime point is the result o f triplicate 
incubations.
Pheriyfolanme incorporation
into Isolated rat glomeruli»•)
a-
10-
Time (hr)
Fig.ti.L2
Ttme-coune o f the incorporation o f 3H-phenylalanine into total glomerular protein. 0.5 m l 
o f Earles-HEPES buffer containing 2 J  uO  o f the labelled amino add were added at timeO 
to 0 J  nd aliquots o f rat glomerular suspension and incubated up to 4 hr. The ordinate 
represents specific activity incorporated into TCA-predpitable labelled material. Each 
line corresponds to a different experiment and each time point is the result o f triplicate 
incubations.
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Fig. 6.13
Time-coursc o f the incorporation o f 3H-leucinc into total glomerular protein. 0.5 ml of 
Earles-HEPES buffer containing 2.5 uCi o f the labelled amino acid were added at time 0 to 
0.5 ml aliquots of rat glomerular suspension and incubated up to 4 hr.'The ordinate 
represents specific activity incorporated into TCA-precipitable labelled material. Each 
time point is the result o f triplicate incubations.
Proline incorpora tion
into isolated rat glomeruli
2 0 - i
15 -
10-
5 -
1 2 3 4
Time (hr)
Fig. 6.1.4
Time-course o f the incorporation o f 3H-proline into total glomerular protein. 0.5 ml o f 
Earles-HEPES buffer containing 2.5 uCi o f the labelled amino acid were added at time 0 to 
0.5 ml aliquots o f rat glomerular suspension and incubated up to 4 hr. The ordinate 
represents specific activity incorporated into TCA-precipitable labelled material. Each 
line corresponds to a different experiment and each time point is the result o f triplicate 
incubations.
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Tyrosine incorporation
Into Isolated rat glomeruli
0 1 2 3 4
Time (hr)
Fig. 6.15
Time-course o f the incorporation o f 3H-tyrosine into total glomerular protein. 0.5 ml o f 
Earles-HEPES buffer containing 2.5 uCi o f the labelled amino acid were added at time 0 to 
0.5 ml aliquots o f rat glomerular suspension and incubated up to 4 hr. The ordinate 
represents specific activity incorporated into TCA-precipitable labelled material. Each 
line corresponds to a different experiment and each time point is the result o f triplicate 
incubations.
 ^HIS incorporation into isolated rat glomeruli
Time (hr)
F lg .6 .15
Time-course o f the incorporation o f 3H-histidine into total glomerular protein. 05  ltd o f 
Earles-HEPES buffer containing 2.5 uCi o f the labelled amino acid were added at time 0 to 
0.5 ml aliquots o f rat glomerular suspension and incubated up to 4 hr. The ordinate 
represents specific activity incorporated into TCA-precipitable labelled material. Each 
line corresponds to a different experiment and each time point is the result o f triplicate 
incubations.
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TABLE 6.2.3
INCORPORATION OF PROLINE INTO ISOLATED PIG GLOMERULI EXPOSED TO ADR
DOSE (mM) INCORPO RATIO N* % OF CONTROL
EXPERIMENT 1:
O 2.10 + 0.02 100
31.2 x 10~3 0.48 + 0 .02*** 23
62.5 x 10~3 0.25 + 0.04*** 12
0.125 0.20 . + 0.01*** 10
0.25 0.17 + 0.006*** 8
0.5 0.23 + 0 .014*** 11
EXPERIMENT 2:
0 1.4 + 0.2 100
7.8 x 10"3 1.08 + 0.2** 78
15.6 x 10-3 0.77 + 0.1** 55
31.2 x 10"3 0.58 + 0.08** 42
62.5 x 10"3 0.40 + 0.04** 29
0.125 0.30 + 0.02*** 22
0.25 0.24 + 0.02*** 17
EXPERIMENT 3:
0 1.1 + 0.16 100
7.8 x 10"3 1.04 .+ 0.22 92
15.6 x 10“3 0.74 + 0.03* 65.5
31.2 x 10"3 0.51 + 0.06** 45
62.5 x 10"3 0.36 + 0.01** 32
0.125 0.22 + 0.01*** 19.5
0.25 0.11 + 0.004*** 10
EXPERIMENT 4:
0 5.6 + 0.4 100
7.8 x 10“3 3.2 + 0.37** 56
15.6 x 10-3 2.5 + 0.31*** 44
31.2 x 10-3 1.7 + 0.15*** 29.5
62.5 x 10“3 1.4 + 0.03*** 24.5
0.125 1.2 + 0.13*** 21.1
0.25 1.25 + 0.03*** 22
EXPERIMENT 5:
0 2.0 ,+ i0.2 100
7.8 x 10"3 1.4 + i0.25* 70
15.6 x 10“3 0.8 + i0.09*** 40
31.2 x 10-3 0.6 + i0.07*** 30
62.5 x 10"3 0.4 + i0.00*** 20
* significantly different from control at P < 0.05
** significantly different from control at P < 0.01
*** significantly different from control at P < 0.001
+ pmol proline/mg protein
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TABLE 6 . 2 . 5  EFFECT OF ADR ON THE INCORPORATION OF PRO LINE 
IN TO  ISO LATED  RAT GLOMERULI
Incorporation
Dose (uM)
pmol/mg prot as % of control
Exp. 1  0 0.9 + 0.3 100
31.2 0.25 + 0.08* 28
62.5 0.28 + 0.03* 31
125 0.33 + 0.05* 37
250 0.31 + 0.02* 34
500 0.28 + 0.03* 31
Exp. 2 0 0.41 + 0.1 100
7.8 0.12 + 0.04** 29
15.6 0.09 + 0.03** 22
31.2 0.10 + 0.02** 24
62.5 0.12 + 0.01** 29
125 0.10 + 0.05** 24
250 0.18 + 0.01* 44
500 0.09 + 0.02** 22
Exp. 3 0 0.5 + 0.05 100
7.8 0.11 + 0.005*** 22
15.6 0.09 + 0.014*** 18
31.2 0.10 + 0.04*** 20
62.5 0.11 + 0.016*** 22
125 0.15 + 0.07** 30
* significantly different from control at P < 0.05
** significantly different from control at P < 0.01
*** significantly different from control at P < 0.001
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TABLE 6.2.6
INCORPORATION OF 3 H -P R O LIN E  IN TO  ISO LATED  P IG  GLOMERULI 
EXPOSED TO PAN INCUBATED W ITH  KREBS BUFFER
EXPERIMENT 1:
EXPERIMENT 2:
EXPERIMENT 3:
DOSE (mM) INCORPORATION % OF CONTROL
0 2.10 + 0.27 100
0.5 0.91 ± 0.16** 43
2.5 1.01 ± 0.19** 48
5 0.75 + 0.05*** 36
0 1.4 ± 0.2 100
0.25 1.6 ± 0.24 113
0.5 1.2 ± 0.15 87
1 0.94+0.05* 68
2.5 1.10 ± 0.16 79
5 0.79 + 0.03** 57
0 .1.1 + 0.16 100 
0.25 1.44 + 0.20, 127
0.5 0.98 + 0.08 87
1 0.85 ± 0.08 75
2.5 0.68 ± 0.015* 60
5 0.67+0.06* 59
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TABLE 6.2.6 (CONTINUED)
EXPERIMENT 4:
0 5.6 + 0.42 100
0.25 4.2 + 0.57* 75
0.5 3.8 + 0.33** 67
1 3.4 + 0.28** 60
2.5 3.0 + 0.39** 53
5 2.1 + 0.24*** 38
* Significantly different from control at P < 0.05
** Significantly different from control at P < 0.01
*** Significantly different from control at P < 0.001
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TABLE 6.2.8 EFFECT OF PAN ON THE INCORPORATION OF PROLINE
INTO ISOLATED RAT GLOMERULI INCUBATED WITH TYRODES 
BUFFER
Dose (mM) Incorporation
Exp. 1
Exp. 2
pmol/mg prot as % of
0 0.9 + 0.3 100
0.5 1.3 + 0.28 144
1.0 0.5 + 0.10 55
2.5 0.3 + 0.05* 33
5.0 0.3 + 0.06* 33
0 0.31 + 0.05 100
0.25 0.31 + 0.09 100
0.50 0.34 + 0.006 110
2.50 0.24 + 0.003 77
5.0 0.16 + 0.002** 52
TABLE 6.2.9 STR EFFECT ON PROLINE INCORPORATION INTO ISOLATED 
PIG GLOMERULI INCUBATED WITH KREBS BUFFER
DOSE (mM) INCORPORATION
pmol/mg protein % OF CONTROL
0 . 0
0.5
1.0
2.5
5.0
5.60 ± 0.40 
1.06 ± 0.11** 
0.70 ± 0.11** 
0.10 ± 0.03** 
0.06 + 0.01**
100
19
12
2
1
* Significantly different from control at P < 0.05
** Significantly different from control at P < 0.01
*** Significantly different from control at P < 0.001
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TABLE 6.2.10 EFFECT OF STR THE INCORPORATION OF PROLINE 
BY ISOLATED PIG GLOMERULI INCUBATED WITH 
EARLES-HEPES BUFFER
INCORPORATION
DOSE pmol/mg protein % OF CONTROL AVERAGE OF %
(mM)     ' _____________________________
0 5.101 + 0.594 1.05 + 0.18 100 100 100
0.25 4.753 + 0.428 0.90 + 0.17 93 86 89
0.5 2.260 + 0.518** 0.60 + 0.12* 44 57 50
1.0 0.306 + 0.030*** 0.50 + 0.07** 6 48 27
2.0 0.007 + 0.002*** 0.20 + 0.05** 2 19 10
TABLE 6.2.11 STR EFFECT ON PROLINE INCORPORATION INTO ISOLATED 
RAT GLOMERULI INCUBATED WITH TYRODES BUFFER
DOSE (mM) INCORPORATION
pmol/mg protein % OF CONTROL
0.0 2.12 ± 0.60 100
1.0 0.14 ± 0.01** 6
2.5 0.09 ± 0.01** 4
5.0 0.09 + 0.03** 4
* Significantly different from control at P < 0.05
** Significantly different from control at P < 0.01
*** Significantly different from control at P < 0.001
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TABLE 6.2.12 ETA EFFECT ON PROLINE INCORPORATION INTO ISOLATED PIG
GLOMERULI
DOSE (mM) INCORPORATION (pmol/mg prot) % OF CONTROL
0 6.10 ±  0.500 100.0
0 . 1 0 .36  + 0 . 0 4 0 * * * . 6 . 0
0.2 0.10 ±  0 . 0 2 0 * * * 1 . 5
0 . 5 0.04 + 0 . 0 0 2 * * * 0 . 6
TABLE 6 . 2 . 1 3 INCORPORATION OF 3H-PROLINE INTO 
EXPOSED TO BEA (KREBS)
ISOLATED PIG GLOMERULI
DOSE (mM) INCORPORATION 
(pmol/mg protein)
% OF CONTROL
0 5 .6  + 0 .4 100
1 4 .1  + 0 . 4 * 73
5 4.7  + 0 .5 84
10 3 . 1  + 0 . 5 * * 56
*  S ig n i f ic a n t ly  d i f f e r e n t  from  c o n tro l a t  P < 0 .05
* *  S ig n i f ic a n t ly  d i f f e r e n t  from  c o n tro l a t  P < 0 .01
* * *  S ig n i f ic a n t ly  d i f f e r e n t  from  c o n tro l a t  P < 0 .001
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TABLE 6.2.15 EFFECT OF BEA ON THE INCORPORATION OF PRO 
INTO ISOLATED RAT GLOMERULI INCUBATED WITH 
TYRODES
Dose (mM) Incorporation
pmol/mg prot % of control
0 2.1 + 0.6 100
1 2.4 + 0.0001 114 •
5 1.6 + 0.04 76
10 1.0 + 0.16* 48
Significantly different from control at P < 0.05
TABLE 6.2.16 INCORPORATION OF PRO INTO ISOLATED PIG GLOMERULI 
EXPOSED TO FOLIC ACID
DOSE (mM) INCORPORATION 
(pmol/mg protein)
% OF CONTROL
0 5.6 ± 0.4 100
1 4.2 +0.3** 75
5 2.8 + 0.3*** 50
10 1.5 + 0.16*** 26
** Significantly different from control at P < 0.01
*** Significantly different from control at P < 0.001
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TABLE 6.2.17 EFFECT OF FOLIC ACID ON THE INCORPORATION OF PRO
INTO ISOLATED RAT GLOMERULI
Dose (mM) Incorporation
pmol/mg prot % of control
0 2.1 ± 0.6 100
1 1.9 + 1.6 90
5 1.9 + 0.2 90
10 1.1 + 0.12* 52
★ Significantly different from control at P < 0.05
TABLE 6.2.18 EFFECT OF OTA ON THE INCORPORATION OF PRO INTO
ISOLATED PIG GLOMERULI
DOSE (mM) INCORPORATION 
(pmol/mg protein)
% OF CONTROL
0 2.0 ± 0.20 100
1.6 1.7 ± 0.07 90
3.2 1.2 ± 0.06** 60
** Significantly different from control P < 0.01
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TABLE 6.2.19 
EFFECT OF POLYBRENE ON PROLINE INCORPORATION 
INTO ISOLATED PIG GLOMERULI
DOSE (mg/ml) INCORPORATION
pmol PRO/mg prot % of Control
0 1.12 ± 0.16 100
0.125 0.32 ± 0.08 28
0.250 0.17 + 0.12 15
0.500 0.21 + 0.02 18
---
TABLE 6.2.20 EFFECT OF POLYBRENE ON THE INCORPORATION OF PRO 
INTO ISOLATED RAT GLOMERULI
Dose (mg/ml) Incorporation
pmol/mg prot % of control
Exp. 1 0 0.9 + 0.3 100
1 0.12 + 0.02* 13
5 0.15 + 0.04* 17
10 0.16 + 0.05* 17
Exp. 2 0 0.41 ± 0.05 100
0.5 0.07 + 0.002*** 17
1.0 0.08 + 0.006*** 19
5.0 0.08 + 0.001*** 19
10.0 0.06 + 0.002*** 15
Exp. 3 0 0.31 + 0.05 100
0.125 0.08 + 0.01** 26
0.25 0.06 + 0.005*** 19
0.5 0.07 +0.004** 22
1 0.08 + 0.001** 26
* Significantly different from control at P < 0.05
** Significantly different from control at P < 0.01
*** Significantly different from control at P < 0.001
340
CO
CO
d)
CO
<d
d>
r-1
d)
OS
CM
O
O
d)
CO
o
o
3
rH
0
n•H
T3
•r|
O
id
o m co
o o cn r*
rH rH
*
He
*
m CO m CO
rH O rH o
O O O o
+1 +1 +1 +1
r^ - o\ m CO
oo cn cn CM
O  CT>
o  r~~
H
lO inrH
O *
Id * He
He * *o o O o cn
-rH • • • •
d) cn rH m o
rH ido +1 +1 +1 +1
cn rH o CO
cn cn CM
O
O
m
CO
m CM
o He He He
•H H< He He
d He He He
<D o O O
rH • • • •
oj-H CM in OG
•H +| +1 +1 +1
PI Id
CO cn o cn
m cn t"
rH rH
d
o•H
P
CO
U -~. 
■P 2  
d d 0) —  
o 
d 
o 
u
o
rH
O
O
O
O
O
m rH o
O O o
o O o
v | V I V I
04 04 04
■P ■P ■P
id id id
rH rH rH
O O O
0 0 M• 4J ■P ■p
d d d d
•r| o o o
d> o o o
■P
o e 6 su o o o
04 M M u
mh MH MH
e ■P 4J ■P• d d d
d> r l d) d> d)
■P 0 0 M u
id u d) d) d)
0 •P MH MH MH
■P d MH MH MH
n o •H •H •rl
.0 0 ■o •d •d
3
00 MH >1 >1 >1
1 0 rH rH
o •p 4J ■p
<d d d d
rH &> id id id
id o o o
MH 4J •H •r| •r|
o d *4H MH
d) •r| •r| -r l
rH o d d d
O M Cn Cn tn
6 d) •rl •rl •r|
04 04 CO CO oo
*
He He
Id dP He He He
341
TABLE 6.3.2.
EFFECT OF SHAKING DURING INCUBATION ON THE AMOUNT OF 
METABOLISM OF 14C LABELLED SUBSTRATES BY PIG 
GLOMERULI AFTER 1 HOUR INCUBATION
NOT SHAKING 
SHAKING
pmol/mg protein 
* significantly different from control at P < 0.05
*** significantly different from control at P < 0.001
CO2  Release3
L IN O LE N IC  O LE IC  GLUCOSE
103 ± 0.9 16 ± 0.9 3.3 ± 0.1
156 + 2*** 39 + 3*** 3.7 +0.15*
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TABLE 6.3.3.
OXIDATIVE METABOLISM OF 14C GLUCOSE BY ISOLATED PIG 
GLOMERULI INCUBATED WITH EARLES-HEPES BUFFER
EXPERIMENT 1:
TIME
(H)
1
2-
3
4
EXPERIMENT 2:
1
2
3
4
EXPERIMENT 3:
1
2
3
EXPERIMENT 4:
1
2
3
4
EXPERIMENT 5:
1
2
3
4
EXPERIMENT 6:
1
2
3
4
14C02 RELEASE 
(pmol/mg protein)
32 + 1
7 1 + 3  
120 ±  • 6 
189 + 14
22 + 3 
39 ± 0.6 
56 ± 2 
7 8 + 2
38 ± 3 
66 ± 7 
119 + 2
29 ± 4
68 ± 7
102 + 2 
127 + 11
20 ± 1 
40 ± 0.4 
63 + 3 
72 + 6
11 ± 0.4 
27 + 0.7 
49 ± 1 
65 ± 4
343
TABLE 6.3.3 (CONTINUED)
EXPERIMENT 7
0 0
1 18.1 ± 1.7
2 31 ± 2 . 4
3 6 7 + 2 . 6
4 83 + 7 . 0
EXPERIMENT 8:
0 0
1 • 1 6 . 4 + 4
2 30 ± 1
3 44 + 1
4 63 + 7
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TABLE 6.3.4
T VALUES AT LEVELS OF 5%-0.1% OF PROBABILITY FOR THE 
OXIDATIVE METABOLISM OF 14-C GLUCOSE BY ISOLATED 
PIG GLOMERULI INCUBATED WITH EARLES-HEPES, BETWEEN 
DIFFERENT TIME-POINTS IN SEVERAL EXPERIMENTS
EXPERIMENT 1:
1 2 3
1
2 21.4***
3 25.0*** 12.6***
4 19.4*** 14.3*** 7.8**
EXPERIMENT 2:
1 2 ■ 3
1
2 9.6***
3 29.1*** 14.1***
4 26.9*** 32.3*** 13.5***
TABLE 6.3.4 (CONTINUED)
EXPERIMENT 3:
1 2 3
1
2 6.4**
3 38.9*** 12.6***
EXPERIMENT 4:
1 2 3
• 1 -
2 8.4**
3 28.2*** 8.1**
4 14.5*** 7.8** 3.9*
EXPERIMENT 5:
1 2 3
1 -
2 32.2*** -
3 23.5*** 13.1***
4 14.8*** 9.2*** 2.3
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TABLE 6.3.4 (CONTINUED)
EXPERIMENT 6:
1 2 3
1 -
2 34.4*** -
3 61.1*** 31.2*** -
4 23.3*** 16.2*** 6.7**
EXPERIMENT 7;
1 2 3
1
2 7.6**
3 27.3*** 17.6*** -
4 15.6*** 12 .2*** 3.7*
EXPERIMENT 8;
1 2 3
1
2 5.7**
3 11.6*** 17.1*** -
4 10.0*** 8.1** 4.6**
* P < 0.05 
** P < 0,01 
*** P < 0.001
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TABLE 6.3.5
OXIDADIVE METABOLISM OF 14C-GLUCOSE
BY ISOLATED RAT GLOMERULI
TIME (hr) C02 RELEASE
(pmol/mg prot)
1 9.0 ± 0.32
2 12.0 ±  0.40
3 15.0 + 0.60
4 15.2 + 0.35
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TABLE 6.3.6.
OXIDATIVE METABOLISM OF 14C-LINOLENIC BY ISOLATED PIG 
GLOMERULI INCUBATED WITH EARLES-HEPES BUFFER
EXPERIMENT 1
EXPERIMENT 2
EXPERIMENT 3
EXPERIMENT 4
EXPERIMENT 5
EXPERIMENT 6
TIME 14C02 RELEASE
(H) (pmol/mg protein)
1 7 4 +  2
2- 129 ± 6
3 159 + 7
4 1 7 6 + 1 8
1
2
3
4
38 + 4 
92 + 9 
123 + 3 
186 + 8
1 180 + 19
2 3 9 2 + 2 1
3 5 2 7 + 2 6
4 651 + 29
1 205 + 21
2 1 0 0 + 7
3 174 + 12
4 2 2 2 + 2 1
53 ± 3
100 + 7
174 + 12 
222 + 21
1 4 8 + 4
2 9 6 + 1 8
3 150 ± 16
4 179 + 5
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TABLE 6.3.6. (CONTINUED)
EXPERIMENT 7
EXPERIMENT 8:
1 26 + 5
2 38 + 3
3 57 + 3
4 63 + 3
1
2
3
4
350
i
64 + 3
199 ± 14 
356 + 3 2  
498 + 33
TABLE 6.3.7.
T VALUES AT LEVELS OF 5%-0.1% OF PROBABILITY FOR THE 
OXIDATIVE METABOLISM OF 14-C LINOLENIC ACID 
BY ISOLATED PIG GLOMERULI INCUBATED WITH EARLES-HEPES BUFFER 
BETWEEN DIFFERENT TIME POINTS IN SEVERAL EXPERIMENTS
EXPERIMENT 1:
1 2 3
1
2 15.4*** -
3 20.2*** 5.6**
4 9.7*** 4.3* 1.5
EXPERIMENT 2:
1 2 3
9.5***
2 4 .4 *** 5.6**
28.7*** 13.5*** 12.8***
EXPERIMENT 3:
1 2 3
1
2 13.0***
3 18.7*** 7.0**
4 23.5*** 12.5*** 5.5**
1
2
3
4
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TABLE 6.3.7. (CONTINUED)
EXPERIMENT 4:
1 2 3
1
2 2.4
3 7.3** 2.9*
4 25.4*** 10.5*** 9.1***
.EXPERIMENT 5:
1 2 3
1
2 10.7*** -
3 16.9*** 9.2***
4 13.8*** 9.5*** 3.4*
EXPERIMENT. 6:
1 2 3
1
2 4.5*
3 10.7*** 3.9* -
4 35.4*** 7.7** 3.0*
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TABLE 6.3.7. (CONTINUED)
EXPERIMENT 7:
1 2 3
1 . " ■
2 3.5*
3 9.2*** 7.7** -
4 11.0*** . 10.2*** 2.4
EXPERIMENT 8:
1 2 3
1 -
2 16.3*** -
3 15.7*** 7.8**
4 22.7*** 14.4*** 5.3**
* P < 0.05 
** P < 0.01 
*** P < 0.001
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TABLE 6.3.8
OXIDATIVE METABOLISM OF 14C-LINOLENIC ACID
BY ISOLATED RAT GLOMERULI
TIME (hr) C02 RELEASE
(pmol/mg prot)
231 + 5
320 + 9
340 + 18
368 + 30
354
TABLE 6 . 3 . 9 .
O X ID A T IV E  METABOLISM OF 14C -O L E IC  BY ISOLATED P IG  
GLOMERULI INCUBATED W ITH EARLES-HEPES BUFFER
EXPERIMENT 1
EXPERIMENT 2
EXPERIMENT 3
EXPERIMENT 4
EXPERIMENT 5
EXPERIMENT 6
EXPERIMENT 7
TIME 14C02 RELEASE
(H) (pmol/mg protein)
1 9 ± 1
2 22 + 3
3 2 7 + 0 . 5
4 49 + 3
1 13 ± 1
2 36 + 2
3 71 + 4 '
4 105 + 3
1 6 3 + 1 0
2 195 ± 29
3 . 3 1 3  + 58
4 423 + 27
1 74 + 16
2 123 ± 1
3 179 + 15
4 332 + 43
1 19 ± 0.3
2 4 1 + 1 0
3 65 + 6
4 92 + 9
1 29 ± 1.3
2 . 7 9 + 1 5
3 144 + 8
4 182 ± 19
1 13 + 1.8
2 35 + 8
3 73 ± 2
4 85 ± 4
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TABLE 6.3.10.
T VALUES AT LEVELS OF 5%-0.1% OF PROBABILITY FOR THE 
OXIDATIVE METABOLISM OF 14C OLEIC ACID BY ISOLATED 
PIG GLOMERULUS INCUBATED WITH EARLES-HEPES BUFFER, 
BETWEEN DIFFERENT TIME POINTS IN SEVERAL EXPERIMENTS
EXPERIMENT 1:
1 2 3
1
2 7.1**
3 27.9*** 2.84*
4 21.9*** 11.0*** 12.5***
EXPERIMENT 2:
1 2 3
1
2 17.8***
3 24.4*** 13.5***
4 50.4*** 33.1*** 11.8***
EXPERIMENT 3:
1 2 3
1
2 7.4**
3 7.3** 3.1*
4 21.6*** 10.0*** 3.0*
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TABLE 6.3.10. (CONTINUED)
EXPERIMENT 4:
1 2 3
1 "
2 5.3**
3 8.3** 6.4**
4 9 .7 *** 8.4** 5.8**
EXPERIMENT 5:
1 2 3
1 -
2 3.8*
3 13.3*** 3.6*
4 14.0*** 6 .6 ** 4.3*
EXPERIMENT 6:
1  2 3
1
2 5.7**
3 24.6*** 6 .6 **
4 13.9*** 7.4** 3.2*
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TABLE 6.3.10. (CONTINUED)
EXPERIMENT 7:
1 2
1
2 .4.6**
3 38.6*** 8.0**
4 28.4*** 9.7***
0.05 
0.01 
0.001
3
4 . 6**
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TABLE 6.4.1. EFFECT OF ADRIAMYCIN ON THE OXIDATIVE METABOLISM 
OF 1 4 C-GLUCOSE BY ISOLATED PIG GLOMERULI
co2 RELEASE
DOSE
(mM) pmoles/mg protein % OF CONTROL AVERAGE OF %
0 63 ± 7 65 + 4 1 0 0  1 0 0 1 0 0
0.031 61 ± 2 70 ± 0 97 108 1 0 2
0.062 51 + 4 67 + 3 80 103 91
0.250 45 ± 3* 48 + 3** 71 74 72
1 . 0 34 ± 3** 17 + 5 *** 53 26 39
TABLE 6.4.2. EFFECT OF ADRIAMYCIN ON THE OXIDATIVE 
OF 1 4 C-LINOLENIC ACID BY ISOLATED PIG
METABOLISM
GLOMERULI
co2 RELEASE
DOSE
(mM) pmoles/mg protein % OF CONTROL AVERAGE OF %
0
0.031
179 ± 5 63 ± 
161 + 1 6  28 +
3
2 *** 90 44 67
0.062 122 + 10*** 29 + 3 *** 6 8 46 57
0.250 110 + 5*** 23 + 5*** 61 36 48
1 . 0 62 + 3*** 9 + 3*** 35 14 24
TABLE 6.4.3. EFFECT OF ADRIAMYCIN ON THE OXIDATIVE METABOLISM 
OF 1 4 C-OLEIC ACID BY ISOLATED PIG GLOMERULI
C02  RELEASE
DOSE
(mM) pmoles/mg protein % OF CONTROL
0 85 ± 4
0.031 2 0  + 2 *** 23
0.062 23 + 4*** 27
0.250 15 + 1*** 18Oi—
1 7 + 3*** 8
* significantly different from control at P < 0.05
** significantly different from control at P < 0.01
*** significantly different from control at P < 0.001
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TABLE 6.4.4 EFFECT OF PUROMYCIN AMINONUCLEOSIDE ON THE OXIDATIVE 
METABOLISM OF 14C-GLUCOSE BY ISOLATED PIG GLOMERULI
14C02 RELEASE
DOSE
(mM) pmol/mg protein % OF CONTROL AVERAGE OF %
0 63 ± 3 65 ± 3
0.062 58 ± 1 52 + 4* 92 80 86
0.125 51 + 2** 54 + 3* 81 83 82
0.625 47 + 2** 44 + 2*** 75 68 71
2.5 32 + 7** 29 + 2*** 51 45 48
TABLE 6.4.5. EFFECT OF PUROMYCIN AMINONUCLEOS IDE ON THE OXIDATIVE
METABOLISM OF 14C-LINOLENIC ACID BY ISOLATED PIG GLOMERULI
14C02 RELEASE
DOSE
(mM) pmol/mg protein % OF CONTROL AVERAGE
0
0.062
179 + 5 
148 + 15*
63 ± 
31 +
3
3*** 83 49 66
0.125 137 + 11** 30 + 2*** 76 48 62
0.625 136 + 15** 30 + ]_ * * * 76 48 62
2.5 105 + 5*** 29 + 2*** 59 46 52
TABLE 6.4.6. EFFECT OF PUROMYCIN AMINONUCLEOS IDE ON THE OXIDATIVE 
METABOLISM OF 14C-OLEIC ACID BY ISOLATED PIG GLOMERULI
14C02 RELEASE
DOSE
(mM) pmol/mg protein % OF CONTROL
0
0.062
0.125
0.625
2.5
85 + 4 
31 + 1*** 
30 ± 2*** 
29 + 3*** 
22 + 5***
36
35
34
26
* significantly different from control at P < 0.05
** significantly different from control at P < 0.01
*** significantly different from control at P < 0.001
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TABLE 6.4.7. EFFECT OF STREPTOMYCIN ON THE OXIDATIVE METABOLISM
OF 14C-GLUCOSE BY ISOLATED PIG GLOMERULI
14C02 RELEASE
DOSE
(mM) pmol/mg protein % OF CONTROL AVERAGE OF %
0 83 + 7 65 ± 4 100 100 100
0.25 87 + 4 43 ± 2** 105 66 85
0.5 90 + 13 39 + 2*** 108. 60 84
1.0 77 + 6 39 ± 1*** 93 60 76
2.0 86 + 8 39 ± 3*** 97 6.0 78
TABLE 6.4.8. EFFECT 
OF 14C
OF STREPTOMYCIN ON THE OXIDATIVE METABOLISM 
-LINOLENIC ACID BY ISOLATED PIG GLOMERULI
14c o 2 RELEASE
DOSE
(mM) pmol/mg protein % OF CONTROL AVERAGE OF %
0 498 + 33 179 + 5
0.25 396 + 54* 185 ± 10 79 103 91
0.5 362 + 61* 172 + 17 73 96 84
1.0 265 + 15*** 133 + g * * * 53 70 63
2.0 250 ± 55** 81 ± g*** 50 45 47
TABLE 6.4.9. EFFECT OF STREPTOMYCIN ON THE 
OF 14C-OLEIC ACID BY ISOLATED
OXIDATIVE METABOLISM 
PIG GLOMERULI
CM
oOi—i
RELEASE
DOSE
(mM) pmol/mg protein % OF CONTROL
0 182 + 19
0.25 140 ± 20 77
0.5 149 + 14 82
1.0 150 + 30 82
2.0 152 + 1 82
* significantly different from control at P < 0.05
** significantly different from control at P < 0.01
*** significantly different from control at P < 0.001
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TABLE 6.4.10. ETA EFFECT ON 14C-GLUCOSE OXIDATION BY ISOLATED
PIG GLOMERULI
14C02 release
DOSE
(mM) pmol/mg protein % OF CONTROL
0 51 ± 9 100
0.1 50 ± 5 98
0.2 44 + 7 86
0.5 24 + 2** 47
TABLE 6.4.11. ETA EFFECT ON 14 
BY ISOLATED PIG
C-LINOLENIC ACID 
GLOMERULI
METABOLISM
14C02 RELEASE
DOSE
(mM) pmol/mg protein % OF CONTROL
0 63 ± 3 100
0.1 20 + 2*** 32
0.2 11 + 2*** 17
0.5 9 + 3*** 14
TABLE 6.4.12. ETA EFFECT ON 14 
BY ISOLATED PIG
C-OLEIC ACID METABOLISM 
GLOMERULI
14C02 RELEASE
DOSE
(mM) pmol/mg protein % OF CONTROL
0 85 ± 1 100
0.1 20 +.4*** 23
0.2 7 + ]_*** 8
0.5 0 0
significantly different from control at P < 0.05
** significantly different from control at P < 0.01
*** significantly different from control at P < 0.001
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TABLE 6.4.13. EFFECT OF BEA ON THE OXIDATIVE METABOLISM OF 14C-GLUCOSE
BY ISOLATED PIG GLOMERULI
14C02 r e l e a s e
DOSE
(mM) pmol/mg protein % OF AVERAGE
CONTROL OF %
0 72 + 6 83 ± 7 51 + 9
1 87 + 3* 93 + 6 63 + 10 121 112 123 119
5 69 + 6 126 + 13** 97 + 14** 96 151 190 146
10 64 + 5 162 + 27** 106 + 13** 89 195 208 164
TABLE 6.4.14 EFFECT OF BEA
14c-linolenic
ON THE OXIDATIVE METABOLISM OF 
BY ISOLATED PIG GLOMERULI
14C02 release
DOSE
(mM) pmol/mg protein % OF CONTROL
0
1
5
10
498 + 33 
555 + 90 
477 + 10 
343 + 20
224 + 20 100 100 
73 + 6*** i n  33 
36 + 5*** 96 16 
24 + 3*** 69 11
TABLE 6.4.15. EFFECT OF BEA ON THE OXIDATIVE METABOLISM OF 14C-OLEIC 
BY ISOLATED PIG GLOMERULI
14C02 RELEASE
DOSE
(mM) pmol/mg protein % OF CONTROL
OF %
0 182 + 1 9  9 2 + 9  100 100
1 229 + 18* 29 ± 4*** 126 31
5 182 + 2 3  13 + 1*** 100 14
10 123 +19* 6 + 0.8*** 68 6
* significantly different from control at P < 0.05
** significantly different from control at P < 0.01
*** significantly different from control at P < 0.001
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TABLE 6.5.3 EFFECT OF OTA ON GLUCOSE METABOLISM BY ISOLATED RAT GLOMERULI
C02 RELEASE
DOSE
(mM) pmol C02/mg protein % of Control
0 15.2 ± 0.3 100
0.01 45.8 ± 6.6** 301
0.10 52.5 ± 5.3*** 345
1.00 9.1 ± 0.2*** 60
* SIGNIFICANTLY DIFFERENT FROM THE CONTROL GROUP AT P < 0.01 
*** AT P < 0.001 •
TABLE 6.5.4 EFFECT OF OTA ON LINOLENIC ACID METABOLISM BY ISOLATED RAT
GLOMERULI
C02 RELEASE
DOSE
(mM) pmol C02/mg protein % of Control
0 325.0 ± 1 8  100
0.01 380.2 + 17* 117
0.10 389.6 ± 34* 120
1.00 24.4 ± 1.2*** 7.5
* SIGNIFICANTLY DIFFERENT FROM THE CONTROL GROUP AT P < 0.05
*** AT P < 0.001
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APPENDIX 2
TABLE 6 . 6 . 1 ,
INCORPORATION OF 3H-PROLINE INTO RAT TUBULES 
USING TWO DIFFERENT INCUBATION BUFFERS
INCORPORATION (pmol/mg prot)
TIME TYRODES EARLES-HEPES
1 0.17 + 0.008 0.38 +
- * * *  
0 .03
2 0.25 + 0.017 0.65 +
* *
0 . 09
3 0.42 + 0.0006 1.60 +
* * *
0 .17
4 0.82 + 0.046 2 . 4 +
* *
0 .33
Significantly different from Tyrodes at P < 0 .01  
Significantly different from Tyrodes at P < 0 .001
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TABLE 6.6.3
T VALUES AT LEVELS OF 5%-0.1% OF PROBABILITY FOR THE INCORPORATION OF 
DIFFERENT AMIN ACIDS AT VARIOUS TIME-POINTS
INCORPORATION OF TRP INTO ISOLATED RAT TUBULE INCUBATED WITH HEPES
1 2 3
1
**
2 6.62 —
*** ***
3 17.8 9.9
*** * * *
4 19.2 16.7 12.2
INCORPORATION OF PHE INTO ISOLATED RAT TUBULE INCUBATED WITH HEPES
1 2 3
1 -
2 3.7* -
3 20.5***
★ *
5 -
.4- 31.0***
***
9.3
. _** 
8.3
INCORPORATION OF TYR INTO ISOLATED RAT TUBLE INCUBATED WITH HEPES
1 2 3
1 -
***2 22.1
•kick **
3 11.2 5 —
* * * kick
4 34.4 23.5 9.0
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TABLE 6.6.3 (CONTINUED)
INCORPORATION OF LEU INTO ISOLATED RAT TUBULE
1 2 3
1 -
**
2 8.5
* * * *
3 9.5 4.1
4
★
4.1 1.4 0.6
INCORPORATION OF PRO INTO ISOLATED RAT TUBULE
1 2 3
1 -
2
***
35.6 -
3
* * ★
14.9 8.2** -
4
* * *
10.1 6.8** 2.5
INCORPORATION OF HIS INTO ISOLATED RAT TUBULE
1 2 3
1
**
2 5
***
3 10 4.9
*** ***
4 24.4 17.0 11.0
* P < 0.05* ★ _
P < 0.01 *** —
P < 0.001
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TABLE 6.6.4
T VALUES AT LEVELS OF 5%-0.1% PROBABILITY FOR THE 
INCORPORATION OF DIFFERENT AMINO ACIDS INTO ISOLATED RAT TUBULE
AFTER 4 HR OF INCUBATION
TRP PHE TYR LEU PRO HIS
TRP -
PHE
***
22.2 -
TYR
***
22 3.8* -
LEU
* * *
22.8 6.3**
* *
7.9 -
PRO
***
19.5 7.3**
**
6.7
„ ** 
9.3
HIS
* * *
22.6 6.8**
**
9.5
**
3.1 8.6
AFTER 3 HR OF INCUBATION
TRP PHE TYR LEU PRO HIS
PHE
***
27.7 -
TYR
* * *
27.7 1.5 -
LEU
***
28.2
**
4.3 1.7 -
PRO
* * *
21.7
* * ★
11.9
* * *
11.8
* * *
13.2 -
HIS
_. *** 
29.3
***
11.6
* *
6.4
**
5.5
***
15.9 -
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7TABLE 6.6.4 (CONTINUED)
AFTER 2 HR OF INCUBATION
TRP PHE TYR LEU PRO
PHE
* * *
19.6 -
TYR
_ * * *
20.4 0.17 -
LEU
* * *
20.4 0.50 0.96 -
PRO
* * *
17.0
* * *
11.4
_  *** 
33.6
_ k k k
29.4 -
HIS
***
21.7
**
4.8
* * *
11.2
„ „*** 
9.3
***
34.3
AFTER 1 HR OF INCUBATION
TRP PHE TYR LEU PRO .
PHE
***
51.3 -
T.YR
* * *
53.3
★ ★
5.5 -
LEU
k k k
50.4 0.96 2.8 -
PRO
***
47.6
★ * *
20.1
* * *
42.5
***
15.3 -
HIS
***
54.8
* * *
12.8
■kick
11
k k k
9.1
* * *
36.4
P < 0.05* *
P < 0.01
* * *
P < 0.001
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TABLE 6.6.5 
OXIDATIVE METABOLISM OF GLUCOSE 
BY ISOLATED RAT PROXIMAL TUBULAR FRAGMENTS
TIME CO« RELEASE (pmol/mg protein)
(Hr)
1 9.3 ± 1 . 1  4.4 ±  0.4
2 27.0 ±  0.5 13.0 ±  1.3
3 30.0 ± 4.4 15.0 ±  2.5
4 26.0 ±  2.9 19.0 + 2.0
TABLE 6.6.6 
OXIDATIVE METABOLISM OF FATTY ACIDS+
BY ISOLATED RAT PROXIMAL TUBULAR FRAGMENTS
TIME STEARIC* PALMITIC* OLEIC LINOLENIC
1 23.2 ± 1.3 65 ± 4 271 ±  4 602 ±  5
2 31.5 ± 3.4 100 ± 12 470 ±  17 887 ±  67
3 34 ± 3 . 4  108 ± 9 581 ± 16 975 ±  2
4 41.5 + 7.0 122 + 7 655 ±  20 1043 ±  11
* Blanks without tubules gave half of the counts obtained with 
tubules
+. Mevalonic acid did not undergo metabolism under the conditions 
of this experiment
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TABLE 6.6.11
EFFECT OF OCA ON GLUCOSE METABOLISM BY ISOLATED RAT TUBULES
C02 RELEASE
DOSE
(mM) pmol C02/mg protein As % of Control
0 (CONTROL) 26 + 2.9
f
100
0.01 69 + 5.2*** 266
0.10 58 + 7.0** 224
1.00 19 + 1.6* 72
SIGNIFICANTLY DIFFERENT FROM THE CONTROL GROUP AT P < 0.05*
** AT P < 0.01
*** AT P < 0.001
TABLE 6.6.12 
EFFECT OF OCA ON LINOLENIC ACID METABOLISM 
BY ISOLATED METABOLISM BY ISOLATED RAT TUBULES
C02 RELEASE
DOSE
(mM) pmol C02/mg protein As % of Control
0 (CONTROL) 87.9+7.1 100
0.01 125.8 ± 4.3** 143
0.10 116.6 ± 10.4* 133
1.00 9.8 + 0.6*** 11
* SIGNIFICANTLY DIFFERENT FROM THE CONTROL GROUP AT P < 0.05,
** AT P < 0.01, *** AT P < 0.001
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Phenylalanine incorporation
into proximal tubular fragments
CL8-
431 20
Time (hr)
Fig. 6.6.1
Time-course o f the incorporation o f 3H-phcnyIalanine into total proximal tubular protein. 
O.S ml o f Earles-HEPES buffer containing 23 uCi o f the labelled amino acid were added at 
time 0 to 0.5 ml aliquots o f rat PTF suspension and incubated up to 4 hr. The ordinate 
represents specific activity incorporated into TCA-precipitable labelled material. Each 
line corresponds to a different experiment and each time point is the result of triplicate 
incubations.
Tryptophan incorporation
into proximal tubular fragments
E 20-
2  10-
Time (hr)
Fig. 6.6.2
Time-course o f the incorporation o f ^ H-tryptophan into total proximal tubular protein. 0.5 
ml o f Earles-HEPES buffer containing 2.5 uCi o f the labelled amino acid were added at time 
0 to 0.5 ml aliquots o f rat PTF suspension and incubated up to 4 hr. The ordinate 
represents specific activity incorporated into TCA-precipitable labelled material. Each 
line corresponds to a different experiment and each time point is the result of triplicate 
incubations.
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Tyrosine incorporation
Into rat proximal tubular fragments
o>
2-
41 2 30
Time (hr)
Fig.fi.6J
Tune-course o f the incorporation o f 3H-tyrosinc into total proximal tubular protein. 0.5 ml 
o f Earles-HEPES buffer containing 2.5 uCi o f the labelled amino acid were added at time 0 
to 0.5 ml aliquots o f rat PTF suspension and incubated up to 4 hr. The ordinate represents 
specific activity incorporated into TCA-precipitable labelled material. Each line 
corresponds to a different experiment and each time point is the result o f triplicate 
incubations.
Proline incorporation
into proximal tubular fragments
40 31 2
Time (hr)
Fig. fi.fi.4
Time-course of the incorporation o f H-proline into total proximal tubular protein. 0.5 ml 
o f Earles-HEPES buffer containing 2.5 uCi o f the labelled amino acid were added at time 
to 0.5 ml aliquots o f rat PTF suspension and incubated up to 4 hr. The ordinate represents 
specific activity incorporated into TCA-precipitable labelled material. Each line 
corresponds to a different experiment and each time point is the result o f triplicate 
incubations.
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LEU incorporation into isolated ra t tubule
1.5
0 1 2 3 4
Time (hr)
Fig. 6.6 £
Time-course of the incorporation of ^ H-leucine into total proximal tubular protein. 0.5 ml 
of Earles-HEPES buffer containing 2.5 uCi of the labelled amino acid were added at time 0 
to 0.5 ml aliquots of rat PTF suspension and incubated up to 4 hr. The ordinate represents 
specific activity incorporated into TCA-precipitable labelled material. Each time point 
is the result of triplicate incubadons.
HIS incorporation in to  isolated ra t tubule
.5-
40 321
Time (hr)
Fig. 6.6.6
Time-course of the incorporation of ^ H-histidine into total proximal tubular protein. 0.5 
ml of Earles-HEPES buffer containing 2.5 uCi of the labelled amino acid were added at time 
0 to 0.5 ml aliquots of rat PTF suspension and incubated up to 4 hr. The ordinate 
represents specific activity incorporated into TCA-precipitable labelled material. Each 
line corresponds to a different experiment and each time point is the result of triplicate 
incubations.
381
